
<html lang="en"     class="pb-page"  data-request-id="619a5332-bb95-4b6f-91a7-f9c3907e8101"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-2;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b01085;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor" /></meta><meta name="dc.Creator" content="Takao  Uno" /></meta><meta name="dc.Creator" content="Yuichi  Kawai" /></meta><meta name="dc.Creator" content="Satoshi  Yamashita" /></meta><meta name="dc.Creator" content="Hiromi  Oshiumi" /></meta><meta name="dc.Creator" content="Chihoko  Yoshimura" /></meta><meta name="dc.Creator" content="Takashi  Mizutani" /></meta><meta name="dc.Creator" content="Tatsuya  Suzuki" /></meta><meta name="dc.Creator" content="Khoon Tee  Chong" /></meta><meta name="dc.Creator" content="Kazuhiko  Shigeno" /></meta><meta name="dc.Creator" content="Mitsuru  Ohkubo" /></meta><meta name="dc.Creator" content="Yasuo  Kodama" /></meta><meta name="dc.Creator" content="Hiromi  Muraoka" /></meta><meta name="dc.Creator" content="Kaoru  Funabashi" /></meta><meta name="dc.Creator" content="Koichi  Takahashi" /></meta><meta name="dc.Creator" content="Shuichi  Ohkubo" /></meta><meta name="dc.Creator" content="Makoto  Kitade" /></meta><meta name="dc.Description" content="The molecular chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and surv..." /></meta><meta name="Description" content="The molecular chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and surv..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 7, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01085" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01085" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01085" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01085" /></link>
        
    
    

<title>Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01085" /></meta><meta property="og:title" content="Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0020.jpeg" /></meta><meta property="og:description" content="The molecular chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and survival. A novel series of HSP90 inhibitors were discovered by structure–activity relationship (SAR)-based optimization of an initial hit compound 11a having a 4-(4-(quinolin-3-yl)-1H-indol-1-yl)benzamide structure. The pyrazolo[3,4-b]pyridine derivative, 16e (TAS-116), is a selective inhibitor of HSP90α and HSP90β among the HSP90 family proteins and exhibits oral availability in mice. The X-ray cocrystal structure of the 16e analogue 16d demonstrated a unique binding mode at the N-terminal ATP binding site. Oral administration of 16e demonstrated potent antitumor effects in an NCI-H1975 xenograft mouse model without significant body weight loss." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01085"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01085">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01085&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01085&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01085&amp;href=/doi/10.1021/acs.jmedchem.8b01085" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 531-551</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01031" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01139" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Takao Uno</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takao Uno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b7c3d6dcd6d89ac2d9d8f7c3d6dedfd899d4d899ddc7"><span class="__cf_email__" data-cfemail="0571646e646a28706b6a4571646c6d6a2b666a2b6f75">[email protected]</span></a>. Phone: +81-29-865-4527. Fax: +81-29-865-2170.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takao++Uno">Takao Uno</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3259-4603" title="Orcid link">http://orcid.org/0000-0002-3259-4603</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuichi Kawai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuichi Kawai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuichi++Kawai">Yuichi Kawai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Satoshi Yamashita</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Satoshi Yamashita</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Yamashita">Satoshi Yamashita</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiromi Oshiumi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiromi Oshiumi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Formulation Research, CMC Division, Taiho Pharmaceutical Co. Ltd., Kawauchi-cho, Tokushima 771-0194, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiromi++Oshiumi">Hiromi Oshiumi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chihoko Yoshimura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chihoko Yoshimura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chihoko++Yoshimura">Chihoko Yoshimura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takashi Mizutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takashi Mizutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takashi++Mizutani">Takashi Mizutani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tatsuya Suzuki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatsuya Suzuki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatsuya++Suzuki">Tatsuya Suzuki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Khoon Tee Chong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Khoon Tee Chong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Khoon+Tee++Chong">Khoon Tee Chong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kazuhiko Shigeno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kazuhiko Shigeno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kazuhiko++Shigeno">Kazuhiko Shigeno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mitsuru Ohkubo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mitsuru Ohkubo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mitsuru++Ohkubo">Mitsuru Ohkubo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yasuo Kodama</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yasuo Kodama</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yasuo++Kodama">Yasuo Kodama</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiromi Muraoka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiromi Muraoka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiromi++Muraoka">Hiromi Muraoka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kaoru Funabashi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kaoru Funabashi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kaoru++Funabashi">Kaoru Funabashi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Koichi Takahashi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Koichi Takahashi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Koichi++Takahashi">Koichi Takahashi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuichi Ohkubo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuichi Ohkubo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuichi++Ohkubo">Shuichi Ohkubo</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Makoto Kitade</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Makoto Kitade</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Technology Laboratory, CMC Division, Taiho Pharmaceutical Co. Ltd., Kamikawa-machi, Kodama-gun, Saitama 367-0241, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Makoto++Kitade">Makoto Kitade</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01085&amp;href=/doi/10.1021%2Facs.jmedchem.8b01085" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 531–551</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 7, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 July 2018</li><li><span class="item_label"><b>Published</b> online</span>7 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 January 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01085</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D531%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTakao%2BUno%252C%2BYuichi%2BKawai%252C%2BSatoshi%2BYamashita%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D2%26contentID%3Dacs.jmedchem.8b01085%26title%3DDiscovery%2Bof%2B3-Ethyl-4-%25283-isopropyl-4-%25284-%25281-methyl-1H-pyrazol-4-yl%2529-1H-imidazol-1-yl%2529-1H-pyrazolo%255B3%252C4-b%255Dpyridin-1-yl%2529benzamide%2B%2528TAS-116%2529%2Bas%2Ba%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BAvailable%2BHSP90%2BInhibitor%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D551%26publicationDate%3DJanuary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01085"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2521</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01085" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Takao&quot;,&quot;last_name&quot;:&quot;Uno&quot;},{&quot;first_name&quot;:&quot;Yuichi&quot;,&quot;last_name&quot;:&quot;Kawai&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Yamashita&quot;},{&quot;first_name&quot;:&quot;Hiromi&quot;,&quot;last_name&quot;:&quot;Oshiumi&quot;},{&quot;first_name&quot;:&quot;Chihoko&quot;,&quot;last_name&quot;:&quot;Yoshimura&quot;},{&quot;first_name&quot;:&quot;Takashi&quot;,&quot;last_name&quot;:&quot;Mizutani&quot;},{&quot;first_name&quot;:&quot;Tatsuya&quot;,&quot;last_name&quot;:&quot;Suzuki&quot;},{&quot;first_name&quot;:&quot;Khoon&quot;,&quot;last_name&quot;:&quot;Tee Chong&quot;},{&quot;first_name&quot;:&quot;Kazuhiko&quot;,&quot;last_name&quot;:&quot;Shigeno&quot;},{&quot;first_name&quot;:&quot;Mitsuru&quot;,&quot;last_name&quot;:&quot;Ohkubo&quot;},{&quot;first_name&quot;:&quot;Yasuo&quot;,&quot;last_name&quot;:&quot;Kodama&quot;},{&quot;first_name&quot;:&quot;Hiromi&quot;,&quot;last_name&quot;:&quot;Muraoka&quot;},{&quot;first_name&quot;:&quot;Kaoru&quot;,&quot;last_name&quot;:&quot;Funabashi&quot;},{&quot;first_name&quot;:&quot;Koichi&quot;,&quot;last_name&quot;:&quot;Takahashi&quot;},{&quot;first_name&quot;:&quot;Shuichi&quot;,&quot;last_name&quot;:&quot;Ohkubo&quot;},{&quot;first_name&quot;:&quot;Makoto&quot;,&quot;last_name&quot;:&quot;Kitade&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;531-551&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01085&quot;},&quot;abstract&quot;:&quot;The molecular chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and survival. A novel series of HSP90 inhibitors were discovered by structure–activity relationship (SAR)-based optimization of an initial hit compound 11a having a 4-(4-(quinolin-3-yl)-1H-indol-1-yl)benzamide structure. The pyrazolo[3,4-b]pyridine derivative, 16e (TAS-116), is a selective inhibitor of HSP90α and HSP90β among the HSP90 family proteins and exhibits oral availability in mice. The X-ray cocrystal structure of the 16e analogue 16d demonstrated a unique binding mode at the N-terminal ATP binding site. Oral administration of 16e demonstrated potent antitumor effects in an NCI-H1975 xenograft mouse model without significant body weight loss.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01085&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01085" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01085&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01085" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01085&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01085" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01085&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01085&amp;href=/doi/10.1021/acs.jmedchem.8b01085" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01085" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01085" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01085%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DUno%26date%3D2019%26atitle%3DDiscovery%2Bof%2B3-Ethyl-4-%25283-isopropyl-4-%25284-%25281-methyl-1H-pyrazol-4-yl%2529-1H-imidazol-1-yl%2529-1H-pyrazolo%255B3%252C4-b%255Dpyridin-1-yl%2529benzamide%2B%2528TAS-116%2529%2Bas%2Ba%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BAvailable%2BHSP90%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D2%26spage%3D531%26epage%3D551%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/jmcmar.2019.62.issue-2/20190124/jmcmar.2019.62.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The molecular chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and survival. A novel series of HSP90 inhibitors were discovered by structure–activity relationship (SAR)-based optimization of an initial hit compound <b>11a</b> having a 4-(4-(quinolin-3-yl)-1<i>H</i>-indol-1-yl)benzamide structure. The pyrazolo[3,4-<i>b</i>]pyridine derivative, <b>16e</b> (TAS-116), is a selective inhibitor of HSP90α and HSP90β among the HSP90 family proteins and exhibits oral availability in mice. The X-ray cocrystal structure of the <b>16e</b> analogue <b>16d</b> demonstrated a unique binding mode at the N-terminal ATP binding site. Oral administration of <b>16e</b> demonstrated potent antitumor effects in an NCI-H1975 xenograft mouse model without significant body weight loss.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Heat shock protein 90 (HSP90) is an adenosine triphosphate (ATP)-dependent molecular chaperone.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> ATP binds to the N-terminal of HSP90, and its hydrolysis facilitates folding of substrate proteins, referred to as HSP90 clients. Inhibition of HSP90 leads to the destabilization of HSP90 clients. HSP90 regulates more than 200 HSP90 clients, including protein kinases, steroid hormone receptors, and transcription factors.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Many of the HSP90 clients are oncoproteins that are involved in tumor development and survival. It is also known that HSP90 is overexpressed in cancer cells and tumor tissues, where it exists in a highly activated state.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5−8)</a> Therefore, HSP90 is considered to play a crucial role in cancer cell growth and survival. On the basis of these findings, ATP-competitive inhibitors acting at the N-terminal of HSP90 have been developed as therapeutic agents for cancer (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Although some HSP90 inhibitors have shown clinical efficacies, potential off-target and/or HSP90-related toxicities have proved problematic.<a onclick="showRef(event, 'ref3 ref4 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref9 ref10">(3,4,9,10)</a> For instance, the first-generation <b>1</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (geldanamycin) analogues, such as <b>2</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (17-AAG), <b>3</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (17-DMAG), and their derivative <b>4</b><a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> (IPI-504), have shown excess hepatotoxicity probably because of their quinone structure.<a onclick="showRef(event, 'ref11 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref11 ref16 ref17">(11,16,17)</a> Although, small second-generation analogues with different structures have shown low hepatotoxicity, some analogues such as purine-based derivative <b>5</b> (BIIB021)<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> exhibited neurological toxicities in a phase I trial.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition, visual disturbances have been observed as an HSP90-related adverse event, although the frequency and degree varied among the compounds.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> For instance, in a phase I trial of <b>7</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (NVP-AUY922) derived from the natural product <b>6</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (radicicol), 43% of patients experienced visual disturbances.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Further, clinical development of <b>8</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (PF-04929113) was discontinued because of ocular toxicity observed in a phase I study.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These results suggest that HSP90 inhibitors with different structures may exhibit an acceptable toxic profile with minimal off-target and HSP90-related toxicities. Alternatively, the use of a C-terminal inhibitor is another strategy to inhibit the HSP90 activity.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The C-terminal contains a nucleotide binding motif and mediates dimerization of HSP90.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It has been reported that N-terminal HSP90 inhibitors induce a heat shock response (HSR) that is potentially involved in drug resistance upon HSP90 inhibition.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> During recent years, several C-terminal HSP90 inhibitors have been discovered. These inhibitors downregulate HSP90 clients and exhibit antiproliferative activity in several cancer cell lines without HSR.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> The clinical evaluation of efficacy and toxicities of this class of compounds is the next challenge.</div><div class="NLM_p">In this milieu, we aimed to develop a novel N-terminal HSP90 inhibitor that is different from the known N-terminal inhibitors, such as <b>1</b>, <b>5</b>, <b>6</b>, and their derivatives, and with superior druggability with respect to target selectivity and pharmacologic and pharmacokinetic (PK) profiles.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of selected small-molecular HSP90 inhibitors <b>1–10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Drug Design Strategies</h3><div class="NLM_p">Several X-ray cocrystal structures of small-molecular HSP90 inhibitors in complex with the N-terminal ATP binding site of human HSP90α have been reported.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> In this study, we designed a novel scaffold as the HSP90 inhibitor using these X-ray cocrystal structures. First, we investigated the X-ray cocrystal structure of the first- and second-generation HSP90 inhibitors to analyze the binding mode to the HSP90 N-terminal ATP binding site.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> These binding modes have been commonly observed, forming a water-mediated hydrogen bond network with Asp93 and Thr184. Furthermore, the second-generation HSP90 inhibitor <b>8</b> analogues<a onclick="showRef(event, 'ref25 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref25 ref32 ref33">(25,32,33)</a> form hydrogen bonds with Tyr139 and Lys58 in addition to the above two common hydrogen bonds. Second, we focused on the structures of <b>8</b><a onclick="showRef(event, 'ref25 ref32'); return false;" href="javascript:void(0);" class="ref ref25 ref32">(25,32)</a> and <b>10</b>,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> which are different from natural products, such as <b>1</b> and <b>6</b> analogues, and purine analogues such as <b>5</b>. However, the X-ray cocrystal structures of <b>8</b> and <b>10</b>, neither with each other nor with HSP90 individually, have been reported. Therefore, we speculated the binding mode of <b>8</b> and <b>10</b> based on the previously reported X-ray cocrystal structure of <b>8</b> analogues (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DOB">3DOB</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MNR">3MNR</a>)<a onclick="showRef(event, 'ref25 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref25 ref32 ref33">(25,32,33)</a> and made a superposition of <b>8</b> and <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A shows the simplified scheme including four key hydrogen bonds of <b>8</b> and <b>10</b> with the HSP90 N-terminal ATP binding site. The speculated binding modes common to <b>8</b> and <b>10</b> are as follows. (i) The carboxamide group of <b>8</b> and pyrrolopyridine group of <b>10</b> act as adenine mimics with the amide group forming hydrogen bonds with Asp93 and Thr184. (ii) The hydroxyl group of the <i>trans</i>-4-hydroxycyclohexylamino moiety forms hydrogen bonds with Lys58. (iii) The carbonyl group of <b>8</b> and the nitrogen atom of 3-quinoline group of <b>10</b> form a hydrogen bond with Tyr139. Through the superposition of the speculated binding mode of compounds <b>8</b> and <b>10</b>, we designed a hybrid compound <b>11a</b> by combining these key hydrogen bonds (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The hybrid compound <b>11a</b> exhibited moderate HSP90 binding inhibitory activity (IC<sub>50</sub> = 9.5 μM). The result encouraged us to develop a novel HSP90 inhibitor. Subsequently, this compound was also reported by Mailliet et al.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Therefore, we devised two drug design strategies aiming to further enhance the HSP90 binding inhibitory activity, as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C. Strategy 1 involved the introduction of a substituent to fill the small hydrophobic pocket and the introduction of a nitrogen atom into the indole core. This strategy was supported by a previous study by Huang et al.,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> which reported that the filling of a small hydrophobic pocket contributed significantly to the HSP90 binding inhibitory activity. Strategy 2 involved exploration of an alternative structure of the 3-quinoline group based on the structure–activity relationship (SAR) study.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Superposition of the speculated binding mode of <b>8</b> and <b>10</b>, a hybridization strategy used to design novel HSP90 inhibitors. (B) Structure and HSP90 binding inhibitory activity of 4-(1<i>H</i>-indol-1-yl)benzamide hit <b>11a</b>. (C) Drug design strategies to enhance the HSP90 binding inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Strategy 1: SAR Exploration of the Indole Core in the Initial Hit <b>11a</b></h3><div class="NLM_p">As mentioned above, the introduction of an alkyl chain at the C-3 position of the indole ring in <b>11a</b> with the intent to fill the small hydrophobic pocket formed by the residues Ala111, Val138, and Tyr139 is likely to enhance the HSP90 binding inhibitory activity. To confirm this hypothesis, we designed compound <b>11b</b>, in which the C-3 position of the indole ring in <b>11a</b> was substituted with a methyl group. In addition, we also designed compound <b>12a</b>, in which a nitrogen atom was introduced into the indole ring of <b>11a</b>. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows the HSP90 inhibitory activity of <b>11a</b> and <b>12a</b>, determined based on the binding of HSP90 by the alphascreen competitive assay. The HSP90 binding inhibitory activity of <b>11b</b> was significantly enhanced by the introduction of a methyl group at the C-3 position of the indole ring. In addition, the indazole derivative <b>12a</b>, which is an N-inserted derivative of <b>11a</b>, also exhibited good HSP90 binding inhibitory activity. On the basis of these results, we aimed to further enhance the HSP90 binding inhibitory activity and investigated the effect of introduction of various alkyl chains at the C-3 position in the indazole derivative <b>12a</b>. Most alkyl-substituted indazole derivatives showed good HSP90 binding inhibitory activity with IC<sub>50</sub> values less than 100 nM. Among them, <b>12c</b> with an isopropyl group at the C-3 position in <b>12a</b> presented the highest affinity toward HSP90. On the basis of its potent HSP90 binding inhibitory activity, we selected the 3-isopropyl derivative <b>12c</b> as the hit compound for further optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Data of Compounds with 3-Alkyl and Nitrogen Substitution at the Indole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0012.gif" alt="" id="GRAPHIC-d7e687-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char="±">HSP90α IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">9524 ± 4870</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">585 ± 85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">365 ± 64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="char" char="±">67 ± 16</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the alphascreen competitive assay. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div></div></div><div class="NLM_p">At this point of the study, the 3-isopropyl derivative <b>12c</b> represented the most advanced analogue and demonstrated potent HSP90 binding inhibitory and tumor cell growth inhibitory activities in SK-BR-3 cells (HER2-overexpressing human breast cancer cell line); however, it evidently exhibited hERG inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Therefore, with the aim to lower the hERG inhibitory activity of <b>12c</b>, we examined the reduction in lipophilicity by introducing a nitrogen atom into the indazole ring. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> shows the HSP90 binding inhibitory and tumor cell growth inhibitory activities of <b>12c</b> in SK-BR-3 cells, as well as its in vitro hERG inhibitory activity. Compound <b>13a</b>, in which a nitrogen atom was inserted at the X position of indazole in <b>12c</b>, showed highly attenuated HSP90 binding and cellular activities in SK-BR-3 cells compared with those of <b>12c</b>. In addition, compound <b>13b</b>, in which a nitrogen atom was inserted at the Y position, did not exhibit lowered lipophilicity and hERG inhibition. Furthermore, <b>13b</b> also exhibited significantly attenuated cellular activity in SK-BR-3 cells. On the contrary, compound <b>13c</b>, in which a nitrogen atom was inserted at the Z position, showed equally potent HSP90 binding inhibitory and cellular activities in SK-BR-3 cells when compared with those of <b>12c</b>. In addition, the pyrazolo[3,4-<i>b</i>]pyridine derivative <b>13c</b> showed lower hERG inhibitory activity than that of indazole <b>12c</b>. Further, nitrogen substitution at the Z position lowered the log <i>D</i> value of the resulting pyrazolo[3,4-<i>b</i>]pyridine analogue. On the basis of these results, we decided to perform SAR study of the pyrazolo[3,4-<i>b</i>]pyridine <b>13c</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Data of Compounds with Nitrogen Substitution at the Indazole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0013.gif" alt="" id="GRAPHIC-d7e875-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char="±">HSP90α IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">SK-BR-3 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">log <i>D</i><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">hERG % Inhibition (at 10 μM)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char="±">67 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char="±">470 ± 55</td><td class="colsep0 rowsep0" align="char" char="±">1721 ± 351</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">473 ± 430</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">57 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char="±">58 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">54 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the alphascreen competitive assay. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">SK-BR-3 cells were cultured with the compounds for 72 h. Cell survival was then measured and the IC<sub>50</sub> value was calculated. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">log <i>D</i> value at pH 7.4.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The log <i>D</i> values (nM) are represented as mean ± SD (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">The hERG inhibitory activity of compounds at a concentration of 10 μM. The values of hERG percent inhibition are shown as mean ± SE (<i>n</i> = 3).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Strategy 2: SAR Exploration of an Alternative Structure of the 3-Quinoline Group</h3><div class="NLM_p">To further enhance the HSP90 binding and cellular activities, we examined the effect of introduction of other C-4 substituents in place of the 3-quinoline group. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows the HSP90 binding inhibitory and growth inhibitory activities in SK-BR-3 cells. Naphthalene <b>14a</b> and phenyl <b>14b</b>, in which the nitrogen atom at the N-3 position of the 3-quinoline group was removed, significantly decreased the HSP90 binding and cellular activities. The results suggested that the nitrogen atom in the 3-quinoline group is essential for the formation of hydrogen bond with Tyr139, similar to that of our speculated binding mode (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Therefore, we examined the effect of introduction of various substituted pyridine groups. 3-Pyridine <b>14c</b> and its 6- and 5-methoxy substituted derivatives <b>14d</b> and <b>14e</b> and other bicyclic 3-pyridine derivatives <b>14f</b> and <b>14g</b>, other than the 3-quinoline group, tended to exhibit reduced potencies against HSP90 binding and tumor cell growth. On the contrary, thiophene <b>14h</b> and furan <b>14i</b> with sulfur and oxygen atoms at the C-4 position, respectively, did not exhibit measurable HSP90 binding and cellular activities. In contrast, imidazole <b>15a</b> showed marginally higher inhibitory activity against HSP90 binding than that by <b>14h</b> and <b>14i</b>. In addition, compound <b>15b</b> with a phenyl group at the C-4 position of imidazole showed significantly enhanced inhibitory activity against HSP90 binding and tumor cell growth. On the basis of these findings, the 4-phenylimidazole derivative <b>15b</b> was selected for further optimization as a candidate with an alternative structure of the 3-quinoline group.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Preliminary Structure and Biological Data of 3-Quinoline Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0014.gif" alt="" id="GRAPHIC-d7e1166-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the alphascreen competitive assay. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">SK-BR-3 cells were cultured with the compounds for 72 h. Cell survival was then measured and the IC<sub>50</sub> value was calculated. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Exploration of an Alternative Structure of the 3-Quinoline Group</h3><div class="NLM_p">To further enhance the HSP90 binding inhibitory and growth inhibitory activities in SK-BR-3 cells, we examined the effect of introduction of other C-4 substituents in place of the phenyl group in <b>15b</b>. <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> shows HSP90 binding inhibitory and growth inhibitory activities in SK-BR-3 cells. The 4-methoxy phenyl derivative <b>15c</b> retained the HSP90 binding and cellular activities, but the 4-phenoxyphenyl derivative <b>15d</b> showed reduced potencies against HSP90 binding and tumor cell growth. Various heterocyclic derivatives <b>15e–k</b> have a tendency to increase the inhibitory activity against HSP90 binding and tumor cell growth. Among them, compound <b>15k</b> with a methyl pyrazole group showed the most potent growth inhibitory activity in SK-BR-3 cells. Furthermore, <b>15k</b> showed more potent inhibitory activity against HSP90 binding and tumor cell growth than those of the 3-quinoline derivative <b>13c</b>. With strategies 1 and 2, we succeeded in identifying the most potent methyl pyrazole derivative <b>15k</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Data of Compounds with 4-Substitution at the Imidazole Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0016.gif" alt="" id="GRAPHIC-d7e1234-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0017.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the alphascreen competitive assay. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">SK-BR-3 cells were cultured with the compounds for 72 h. Cell survival was then measured and the IC<sub>50</sub> value was calculated. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Optimization of the Benzamide Group</h3><div class="NLM_p">At this point of the study, the methyl pyrazole derivative <b>15k</b> represented the most advanced analogue and demonstrated potent inhibitory activity against HSP90 binding and tumor cell growth. However, compound <b>15k</b> did not exhibit measurable oral exposure in mice (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), although it had good metabolic stability (data not shown). This suggested that the low oral exposure in mice might be attributed to the large molecular weight (MW) and topological polar surface area (TPSA), high log <i>D</i> value, and low solubility at neutral pH (pH 7.4). Therefore, to improve its oral exposure in mice, we examined the optimization of benzamide substituents to reduce MW, TPSA, and log <i>D</i> value and to improve solubility at pH 7.4. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> shows the HSP90 binding inhibitory and growth inhibitory activities in SK-BR-3 cells and also their MW, TPSA, log <i>D</i>, solubility at pH 7.4, and oral exposure in mice [AUC<sub>0-6h</sub> (μM × h)]. Although the cellular activity of compound <b>16a</b>, without the 4-aminocyclohexanol group, was highly attenuated, it showed a certain level of oral exposure in mice. The result suggested that the reduction in MW, TPSA, and log <i>D</i> value of <b>16a</b> might be important for improving oral exposure. Compound <b>16b</b>, having a 4-aminomethyl group with minimized 4-aminocyclohexanol structure, showed attenuated cellular activity when compared with that of <b>15k</b>. On the contrary, <b>16c</b> having a 3-aminomethyl group at R<sub>3</sub> position showed HSP90 binding inhibitory activity similar to that of <b>15k</b>, and the cellular activity also increased when compared with that of <b>16a</b> and <b>16b</b>. Furthermore, by shifting the substitution position from C-4 to C-3, the log <i>D</i> value of <b>16c</b> decreased significantly. In addition, the oral exposure of <b>16c</b> in mice was similar to that of compound <b>16a</b>. On the basis of these results, we successfully acquired a favorable derivative with oral exposure in mice by minimizing the 4-aminocyclohexanol group, thus reducing the MW, TPSA, and log <i>D</i> value. In addition, these results suggested that the position of substitution is better in R<sub>3</sub> than in R<sub>4</sub>. To further improve their oral exposure in mice, we examined the introduction of other R<sub>3</sub> substituents in place of the 3-aminomethyl group. Compound <b>16d</b>, in which the aminomethyl group was converted to methyl group as the smallest alkyl group, with reduced TPSA and an increased log <i>D</i> value, showed attenuated inhibitory activity against HSP90 binding and tumor cell growth when compared with those of <b>16c</b>. In contrast, the solubility of <b>16d</b> at pH 7.4 was highly improved and its oral exposure in mice was also highly improved when compared with those of <b>16c</b>. Compound <b>16e</b> with ethyl group showed increased inhibitory activity against HSP90 binding and tumor cell growth. In particular, the oral exposure of <b>16e</b> in mice was further improved when compared with that of <b>16d</b>. On the basis of these results, we succeeded in obtaining <b>16e</b> with favorable oral exposure in mice by optimizing the balance of MW, TPSA, and log <i>D</i> value of <b>15k</b> and improving the solubility of <b>15k</b> at pH 7.4. These results suggest that the 4-aminocyclohexanol group in the methylpyrazole derivative <b>15k</b> has a negligible effect against the HSP90 binding inhibitory activity when compared with that of <b>16e</b>. That is, it suggests that the contribution of interactions, which might be formed by the 4-(1<i>H</i>-imidazol-4-yl)-1-methyl-1<i>H</i>-pyrazole and 3-ethylbenzamide groups of <b>16e</b>, is more important for the HSP90 binding inhibitory activity. In addition, these results also suggest that the solubility at pH 7.4 greatly affects oral exposure in mice.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biological Data of Compounds with Substitution at the Benzamide Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0018.gif" alt="" id="GRAPHIC-d7e1411-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0019.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">log <i>D</i> value at pH 7.4.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The log <i>D</i> values (nM) are shown as mean ± SD (<i>n</i> = 3).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Solubility at pH 7.4.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Solubility (μM) is shown as mean ± SD (<i>n</i> = 3).</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the alphascreen competitive assay. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">SK-BR-3 cells were cultured with the compounds for 72 h. Cell survival was then measured and the IC<sub>50</sub> value was calculated. The IC<sub>50</sub> values (nM) are shown as mean ± SE (<i>n</i> = 3).</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Balb/cA male mice (<i>n</i> = 2) were orally administered at a dose of 50 mg/kg.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Not detected at all time points (lower limit of quantification = 0.03 μM).</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">Not tested.</p></div></div><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Structural Analysis and Discussion of Compound <b>16d</b></h3><div class="NLM_p">To rationalize the structural basis for the potent HSP90 binding affinity of 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide <b>16e</b>,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> we tried to acquire its X-ray cocrystal structure in complex with the N-terminal ATP binding site of human HSP90α. However, we were unable to obtain it. Therefore, we determined the X-ray cocrystal structure of <b>16d</b> as <b>16e</b> (TAS-116) analogue in complex with the N-terminal ATP binding site of human HSP90α (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). As expected, the carboxamide group behaved as an adenine mimic and formed a water-mediated hydrogen bond network with Asp93 and Thr184. The phenyl group is sandwiched between Met98 and Asn51. This suggests that the alkyl group in the benzamide ring at C-3 position might lead to an appropriate twist conformation against the pyrazolo[3,4-<i>b</i>]pyridine ring. The pyrazolo[3,4-<i>b</i>]pyridine core occupies a hydrophobic region formed by Leu107, Phe138, and Trp162. In addition, the isopropyl group at the C-3 position in the pyrazolo[3,4-<i>b</i>]pyridine core fills the small hydrophobic pocket formed by Ala111, Tyr139, and Val136. This helical specific pocket formed by the rearrangement of Ile110-Gly114 residues has also been previously observed in other HSP90 inhibitors.<a onclick="showRef(event, 'ref30 ref39'); return false;" href="javascript:void(0);" class="ref ref30 ref39">(30,39)</a> Furthermore, the nitrogen atom at the N-2 position of pyrazolo[3,4-<i>b</i>]pyridine forms a water-mediated hydrogen bond network with Asn51. As expected, the nitrogen atom at the N-3 position of the imidazole group at the C-4 position of pyrazolo[3,4-<i>b</i>]pyridine forms a hydrogen bond with Tyr139. Moreover, the methylpyrazole group introduced at the imidazole C-4 position occupies a hydrophobic subpocket with Phe22, Ile26, Ile104, Gly108, and Phe170 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). These results suggest that the enhancement of the HSP90 binding inhibitory activity and the binding mode of <b>16d</b> observed by X-ray cocrystal structure analysis are correlated. On the basis of these results, the <b>16e</b> (TAS-116) analogue <b>16d</b> was considered to have a unique binding mode that has not been observed in the typical first- and second-generation HSP90 inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The hydrogen bond with Tyr139 and water-mediated hydrogen bond network with Gln23 were observed in other HSP90 inhibitors by Vallée et al.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Cocrystal structure of compound <b>16d</b> bound to the N-terminal ATP binding site of human HSP90. (B) Molecular surface representation of the cocrystal structure of compound <b>16d</b> in hydrophobic (red) to nonhydrophobic (white) gradient (PDB:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of its promising HSP90 inhibitory activity and oral availability profile, the in vitro profile and PK properties of compound <b>16e</b> were characterized.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Compound <b>16e</b> selectively binds to HSP90α/β than to the highly homologous HSP90 family proteins GRP94 and TRAP1, as determined by the fluorescence polarization competitive binding assay with geldanamycin-fluorescein isothiocyanate.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> In addition, <b>16e</b> did not inhibit other ATPases, such as HSP70 and HSP48, among different protein kinases tested. Regarding the toxicity of <b>16e</b> toward noncancer cell lines, the IC<sub>50</sub> value of normal human stromal cells was more than 5 μM.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Furthermore, <b>16e</b> demonstrated good metabolic stability in isolated hepatocytes of rodent and nonrodent species (data not shown). Moreover, <b>16e</b> did not inhibit the major human cytochrome P450 enzyme in vitro at in vivo <i>e</i>ffective concentrations of <b>16e</b>. It also showed good bioavailability in rodent and nonrodent species. Further, <b>16e</b> was distributed less in the eye tissues than in the plasma of rats; consequently, <b>16e</b> did not cause any detectable ocular toxicity, while <b>7</b> induced photoreceptor cell death in rats.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These results suggest that the novel orally available HSP90α/β selective inhibitor <b>16e</b> has a favorable profile as a potential clinical candidate.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vivo Pharmacology of <b>16e</b></h3><div class="NLM_p">On the basis of the favorable in vitro profiles and PK properties, compound <b>16e</b> was further evaluated in a human tumor xenograft model. Shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A is the in vivo antitumor activity of <b>16e</b> in an NCI-H1975 (EGFR L858R/T790M)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> xenograft model of mice, and the mean body weight change (BWC) (%) is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B. Reflecting its potent HSP90 inhibitory activity, compound <b>16e</b> exhibited potent efficacy (tumor/control ratio [T/C]: 27%) after the daily oral administration of <b>16e</b> for 14 days at a dose of 10 mg/kg without significant body weight loss in mice. The level of tumor proteins at 12 h after the last administration of <b>16e</b> for 3 days at a dose of 10.0 mg/kg, determined by western blot analysis, is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C. Compound <b>16e</b> induced a marked decrease in the level of EGFR, thus inhibiting downstream signaling, such as phospho-AKT, phospho-RPS6, and phospho-MAPK 1/3. These results suggest that <b>16e</b> has antitumor effects in an EGFR-driven tumor model. In addition, these results suggested that <b>16e</b> demonstrates its antitumor effects by decreasing the level of mutant EGFR, thereby inhibiting the mutant EGFR-activated AKT and MAPK 1/3 signaling pathways, which are involved in the survival and proliferation of tumors. Therefore, <b>16e</b> might be used to develop an effective chemotherapy for HSP90 client-driven cancer such as lung cancer-expressing mutant EGFR.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Antitumor efficacy of <b>16e</b> (TAS-116) in athymic nude mice bearing NCI-H1975 human lung cancer xenografts. (B) BWC of the tumor-bearing mice administered <b>16e</b> (TAS-116). (C) Pharmacodynamic activity of <b>16e</b> (TAS-116) in the NCI-H1975 tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">The initial hit compound <b>11a</b> and 3-substitued indole derivative <b>11b</b> were synthesized by the method shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Commercially available 4-bromoindole <b>17a–b</b> were reacted with 3-quinolineboronic acid under the Suzuki−Miyaura cross-coupling condition<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> involving catalytic tetrakis(triphenylphosphine)palladium (0) (Pd(PPh<sub>3</sub>)<sub>4</sub>) and sodium carbonate (Na<sub>2</sub>CO<sub>3</sub>) in 1,2-dimethoxyethane (DME) and H<sub>2</sub>O at 100 °C for 14 h to obtain substituted indoles <b>18a–b</b>, with a yield of 50 and 87%, respectively. Copper-catalyzed cross-coupling reaction of intermediates <b>18a–b</b> with 2-amino-substituted benzonitrile (<b>19</b>) was carried out in the presence of catalytic copper(I) iodide (CuI), <i>N</i>,<i>N</i>′-dimethylethylene diamine (DMEDA), and cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>) in 1,4-dioxane at 110 °C for 14 h<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> to obtain the corresponding benzonitriles <b>20a–b</b>, with a good yield (95 and 96%, respectively). The hydrolysis of the obtained benzonitriles <b>20a–b</b> with 4 M sodium hydroxide (NaOH) and 30% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in a mixture of dimethyl sulfoxide (DMSO)<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and ethanol (EtOH) resulted in the desired benzamide compounds <b>11a–b</b>, with a yield of 65 and 97%, respectively.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Indole Derivatives <b>11a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-quinolineboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, 100 °C, 14 h, <b>18a</b>: 50%, <b>18b</b>: 87%; (b) <b>19</b>, CuI, DMEDA, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 14 h, <b>20a</b>: 95%, <b>20b</b>: 96%; and (c) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C-rt, 2.5 h, <b>11a</b>: 65%, <b>11b</b>: 97%.</p></p></figure><div class="NLM_p">To examine the substitution effects of the nitrogen atom at the C-6 position (<b>12a</b>) in <b>11a</b> and the introduction of methyl (<b>12b</b>) and isopropyl (<b>12c</b>) moieties as representative alkyl substituents at the C-3 position, the compounds were synthesized as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The synthesis of derivatives <b>12a–c</b> commenced with 3-quinolineboronic acid under the Suzuki−Miyaura cross-coupling condition<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> involving catalytic [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>) and Na<sub>2</sub>CO<sub>3</sub> in 1,4-dioxane and H<sub>2</sub>O at 100 °C for 3 h to obtain 3-quinoline-substituted indazoles <b>22a–c</b> (56–94%). Copper-catalyzed cross-coupling reaction of the intermediates <b>22a–c</b> with 2-amino-substituted benzonitrile (<b>19</b>) was carried out in the presence of catalytic CuI, DMEDA, and tripotassium phosphate (K<sub>3</sub>PO<sub>4</sub>) as a base in 1,4-dioxane at 110 °C for 24 h<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> to obtain the corresponding benzonitriles <b>23a–c</b> (64–98%). The hydrolysis of the obtained benzonitriles <b>23a–c</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>12a–c</b> (66–84%).</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Indazole Derivatives <b>12a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-quinolineboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C, 3 h, 56%–94%.; (b) <b>19</b>, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 64%–98%; and (c) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 66–84%.</p></p></figure><div class="NLM_p">The 1<i>H</i>-pyrazolopyridine derivatives <b>13a–c</b> with substitution of the nitrogen atom in <b>12c</b> were synthesized as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Lithiation of commercially available 2,4-dichloropyridine (<b>24a</b>), 3,5-dibromopyridine (<b>24b</b>), and 2-fluoro-3-iodopyridine (<b>24c</b>) was carried out in the presence of lithium diisopropylamide (LDA) in tetrahydrofuran (THF) at −78 °C, followed by alkylation with isobutyl anhydride to obtain 1-(2,4-dihalopyridin-3-yl)-2-methylpropan-1-one intermediates. Finally, intramolecular cyclization with hydrazine monohydrate was carried out to obtain C3-isopropyl-substituted 1<i>H</i>-pyrazolopyridines (<b>25a–c</b>) (17–42%). Compound <b>25c</b> was obtained by the halogen dance reaction<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> of <b>24c</b>. The obtained 4-halo-3-isopropyl-1<i>H</i>-pyrazolopyridines (<b>25a–c</b>) were reacted with 3-quinolineboronic acid under the Suzuki−Miyaura cross-coupling condition<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> involving catalytic Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> and Na<sub>2</sub>CO<sub>3</sub> in 1,4-dioxane and H<sub>2</sub>O at 100 °C to obtain 3-quinoline-substituted pyrazolopyridines (<b>26a–c</b>) (76–92%). In the next step, copper-catalyzed cross-coupling reaction of 3-quinoline-substituted pyrazolopyridines <b>26a–c</b> with 2-amino-substituted benzonitrile (<b>19</b>) was carried out in the presence of catalytic CuI, DMEDA, and K<sub>3</sub>PO<sub>4</sub> in 1,4-dioxane at 110 °C for 24 h<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> to obtain the corresponding benzonitriles <b>27a–c</b> (81–95%). The hydrolysis of the obtained benzonitriles <b>27a–c</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>13a–c</b> (28–91%).</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrazolopyridine Derivatives <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <b>24a–c</b>, DIPA, <i>n</i>-BuLi, THF, −78 °C, 15 min; (2) isobutylanhydride, −78 °C, 1 h; (3) N<sub>2</sub>H<sub>4</sub> aq, 60–110 °C, 1–24 h, 17–42%; (d) 3-quinolineboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C, 3 h, 76–97%; (d) <b>19</b>, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 81%–95%; (e) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 28–91%.</p></p></figure><div class="NLM_p">We then focused on the 3-quinoline group of compound <b>13c</b> at the C-4 position. We selected a 3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine in the terminal core structure and carried out further optimization of the 3-quinoline group at the C-4 position.</div><div class="NLM_p">The synthesis of the C-4 aryl derivatives <b>14a–i</b> is shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The obtained intermediate <b>25c</b> was treated with sodium hydride (NaH) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) and then coupled with 2,4-difluorobenzonitrile at 60 °C to obtain 2-fluorobenzonitrile <b>28</b> as a mixture of the desired product and C-2-substituted regioisomer <b>28a</b>. The obtained mixture of <b>28</b> and <b>28a</b> was reacted with <i>trans</i>-4-aminocyclohexanol in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) in DMSO to obtain the desired intermediate <b>29</b> by column chromatography on silica gel with 15% yield in two steps. In the next step, Suzuki−Miyaura cross-coupling reaction<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> of <b>29</b> with various boronic acids or boronic acid pinacol esters mediated by catalytic Pd(PPh<sub>3</sub>)<sub>4</sub> and Na<sub>2</sub>CO<sub>3</sub> in DME and H<sub>2</sub>O was carried out at 100 °C for 4 h to obtain 4-substituted benzonitriles <b>30a–i</b> (82%-quant.). Finally, the hydrolysis of the obtained benzonitriles <b>30a–i</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>14a–i</b> (75–97%).<named-content content-type="anchor" rid="sch5" type="simple"></named-content></div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of pyrazolo[3,4-<i>b</i>]pyridine Derivatives <b>14a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,4-difluorobenzonitrile, NaH, DMF, 60 °C, 1 h; (b) <i>trans</i>-4-aminocyclohexanol, DIPEA, DMSO, 125–150 °C, 8 h, 15%, 2 steps; (c) boronic acids or boronic acid pinacol esters, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, 100 °C, 4 h, 82%-quant.; and (d) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, rt, 30 min, 75–97%.</p></p></figure><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Imidazole Derivatives <b>15a–k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) imidazoles, CuO nanopowder, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 20 h, 45–90% and (b) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 50%-quant. The synthesis of the 4-aryl-1<i>H</i>-imidazole derivatives <b>15a–k</b> is shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Copper-mediated cross-coupling reaction of the obtained intermediate <b>29</b> with various 4-aryl-1<i>H</i>-imidazoles mediated by copper(II) oxide (CuO) nanopowder under basic conditions using potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) in DMF was carried out at 120 °C for 20 h<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> to obtain 4-substituted benzonitriles <b>31a–k</b> (45–90%). Finally, the hydrolysis of the obtained benzonitriles <b>31a–k</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>15a–k</b> (50%-quant.).</p></p></figure><div class="NLM_p">To examine the substituent effects on the benzamide group, 2- or 3-substituted benzamide derivatives (<b>16a–e</b>), other than the 4-aminocyclohexanol group, were synthesized by the method shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. N-Protection of the obtained intermediate <b>25c</b> with <i>p</i>-methoxybenzylchloride (PMBCl) in the presence of NaH in DMF at room temperature for 1 h yielded PMB-protected pyrazolopyridine <b>32</b> with 91% yield. Copper-catalyzed cross-coupling reaction of the obtained compound <b>32</b> and 4-(1<i>H</i>-imidazol-4-yl)-1-methyl-1<i>H</i>-pyrazole dihydrochloride (<b>33</b>) was carried out in the presence of catalytic copper(I) oxide (Cu<sub>2</sub>O), 4,7-dimethoxy-1,10-phenanthroline, polyethylene glycol (PEG), and Cs<sub>2</sub>CO<sub>3</sub> in DMSO at 110 °C for 24 h<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> to obtain the desired 4-(1<i>H</i>-imidazol-4-yl)-1-methyl-1<i>H</i>-pyrazole intermediate (<b>34</b>), with a yield of 62%. The PMB group of <b>34</b> was treated with TFA and anisole<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> to obtain pyrazolopyridine intermediate <b>35</b>, with a yield of 88%. The condensation of intermediate <b>37</b> with commercially available 4-fluorobenzonitriles was carried out in the presence of Cs<sub>2</sub>CO<sub>3</sub> in DMF at 50–120 °C for 0.5–14 h to obtain 3-substituted benzonitriles <b>36a</b>, <b>36d</b>, and <b>36e</b> (81–91%). Copper-catalyzed cross-coupling reaction of the intermediate <b>37</b> with 4-iodo-2-(methylamino)benzonitrile was carried out in the presence of catalytic CuI, DMEDA, and K<sub>3</sub>PO<sub>4</sub> as a base in 1,4-dioxane at 110 °C for 24 h<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> to obtain the corresponding benzonitrile <b>36b</b> (36%). Finally, the hydrolysis of the obtained benzonitriles <b>36a</b>, <b>36b</b>, <b>36d</b>, and <b>36e</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>16a</b>, <b>16b</b>, <b>16d</b>, and <b>16e</b> (45–95%), respectively.</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Introduction of Various Benzamide Groups to the 1<i>H</i>-imidazole-1-yl-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine Scaffold <b>16a</b>, <b>16b</b>, <b>16d</b>, and <b>16e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PMBCl, NaH, DMF, 0 °C to rt, 2 h, 91%; (b) <b>33</b>, Cu<sub>2</sub>O, 4,7-dimethoxy-1,10-phenanthroline, Cs<sub>2</sub>CO<sub>3</sub>, PEG, DMSO, 110 °C, 24 h, 62%; (c) TFA, anisole, reflux, 5 h, 88%; (d) benzonitriles, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50–120 °C, 0.5–14 h, 81–91%; (e) 4-iodo-2-(methylamino)benzonitrile, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 36%; and (f) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 45–95%.</p></p></figure><div class="NLM_p">The preparation of the 3-amino-substituted derivative <b>16c</b> has been summarized in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. The condensation of intermediate <b>35</b> with commercially available 4-chrolo-3-nitrobenzonitrile was carried out in the presence of Cs<sub>2</sub>CO<sub>3</sub> in DMF at 80 °C for 14 h to obtain 3-nitrobenznitrile <b>37</b> (70%). The reduction of the nitro group with iron powder and ammonium chloride (NH<sub>4</sub>Cl) in THF, EtOH, and H<sub>2</sub>O at 80 °C for 4 h<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> yielded 39% of 3-amino benzonitrile <b>38</b>. The monomethylation of 3-amino benzonitrile <b>38</b> was carried out in the presence of copper(II) acetate (Cu(OAc)<sub>2</sub>), methylboronic acid, and pyridine in 1,4-dioxane at 120 °C for 2 h<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> to obtain 3-methylamino benzonitrile <b>39</b> (38%). Finally, the hydrolysis of the obtained benzonitrile <b>39</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compound <b>16c</b> with 83% yield.</div><figure id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Introduction of the 3-(Methylamino)benzamide Group to the 1<i>H</i>-Imidazole-1-yl-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine Scaffold <b>16c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-3-nitrobenzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 14 h, 70%; (b) Fe, NH<sub>4</sub>Cl, THF, EtOH, H<sub>2</sub>O, 80 °C, 4 h, 39%; (c) methylboronic acid, Cu(OAc)<sub>2</sub>(II), pyridine, 1,4-dioxane, 120 °C, 2 h, 38%; and (d) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C, 2 h, 83%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>16e</b> (TAS-116), a potent and highly selective HSP90α/β inhibitor with a unique binding mode, was discovered by SAR-based optimization of an initial hit compound <b>11a</b>. The main findings of this study are as follows. (i) The introduction of an isopropyl group at the C-3 position of the initial hit <b>11a</b> significantly increased the HSP90 binding inhibitory activity. (ii) The introduction of a nitrogen atom at the C-2 position of the initial hit <b>11a</b> also significantly increased the HSP90 binding inhibitory activity. (iii) The introduction of a nitrogen atom into the indazole ring of <b>12c</b> resulted in lower lipophilicity and hERG inhibitory activity than those by <b>12c</b>. (iv) The discovery of 4-(1<i>H</i>-imidazol-4-yl)-1-methyl-1<i>H</i>-pyrazole group, as an alternative structure of the 3-quinoline group, maximized the HSP90 inhibitory activity and tumor cell growth inhibitory activity in SK-BR-3 cells. (v) Compound <b>16e</b> with favorable oral exposure in mice was discovered by optimizing the balance among the MW, TPSA, and log <i>D</i> value and by improving the solubility of <b>15k</b> at pH 7.4. (vi) The X-ray cocrystal structure analysis of TAS-116 analogue <b>16d</b> demonstrated a unique binding mode.</div><div class="NLM_p last">Compound <b>16e</b> also exhibited good oral absorption in mice. The oral administration of <b>16e</b> on a daily basis was well tolerated, resulting in potent antitumor effects by decreasing the amount of mutant EGFR in the NCI-H1975 (human lung cancer) xenograft model. Phase II clinical trial to evaluate the safety and efficacy of <b>16e</b> (TAS-116) is in progress.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Measurement of the HSP90-Binding Activity</h3><div class="NLM_p last">The HSP90-binding activity was measured by the AlphaScreen competitive assay. His-tagged HSP90α NTD was added to a 384-well plate containing the test compounds. After reaction at room temperature for 2 h, biotin-labeled geldanamycin was added, and the mixture was incubated for a further 1 h. The bead mixture containing both nickel-chelated acceptor beads and streptavidin-coated donor beads was added. After incubation for 1 h in dark, the assay plate was measured in a PerkinElmer EnVision plate reader (PerkinElmer Corporation, Waltham, MA, USA). The IC<sub>50</sub> value (nM), the concentration of the inhibitor with 50% displacement rate, was obtained from the concentration displacement rate curve.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Measurement of Cell Growth Inhibition</h3><div class="NLM_p last">Cell growth was measured using the CellTiter-Glo 2.0 Assay kit (Promega Corporation, Madison, WI, USA). SK-BR-3 cells (HTB-30) purchased from the American Type Culture Collection (Manassas, VA, USA) were seeded in a 96-well plate at a concentration of 2500 cells/well. The cells were cultured in a 5% CO<sub>2</sub> incubator at 37 °C overnight, and the compounds were then added to the plate and incubated for further 72 h. Luminescence (CPS, count per second) was measured with a microplate reader. The ratio of treatment to control [T/C (%)] was determined using the following equation. The IC<sub>50</sub> value (nM), the concentration that exerted 50% growth inhibitory rate compared with that of the control group, was calculated from T/C (%). In this assay system, the IC<sub>50</sub> value of 17-AAG, a standard of HSP90 inhibitor, was 10 ± 1 nM.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_m001.gif" alt="" id="_i28" /></img></span>control: without compound (DMSO treatment).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> hERG Binding Assay</h3><div class="NLM_p last">The hERG inhibitory activity (% inhibition at 10 μM compound concentration) was measured using the Predictor hERG fluorescence polarization assay kit (PV5365, Invitrogen), according to the protocol of the manufacturer.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Measurement of log <i>D</i> Values at pH 7.4</h3><div class="NLM_p last">log <i>D</i><sub>7.4</sub>, which is the partition coefficient of the compounds between 1-octanol and aqueous buffer at pH 7.4, was measured by chromatography, following a previously published method.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A Waters 2690 HPLC system with a quaternary pump (Waters, Milford, MA, USA), a PAL liquid handler (CTC Analytics, Zwingen, Switzerland), and an SQ quadrupole mass detector (Waters) equipped with electrospray ionization was used.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Measurement of Solubility at pH 7.4</h3><div class="NLM_p last">Solubility at pH 7.4 was measured by chromatography, following a previously published method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A Waters ACQUITY UPLC system with a binary pump, plate autosampler, thermostated column compartment, sample organizer, and an SQ quadrupole mass detector (Waters, Milford, MA, USA) equipped with electrospray ionization was used.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Cloning, Expression, and Purification of Recombinant Human Hsp90α</h3><div class="NLM_p last">The cDNA of NTD of human Hsp90α (a.a. 1–236) was subcloned into the expression vector pET19b. The construct was then transformed in <i>Escherichia coli</i> BL21 (DE3) cells (Novagen, Madison, WI, USA) in Luria broth at 37 °C. Protein expression was induced with 0.01 mM isopropyl-β-<span class="smallcaps smallerCapital">d</span>-thiogalactopyranoside (IPTG) at an optical density of 0.6 at 595 nm. The cell pellet was resuspended in ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1 mM dithiothreitol (DTT). After sonication, the disrupted debris was removed by centrifugation. The supernatant was applied on to Ni-NTA affinity gels, and the 6 × His-Tag was removed by digestion with enterokinase in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1 mM DTT for 12 h. The protein solution used for crystallization was gel-filtrated in a buffer containing 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, and 1 mM DTT on a preparative grade Superdex75 column (GE Healthcare Life Sciences, Freiburg, Germany).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cocrystal Structural Analysis</h3><div class="NLM_p last">The crystals of NTD of human Hsp90α in complex with compound <b>16d</b> were grown by the hanging-drop vapor diffusion method in a solution of PEG6000, 200 mmol/L NaCl, and 50 mmol/L Tris (pH 7.5) at 4 °C. The protein was concentrated to 25 mg/mL and 2 mmol/L compound was added. For data collection, the crystals were transferred to drops containing an equivalent amount of mother liquor with 25% glycerol. The diffraction data were collected in-house using a Rigaku MicroMax-007 generator with an RAXIS IV++ imaging plate detector. The data were processed using the program iMOSFLM<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> from the CCP4 suite.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The space group was <i>P</i>2<sub>1</sub>. The structure of NTD of human Hsp90α complexed with the inhibitor was determined by molecular replacement using the program MOLREP.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The search model was based on NTD of Hsp90 structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WQ9">3WQ9</a>). The structure of NTD of human Hsp90α in complex with compound <b>16d</b> was refined using REFMAC5.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Manual rebuilding of the models and electron density map interpretation were carried out using COOT.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The final model had the following <i>R</i> values: <i>R</i><sub>work</sub> = 20.7% and <i>R</i><sub>free</sub> = 25.7%. A summary of statistics from the data collection and refinement is given in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_001.pdf" class="ext-link">Table S1</a>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Animal Experiments</h3><div class="NLM_p last">All animal experiments were performed with the approval of the Institutional Animal Care and Use Committee of the Taiho Pharmaceutical Co. Ltd. and carried out according to the Guidelines for Animal Experiments of the Taiho Pharmaceutical Co. Ltd.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> PK Analysis</h3><div class="NLM_p last">The experiments were conducted with 8–11 week old male Balb/c-A mice. Five test compounds were orally administered to the mice at a dose of 50 mg/kg in a vehicle containing 0.5% (w/v) hydroxypropyl methylcellulose (Metolose 60SH-50; Shin-Etsu Chemical Co. Ltd., Tokyo, Japan). Blood samples were collected over a 6 h period after treatment. After centrifugation, the plasma concentration of five test compounds was determined by liquid chromatography-tandem mass spectrometry. The PK parameters were calculated by the noncompartmental methods using Phoenix WinNonlin (Certara LP, Princeton, NJ, USA).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> In Vivo Studies</h3><div class="NLM_p last">NCI-H1975 cells (purchased from ATCC, CRL-5908) were subcutaneously implanted into 6 week old male BALB/cAJcl-nu/nu mice (CLEA Japan, Inc., Kanagawa, Japan) and allowed to grow. Six animals were assigned to each treatment group, and TAS-116 formulated in 0.5% (w/v) hydroxypropyl methylcellulose in H<sub>2</sub>O was administered orally every day. The tumor volume was measured using the following formula: [length × (width)<sup>2</sup>]/2. Statistical significance was calculated by Dunnett’s test to assess the difference in tumor volume between the control and treated groups. Differences with a <i>P</i> value < 0.05 were considered statistically significant. For the pharmacodynamic analysis, the tumors were harvested at the indicated time points after the administration of TAS-116. To evaluate the amount and phosphorylation status of proteins, the excised tumors were homogenized in lysing matrix D (MP Biomedicals, LLC, Santa Ana, CA, USA) containing lysis buffer.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Western Blot Analysis</h3><div class="NLM_p last">The proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred on to polyvinylidene fluoride membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA). The membranes were blocked with Blocking One or Blocking One P blocking reagent (Nacalai Tesque Inc., Kyoto, Japan) and probed with appropriate primary antibodies. The membranes were then incubated with horseradish peroxidase-linked secondary antibodies (Cell Signaling Technology Inc., Danvers, MA, USA), and the proteins were visualized by means of luminol-based enhanced chemiluminescence (Thermo Fisher Scientific Inc., Waltham, MA, USA). The luminescent images were captured using an LAS-3000 imaging system (Fuji Photo Film Co. Ltd., Tokyo, Japan). The primary antibodies used to detect specific proteins were purchased as follows: EGFR (#2242), phospho-p44/42 MAPK (#4370), p44/42 MAPK (#9102), phospho-AKT (#4060), AKT (#4691), phospho-S6 ribosomal protein (Ser235/236; #4858), S6 ribosomal protein (#2217), and anti-GAPDH (#2118) from Cell Signaling Technology Inc. (Danvers, MA, USA).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> General Chemistry Information</h3><div class="NLM_p">All solvents and reagents were obtained from commercial sources and were used as received. All reactions were monitored by ultraperformance liquid chromatography–mass spectrometry (UPLC–MS). The UPLC–MS analysis was performed using an ACQUITY UPLC system (Waters Corporation, Milford, MA, USA) and a Micromass ZQ Mass Spectrometer (Waters Corporation, Milford, MA, USA) equipped with electrospray ionization in the ESI positive mode. The column used was an ACQUITY UPLC BEH C18-column (2.1 mm × 50 mm, 1.7 μm, Waters Corporation) at 40 °C with a flow rate of 0.5 mL/min. Mobile phase A was 0.5% formic acid in water. Mobile phase B was 0.5% formic acid in acetonitrile, which was increased linearly from 5 to 95% over 2 min and 95 to 98% over the next 1.4 min, after which the column was equilibrated to 5% for 1.5 min and detected at 254 nm. Column chromatography was also performed on a Biotage Isolera purification system using prepacked Biotage SNAP Ultra (SI, particle size 25 μm). The yields were not optimized. All final test compounds were purified to >95% chemical purity as measured by UPLC–MS. The proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Varian Mercury-400 (400 MHz), JEOL JNM-AL400 (400 MHz) instrument. All of the <sup>1</sup>H NMR spectra were consistent with the proposed structures. All proton shifts are provided in parts per million (ppm) downfield from the appropriate internal deuterated solvent peak or tetramethysilane (δ) as the internal standard in deuterated solvent, and the coupling constants (<i>J</i>) are in hertz (Hz). The NMR data are reported as follows: chemical shift, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; spt, septet; m, multiplet; dd, doublet of doublets; td, triplet of doublets; and br s, broad singlet), coupling constants, and integration. The broad peaks of the protons of hydroxyl and amino groups are not always indicated. The high-resolution mass spectral (HRMS) analysis was carried out using ACQUITY UPLC I-Class and Vion IMS QTof (Waters Corporation, Milford, MA, USA).</div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(4-(quinolin-3-yl)-1<i>H</i>-indol-1-yl)benzamide (<b>11a</b>)</h4><div class="NLM_p">To a solution of <b>20a</b> (222 mg, 0.48 mmol), DMSO (0.55 mL), and EtOH (2.2 mL), 4 M NaOH aq (0.24 mL, 0.96 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (0.11 mL, 0.96 mmol) were added on ice. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with 2.2 mL of 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq on ice. Water (11 mL) was added to the mixture and the mixture was stirred at room temperature for 10 min. The resulting precipitate was collected by filtration. The precipitate was washed with water and dried under vacuum to obtain 148 mg (65%) of <b>11a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 477.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.51 min. UPLC purity 97.45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.18–1.38 (m, 4H), 1.82 (br d, <i>J</i> = 10.2 Hz, 2H), 1.93–2.06 (m, 2H), 3.37–3.55 (m, 2H), 4.57 (d, <i>J</i> = 4.4 Hz, 1H), 6.75 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 6.84 (d, <i>J</i> = 2.0 Hz, 1H), 6.90 (d, <i>J</i> = 3.4 Hz, 1H), 7.24 (br s, 1H), 7.38–7.45 (m, 2H), 7.66–7.73 (m, 2H), 7.79–7.85 (m, 3H), 7.94 (br s, 1H), 8.06–8.17 (m, 2H), 8.51 (d, <i>J</i> = 7.8 Hz, 1H), 8.65 (d, <i>J</i> = 2.2 Hz, 1H), 9.20–9.28 (m, 1H). HRMS: calcd for C<sub>30</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub>, 477.2285 [M + H]<sup>+</sup>; found, 477.2286.</div><div class="NLM_p last">The following compound <b>11b</b> was prepared from the corresponding indole <b>17b</b> by a method similar to that described for <b>11a</b>.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-methyl-4-(quinolin-3-yl)-1<i>H</i>-indol-1-yl)benzamide (<b>11b</b>)</h4><div class="NLM_p last">Yield 81% (3 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 491.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.58 min. UPLC purity 98.83%. <sup>1</sup>H NMR (400 MHz, DMSO–<i>d</i><sub>6</sub>): δ 1.15–1.37 (m, 4H), 1.77–1.85 (m, 5H), 1.89–2.06 (m, 2H), 4.54 (d, <i>J</i> = 4.0 Hz, 1H), 6.68 (dd, <i>J</i> = 8.4, 2.20 Hz, 1H), 6.77 (d, <i>J</i> = 1.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.3 Hz, 1H), 7.19 (br s, 1H), 7.24–7.37 (m, 1H), 7.55 (s, 1H), 7.63–7.71 (m, 2H), 7.76–7.85 (m, 2H), 7.88 (br s, 1H), 8.04–8.12 (m, 2H), 8.30 (s, 1H), 8.41 (d, <i>J</i> = 2.2 Hz, 1H), 8.47 (d, <i>J</i> = 7.7 Hz, 1H), 8.99 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>31</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>, 491.2447 [M + H]<sup>+</sup>; found, 491.2447.</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(4-(quinolin-3-yl)-1<i>H</i>-indazol-1-yl)benzamide (<b>12a</b>)</h4><div class="NLM_p">To a solution of <b>23a</b> (300 mg, 0.65 mmol), DMSO (0.75 mL), and EtOH (3 mL), 4 M NaOH aq (0.41 mL, 1.63 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (0.19 mL, 1.63 mmol) were added on ice. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq (3 mL) on ice and diluted with CHCl<sub>3</sub>. The mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with 5% NaCl aq, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 208 mg (67%) of <b>12a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 478.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.47 min. UPLC purity 99.84%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.20–1.40 (m, 4H), 1.78–1.92 (m, 2H), 1.97–2.11 (m, 2H), 3.34–3.44 (m, 1H), 3.44–3.55 (m, 1H), 4.55 (d, <i>J</i> = 4.2 Hz, 1H), 6.94 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.03 (d, <i>J</i> = 1.7 Hz, 1H), 7.23 (br s, 1H), 7.61 (d, <i>J</i> = 7.1 Hz, 1H), 7.66–7.76 (m, 2H), 7.81–7.90 (m, 2H), 7.90–8.02 (m, 2H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 8.17 (d, <i>J</i> = 8.1 Hz, 1H), 8.50 (d, <i>J</i> = 7.8 Hz, 1H), 8.63 (s, 1H), 8.79 (d, <i>J</i> = 2.2 Hz, 1H), 9.31 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>29</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>, 478.2238 [M + H]<sup>+</sup>; found, 478.2241.</div><div class="NLM_p last">The following compounds (<b>12b</b>, <b>12c</b>) were prepared from the corresponding indazoles (<b>21b</b>, <b>21c</b>) by a method similar to that described for <b>12a</b>.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-methyl-4-(quinolin-3-yl)-1<i>H</i>-indazol-1-yl)benzamide (<b>12b</b>)</h4><div class="NLM_p last">Yield 46% (3 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 492.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. UPLC purity 99.31%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.18–1.37 (m, 4H), 1.78–1.87 (m, 2H), 1.99–2.08 (m, 2H), 2.13 (s, 3H), 3.32–3.40 (m, 1H), 3.43–3.53 (m, 1H), 4.55 (d, <i>J</i> = 4.0 Hz, 1H), 6.87 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 6.96 (d, <i>J</i> = 2.2 Hz, 1H), 7.19 (br s, 1H), 7.27 (d, <i>J</i> = 7.0 Hz, 1H), 7.57–7.63 (m, 1H), 7.66–7.72 (m, 1H), 7.78–7.86 (m, 2H), 7.89 (d, <i>J</i> = 8.4 Hz, 2H), 8.11 (t, <i>J</i> = 6.9 Hz, 2H), 8.49 (d, <i>J</i> = 7.1 Hz, 1H), 8.52 (s, 1H), 9.05 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>30</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>, 492.2394 [M + H]<sup>+</sup>; found, 492.2398.</div></div><div id="sec4_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(quinolin-3-yl)-1<i>H</i>-indazol-1-yl)benzamide (<b>12c</b>)</h4><div class="NLM_p last">Yield 31% (3 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 520.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.73 min. UPLC purity 99.39%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.03 (d, <i>J</i> = 6.8 Hz, 6H), 1.21–1.38 (m, 4H), 1.79–1.90 (m, 2H), 1.99–2.09 (m, 2H), 2.83 (spt, <i>J</i> = 6.7 Hz, 1H), 3.32–3.41 (m, 1H), 3.46–3.55 (m, 1H), 4.55 (d, <i>J</i> = 4.4 Hz, 1H), 6.89 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.01 (d, <i>J</i> = 2.2 Hz, 1H), 7.16–7.30 (m, 2H), 7.59–7.65 (m, 1H), 7.69–7.75 (m, 1H), 7.80–7.97 (m, 4H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 8.49 (d, <i>J</i> = 7.6 Hz, 1H), 8.55 (d, <i>J</i> = 2.0 Hz, 1H), 9.06 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>32</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>, 520.2707 [M + H]<sup>+</sup>; found, 520.2710.</div></div><div id="sec4_12_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(quinolin-3-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)benzamide (<b>13a</b>)</h4><div class="NLM_p">To a solution of <b>27a</b> (30 mg, 0.06 mmol), DMSO (0.15 mL), and EtOH (0.3 mL), 4 M NaOH aq (44.8 μL, 0.18 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (20.3 μL, 0.18 mmol) were added on ice. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq (0.3 mL) on ice and diluted with CHCl<sub>3</sub>. The mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with 5% NaCl aq, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 28 mg (91%) of <b>13a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 521.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.39 min. UPLC purity 99.41%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.06 (d, <i>J</i> = 6.6 Hz, 6H), 1.19–1.38 (m, 4H), 1.76–1.89 (m, 2H), 1.95–2.10 (m, 2H), 3.05 (spt, <i>J</i> = 6.8 Hz, 1H), 3.33–3.42 (m, 1H), 3.44–3.52 (m, 1H), 4.55 (d, <i>J</i> = 4.0 Hz, 1H), 6.89 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.01 (d, <i>J</i> = 1.8 Hz, 1H), 7.24 (br s, 1H), 7.69–7.74 (m, 1H), 7.80–7.97 (m, 3H), 8.14 (dd, <i>J</i> = 8.1, 2.9 Hz, 2H), 8.48 (d, <i>J</i> = 7.7 Hz, 1H), 8.60 (d, <i>J</i> = 5.9 Hz, 1H), 8.70 (d, <i>J</i> = 2.2 Hz, 1H), 9.18 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>31</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 521.2665 [M + H]<sup>+</sup>; found, 521.2663.</div><div class="NLM_p last">The following compounds (<b>13b</b>, <b>13c</b>) were prepared from the corresponding pyridines (<b>26b</b>, <b>26c</b>) by a method similar to that described for <b>13a</b>.</div></div><div id="sec4_12_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(quinolin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridin-1-yl)benzamide (<b>13b</b>)</h4><div class="NLM_p last">Yield 10% (4 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 521.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.54 min. UPLC purity 96.62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.05 (d, <i>J</i> = 6.6 Hz, 6H), 1.18–1.38 (m, 4H), 1.76–1.90 (m, 2H), 1.94–2.12 (m, 2H), 2.94 (spt, <i>J</i> = 6.8 Hz, 1H), 3.35–3.52 (m, 2H), 4.55 (d, <i>J</i> = 4.4 Hz, 1H), 6.96 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.08 (d, <i>J</i> = 1.8 Hz, 1H), 7.23 (br s, 1H), 7.69–7.75 (m, 1H), 7.81–7.91 (m, 2H), 7.94 (br s, 1H), 8.11 (br d, <i>J</i> = 7.7 Hz, 1H), 8.14 (br d, <i>J</i> = 8.4 Hz, 1H), 8.36 (s, 1H), 8.49 (d, <i>J</i> = 7.7 Hz, 1H), 8.64 (d, <i>J</i> = 2.2 Hz, 1H), 9.11 (d, <i>J</i> = 2.2 Hz, 1H), 9.35 (br s, 1H). HRMS: calcd for C<sub>31</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 521.2665 [M + H]<sup>+</sup>; found, 521.2662.</div></div><div id="sec4_12_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(quinolin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>13c</b>)</h4><div class="NLM_p last">Yield 36% (4 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 521.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.76 min. UPLC purity 98.58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.03 (d, <i>J</i> = 7.0 Hz, 6H), 1.20–1.40 (m, 4H), 1.83–1.92 (m, 2H), 2.03–2.18 (m, 2H), 2.95 (spt, <i>J</i> = 6.9 Hz, 1H), 3.25–3.36 (m, 1H), 3.45–3.54 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.14 (br s, 1H), 7.41 (d, <i>J</i> = 4.8 Hz, 1H), 7.44–7.48 (m, 1H), 7.70–7.79 (m, 2H), 7.80–7.91 (m, 3H), 8.14 (t, <i>J</i> = 9.5 Hz, 2H), 8.41 (d, <i>J</i> = 7.3 Hz, 1H), 8.68 (d, <i>J</i> = 2.2 Hz, 1H), 8.74 (d, <i>J</i> = 4.8 Hz, 1H), 9.13 (d, <i>J</i> = 2.2 Hz, 1H). HRMS: calcd for C<sub>31</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 521.2665 [M + H]<sup>+</sup>; found, 521.2665.</div></div><div id="sec4_12_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(naphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14a</b>)</h4><div class="NLM_p">To a solution of <b>30a</b> (44 mg, 0.087 mmol), DMSO (0.22 mL), and EtOH (0.44 mL), 4 M NaOH aq (66 μL, 0.26 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (30 μL, 0.26 mmol) were added under ice-cooling. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq (0.44 mL) on ice and diluted with CHCl<sub>3</sub>. The mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with 5% NaCl aq, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 42 mg (92%) of <b>14a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 520.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.14 min. UPLC purity 99.39%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.01 (d, <i>J</i> = 7.0 Hz, 6H), 1.20–1.40 (m, 4H), 1.79–1.96 (m, 2H), 2.04–2.17 (m, 2H), 2.96–3.08 (m, 1H), 3.25–3.36 (m, 1H), 3.46–3.54 (m, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 7.13 (br s, 1H), 7.31 (d, <i>J</i> = 4.4 Hz, 1H), 7.47 (dd, <i>J</i> = 8.8, 1.8 Hz, 1H), 7.61 (d, <i>J</i> = 9.5 Hz, 2H), 7.71 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.83 (br s, 1H), 7.88 (d, <i>J</i> = 1.8 Hz, 1H), 8.02–8.06 (m, 2H), 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 8.12–8.16 (m, 1H), 8.42 (d, <i>J</i> = 7.0 Hz, 1H), 8.68 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>32</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>, 520.2707 [M + H]<sup>+</sup>; found, 520.2707.</div><div class="NLM_p last">The following compounds (<b>14b</b>, <b>14c</b>, <b>14d</b>, <b>14e</b>, <b>14f</b>, <b>14g</b>, <b>14h</b>, and <b>14i</b>) were prepared from <b>31</b> and the corresponding boronic acids by a method similar to that described for <b>14a</b>.</div></div><div id="sec4_12_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-phenyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14b</b>)</h4><div class="NLM_p last">Yield 74% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 470.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.98 min. UPLC purity 100%.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.06 (d, <i>J</i> = 6.8 Hz, 6H), 1.21–1.40 (m, 4H), 1.84–1.94 (m, 2H), 2.07–2.16 (m, 2H), 2.98–3.07 (m, 1H), 3.27–3.37 (m, 1H), 3.47–3.56 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.13 (br s, 1H), 7.22 (d, <i>J</i> = 4.6 Hz, 1H), 7.47 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.58 (s, 5H), 7.71–7.95 (m, 3H), 8.42 (d, <i>J</i> = 7.1 Hz, 1H), 8.66 (d, <i>J</i> = 4.9 Hz, 1H). HRMS: calcd for C<sub>28</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>, 470.2551 [M + H]<sup>+</sup>; found, 470.2547.</div></div><div id="sec4_12_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(pyridin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14c</b>)</h4><div class="NLM_p last">Yield 97% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 471.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.47 min. UPLC purity 97.46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.06 (d, <i>J</i> = 7.0 Hz, 6H), 1.15–1.40 (m, 4H), 1.79–1.95 (m, 2H), 2.00–2.18 (m, 2H), 2.84–3.02 (m, 1H), 3.25–3.55 (m, 1H), 4.57 (d, <i>J</i> = 4.4 Hz, 1H), 7.12 (br s, 1H), 7.27 (d, <i>J</i> = 4.8 Hz, 1H), 7.41–7.65 (m, 5H), 7.72–7.90 (m, 3H), 8.06 (d, <i>J</i> = 7.7 Hz, 1H), 8.40 (d, <i>J</i> = 7.3 Hz, 1H), 8.69 (d, <i>J</i> = 4.8 Hz, 1H), 8.72–8.84 (m, 2H). HRMS: calcd for C<sub>27</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>, 471.2508 [M + H]<sup>+</sup>; found, 471.2510.</div></div><div id="sec4_12_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(6-methoxypyridin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14d</b>)</h4><div class="NLM_p last">Yield 93% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 501.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.77 min. UPLC purity 99.29%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.09 (d, <i>J</i> = 6.6 Hz, 6H), 1.18–1.39 (m, 4H), 1.83–1.91 (m, 2H), 2.01–2.15 (m, 2H), 2.97–3.07 (m, 1H), 3.26–3.34 (m, 1H), 3.43–3.54 (m, 1H), 3.94 (s, 3H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 7.12 (br s, 1 H), 7.23 (d, <i>J</i> = 4.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.75 (d, <i>J</i> = 8.8 Hz, 1H), 7.83 (d, <i>J</i> = 2.2 Hz, 2H), 7.97 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 8.38–8.42 (m, 2H), 8.65 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 501.2609 [M + H]<sup>+</sup>; found, 501.2610.</div></div><div id="sec4_12_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(5-methoxypyridin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14e</b>)</h4><div class="NLM_p last">Yield 78% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 501.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.52 min. UPLC purity 97.78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.09 (d, <i>J</i> = 7.0 Hz, 6H), 1.19–1.39 (m, 4H), 1.81–1.91 (m, 2H), 2.04–2.13 (m, 2H), 2.90–3.01 (m, 1H), 3.27–3.32 (m, 1H), 3.46–3.55 (m, 1H), 3.89 (s, 3H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.13 (br s, 1H), 7.29 (d, <i>J</i> = 4.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 7.66–7.69 (m, 1H), 7.71–7.89 (m, 3H), 8.35–8.37 (m, 1H), 8.38–8.42 (m, 1H), 8.45–8.47 (m, 1H), 8.68 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 501.2614 [M + H]<sup>+</sup>; found, 501.2617.</div></div><div id="sec4_12_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(5,6,7,8-tetrahydroquinolin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14f</b>)</h4><div class="NLM_p last">Yield 83% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 525.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.41 min. UPLC purity 99.60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.10 (d, <i>J</i> = 6.6 Hz, 6H), 1.17–1.41 (m, 4H), 1.75–1.83 (m, 2H), 1.83–1.93 (m, 4H), 2.09 (d, <i>J</i> = 11.0 Hz, 2H), 2.82 (t, <i>J</i> = 6.1 Hz, 2H), 2.90 (t, <i>J</i> = 6.4 Hz, 2H), 2.99 (spt, <i>J</i> = 6.8 Hz, 1 H), 3.29–3.34 (m, 1H), 3.43–3.56 (m, 1H), 4.58 (d, <i>J</i> = 4.0 Hz, 1H), 7.13 (br s, 1H), 7.22 (d, <i>J</i> = 4.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8, 1.8 Hz, 1H), 7.67–7.89 (m, 4H), 8.40 (d, <i>J</i> = 7.0 Hz, 1H), 8.48 (d, <i>J</i> = 2.2 Hz, 1H), 8.65 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>31</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub>, 525.2973 [M + H]<sup>+</sup>; found, 525.2975.</div></div><div id="sec4_12_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(1-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14g</b>)</h4><div class="NLM_p last">Yield 75% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 524.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.69 min. UPLC purity 99.11%.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.03 (d, <i>J</i> = 7.0 Hz, 6H), 1.20–1.39 (m, 4H), 1.81–1.92 (m, 2H), 2.05–2.16 (m, 2H), 3.00 (spt, <i>J</i> = 6.7 Hz, 1H), 3.26–3.81 (m, 3H), 3.90 (s, 3H), 6.58 (d, <i>J</i> = 3.3 Hz, 1H), 7.12 (br s, 1H), 7.26 (d, <i>J</i> = 4.8 Hz, 1H), 7.47 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.65 (d, <i>J</i> = 3.3 Hz, 1H), 7.72–7.91 (m, 3H), 8.20 (d, <i>J</i> = 2.2 Hz, 1H), 8.44 (d, <i>J</i> = 1.8 Hz, 1H), 8.65 (d, <i>J</i> = 4.4 Hz, 1H). HRMS: calcd for C<sub>30</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>, 524.2774 [M + H]<sup>+</sup>; found, 524.2776.</div></div><div id="sec4_12_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(thiophen-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>14h</b>)</h4><div class="NLM_p last">Yield 84% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 476.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.91 min. UPLC purity 99.08%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.10 (d, <i>J</i> = 6.6 Hz, 6H), 1.20–1.38 (m, 4H), 1.80–1.97 (m, 2H), 2.02–2.17 (m, 2H), 3.16–3.24 (m, 1H), 3.25–3.34 (m, 1H), 3.45–3.55 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.11 (br s, 1H), 7.20–7.24 (m, 1H), 7.40–7.48 (m, 2H), 7.72–7.90 (m, 5H), 8.40 (d, <i>J</i> = 7.0 Hz, 1H), 8.61 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>26</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>S, 476.2115 [M + H]<sup>+</sup>; found, 476.2116.</div></div><div id="sec4_12_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-(4-(Furan-3-yl)-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-((<i>trans</i>-4-hydroxycyclohexyl)amino)benzamide (<b>14i</b>)</h4><div class="NLM_p last">Yield 85% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 460.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.79 min. UPLC purity 98.14%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.15–1.40 (m, 10H), 1.81–1.93 (m, 2H), 2.04–2.15 (m, 2H), 3.17–3.43 (m, 2H), 3.45–3.54 (m, 1H), 4.58 (br s, 1 H), 6.90–6.92 (m, 1H), 7.12 (br s, 1H), 7.21 (d, <i>J</i> = 4.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.72–7.86 (m, 3H), 7.86–7.95 (m, 1H), 8.14 (br s, 1H), 8.40 (d, <i>J</i> = 7.0 Hz, 1H), 8.59 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>26</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>, 460.2343 [M + H]<sup>+</sup>; found, 460.2343.</div></div><div id="sec4_12_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(4-(1<i>H</i>-Imidazol-1-yl)-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-((<i>trans</i>-4-hydroxycyclohexyl)amino)benzamide (<b>15a</b>)</h4><div class="NLM_p">To a solution of <b>31a</b> (20 mg, 0.045 mmol), DMSO (0.1 mL), and EtOH (0.2 mL), 4 M NaOH aq (34 μL, 0.14 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (15.4 μL, 0.14 mmol) were added on ice. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq (0.2 mL) on ice and then diluted with CHCl<sub>3</sub>. The mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with 5% NaCl aq, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 19 mg (91%) of <b>15a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 460.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.06 min. UPLC purity 99.29%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.08 (d, <i>J</i> = 6.6 Hz, 6H), 1.19–1.38 (m, 4H), 1.79–1.97 (m, 2H), 2.02–2.14 (m, 2H), 2.98–3.17 (m, 1H), 3.24–3.33 (m, 1H), 3.45–3.53 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.15 (br s, 1H), 7.23 (s, 1H), 7.38–7.42 (m, 2H), 7.74–7.79 (m, 3H), 7.84 (br s, 1H), 8.19 (br s, 1H), 8.40 (d, <i>J</i> = 7.0 Hz, 1H), 8.74 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>25</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>, 460.2456 [M + H]<sup>+</sup>; found, 460.2459.</div><div class="NLM_p last">The following compounds (<b>15b</b>, <b>15c</b>, <b>15d</b>, <b>15e</b>, <b>15f</b>, <b>15g</b>, <b>15h</b>, <b>15i</b>, <b>15j</b>, and <b>15k</b>) were prepared from <b>29</b> and the corresponding imidazoles by a method similar to that described for <b>15a</b>.</div></div><div id="sec4_12_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-phenyl-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15b</b>)</h4><div class="NLM_p last">Yield 73% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 536.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.65 min. UPLC purity 96.50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.13 (d, <i>J</i> = 6.6 Hz, 6H), 1.20–1.39 (m, 4H), 1.83–1.91 (m, 2H), 2.05–2.14 (m, 2H), 3.15–3.24 (m, 1H), 3.24–3.36 (m, 1H), 3.45–3.54 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.15 (br s, 1H), 7.24–7.30 (m, 1H), 7.39–7.47 (m, 3H), 7.49 (d, <i>J</i> = 4.8 Hz, 1H), 7.75–7.93 (m, 5H), 8.27 (s, 2H), 8.38–8.46 (m, 1H), 8.78 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>31</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>, 536.2774 [M + H]<sup>+</sup>; found, 536.2776.</div></div><div id="sec4_12_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(4-methoxyphenyl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15c</b>)</h4><div class="NLM_p last">Yield 58% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 566.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.59 min. UPLC purity 96.56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.12 (d, <i>J</i> = 7.0 Hz, 6H), 1.19–1.40 (m, 4H), 1.81–1.93 (m, 2H), 2.02–2.16 (m, 2H), 3.21 (spt, <i>J</i> = 6.8 Hz, 1 H), 3.25–3.35 (m, 1H), 3.44–3.55 (m, 1H), 3.77 (s, 3H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 6.96–7.01 (m, 2H), 7.16 (br s, 1H), 7.42 (dd, <i>J</i> = 8.8, 1.8 Hz, 1H), 7.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.74–7.95 (m, 5H), 8.12–8.15 (m, 1H), 8.23 (d, <i>J</i> = 1.1 Hz, 1H), 8.41 (d, <i>J</i> = 7.3 Hz, 1H), 8.76 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>32</sub>H<sub>35</sub>N<sub>7</sub>O<sub>3</sub>, 566.2889 [M + H]<sup>+</sup>; found, 566.2889.</div></div><div id="sec4_12_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(4-phenoxyphenyl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15d</b>)</h4><div class="NLM_p last">Yield 51% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 628.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.94 min. UPLC purity 99.86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.13 (d, <i>J</i> = 7.0 Hz, 6H), 1.19–1.40 (m, 4H), 1.81–1.92 (m, 2H), 2.03–2.14 (m, 2H), 3.16–3.25 (m, 1H), 3.21 (spt, <i>J</i> = 6.8 Hz, 1H), 3.25–3.35 (m, 1H), 3.45–3.55 (m, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 7.01–7.28 (m, 6H), 7.36–7.45 (m, 3H), 7.47 (d, <i>J</i> = 5.1 Hz, 1H), 7.75–7.94 (m, 5H), 8.20–8.28 (m, 2H), 8.42 (d, <i>J</i> = 7.0 Hz, 1H), 8.77 (d, <i>J</i> = 5.1 Hz, 1H). HRMS: calcd for C<sub>37</sub>H<sub>37</sub>N<sub>7</sub>O<sub>3</sub>, 628.3031 [M + H]<sup>+</sup>; found, 628.3031.</div></div><div id="sec4_12_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(pyridin-3-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15e</b>)</h4><div class="NLM_p last">Yield 50% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 537.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.15 min. UPLC purity 99.09%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.13 (d, <i>J</i> = 6.6 Hz, 6H), 1.21–1.42 (m, 4H), 1.74–1.93 (m, 2H), 2.02–2.16 (m, 2H), 3.18 (spt, <i>J</i> = 6.8 Hz, 1H), 3.25–3.36 (m, 1H), 3.44–3.54 (m, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.16 (br s, 1H), 7.40–7.48 (m, 2H), 7.50 (d, <i>J</i> = 4.8 Hz, 1H), 7.75–7.81 (m, 2H), 7.85 (br s, 1H), 8.22 (dt, <i>J</i> = 8.0, 1.9 Hz, 1H), 8.35–8.49 (m, 4H), 8.79 (d, <i>J</i> = 5.1 Hz, 1H), 9.10 (s, 1H). HRMS: calcd for C<sub>30</sub>H<sub>32</sub>N<sub>8</sub>O<sub>2</sub>, 537.2726 [M + H]<sup>+</sup>; found, 537.2733.</div></div><div id="sec4_12_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(pyridin-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15f</b>)</h4><div class="NLM_p last">Yield 41% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 537.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.22 min. UPLC purity 99.85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.11 (d, <i>J</i> = 7.0 Hz, 6H), 1.20–1.39 (m, 4H), 1.81–1.92 (m, 2H), 2.05–2.14 (m, 2H), 3.14 (spt, <i>J</i> = 6.8 Hz, 1H), 3.10–3.18 (m, 1H), 3.26–3.35 (m, 1H), 3.45–3.55 (m, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 7.16 (br s, 1H), 7.42 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.51 (d, <i>J</i> = 4.8 Hz, 1H), 7.76–7.90 (m, 5H), 8.34–8.46 (m, 2H), 8.55–8.62 (m, 3H), 8.80 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>30</sub>H<sub>32</sub>N<sub>8</sub>O<sub>2</sub>, 537.2721 [M + H]<sup>+</sup>; found, 537.2724.</div></div><div id="sec4_12_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(pyrimidin-5-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15g</b>)</h4><div class="NLM_p last">Yield 50% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 538.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.30 min. UPLC purity 97.94%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.12 (d, <i>J</i> = 6.6 Hz, 6H), 1.17–1.41 (m, 4H), 1.81–1.93 (m, 2H), 2.01–2.17 (m, 2H), 3.16 (spt, <i>J</i> = 6.8 Hz, 1H), 3.24–3.36 (m, 1H), 3.45–3.54 (m, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 7.17 (br s, 1H), 7.41 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.51 (d, <i>J</i> = 4.8 Hz, 1H), 7.78 (dd, <i>J</i> = 5.3, 3.5 Hz, 2H), 7.86 (br s, 1H), 8.39–8.46 (m, 2H), 8.54 (s, 1H), 8.80 (d, <i>J</i> = 5.1 Hz, 1H), 9.10 (s, 1H), 9.26 (s, 2H). HRMS: calcd for C<sub>29</sub>H<sub>31</sub>N<sub>9</sub>O<sub>2</sub>, 538.2679 [M + H]<sup>+</sup>; found, 538.2686.</div></div><div id="sec4_12_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-(4-(4-(Furan-3-yl)-1<i>H</i>-imidazol-1-yl)-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-((<i>trans</i>-4-hydroxycyclohexyl)amino)benzamide (<b>15h</b>)</h4><div class="NLM_p last">Yield 23% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 526.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.50 min. UPLC purity 96.27%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25 (d, <i>J</i> = 6.6 Hz, 6H), 1.38–1.61 (m, 4H), 2.03–2.12 (m, 2H), 2.23–2.31 (m, 2H), 3.13 (spt, <i>J</i> = 6.8 Hz, 1H), 3.40–3.55 (m, 1H), 3.55–3.66 (m, 1H), 3.73–3.81 (m, 1H), 5.62 (br s, 2H), 6.72 (d, <i>J</i> = 1.5 Hz, 1H), 7.15 (d, <i>J</i> = 4.8 Hz, 1H), 7.37 (d, <i>J</i> = 1.1 Hz, 1H), 7.49–7.54 (m, 3H), 7.83 (d, <i>J</i> = 1.5 Hz, 1H), 7.89–7.95 (m, 2H), 8.08 (brd, <i>J</i> = 7.3 Hz, 1H), 8.68 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O<sub>3</sub>, 526.2561 [M + H]<sup>+</sup>; found, 526.2558.</div></div><div id="sec4_12_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(thiophen-3-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15i</b>)</h4><div class="NLM_p last">Yield 40% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 542.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.58 min. UPLC purity 95.41%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25 (d, <i>J</i> = 6.6 Hz, 6H), 1.38–1.63 (m, 4H), 1.98–2.18 (m, 2H), 2.21–2.32 (m, 2H), 3.14 (spt, <i>J</i> = 6.7 Hz, 1H), 3.38–3.60 (m, 1H), 3.63–3.81 (m, 1H), 5.63 (br s, 2H), 7.14–7.18 (m, 1H), 7.16 (d, <i>J</i> = 4.8 Hz, 1H), 7.39–7.57 (m, 5H), 7.72 (d, <i>J</i> = 2.2 Hz, 1H), 7.84 (s, 1H), 7.91 (s, 1H), 8.08 (brd, <i>J</i> = 6.6 Hz, 1H), 8.68 (d, <i>J</i> = 5.1 Hz, 1H). HRMS: calcd for C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O<sub>2</sub>S, 542.2333 [M + H]<sup>+</sup>; found, 542.2333.</div></div><div id="sec4_12_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-(4-(1′<i>H</i>-[1,4′-Biimidazol]-1′-yl)-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-((<i>trans</i>-4-hydroxycyclohexyl)amino)benzamide (<b>15j</b>)</h4><div class="NLM_p last">Yield 52% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 526.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.07 min. UPLC purity 98.39%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.14 (d, <i>J</i> = 7.0 Hz, 6H), 1.20–1.39 (m, 4H), 1.79–1.95 (m, 2H), 2.03–2.15 (m, 2H), 3.13–3.22 (m, 1H), 3.25–3.35 (m, 1H), 3.45–3.55 (m, 1H), 4.59 (d, <i>J</i> = 4.0 Hz, 1H), 7.10 (br s, 1H), 7.17 (br s, 1H), 7.41 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.51 (d, <i>J</i> = 4.8 Hz, 1H), 7.67 (s, 1H), 7.75–7.82 (m, 2H), 7.86 (br s, 1H), 8.11 (d, <i>J</i> = 1.5 Hz, 1 H), 8.20 (br s, 1H), 8.30 (d, <i>J</i> = 1.5 Hz, 1H), 8.41 (d, <i>J</i> = 7.3 Hz, 1H), 8.80 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>28</sub>H<sub>31</sub>N<sub>9</sub>O<sub>2</sub>, 526.2674 [M + H]<sup>+</sup>; found, 526.2681.</div></div><div id="sec4_12_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>15k</b>)</h4><div class="NLM_p last">Yield 41% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 540.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.29 min. UPLC purity 96.57%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.12 (d, <i>J</i> = 6.6 Hz, 6H), 1.17–1.41 (m, 4H), 1.71–1.94 (m, 2H), 2.03–2.14 (m, 2H), 3.19 (spt, <i>J</i> = 6.8 Hz, 1H), 3.25–3.34 (m, 1H), 3.45–3.54 (m, 1H), 3.86 (s, 3H), 4.58 (d, <i>J</i> = 4.4 Hz, 1H), 7.15 (br s, 1H), 7.39–7.46 (m, 2H), 7.70–7.89 (m, 5H), 7.97 (s, 1H), 8.18 (d, <i>J</i> = 1.1 Hz, 1H), 8.41 (d, <i>J</i> = 7.0 Hz, 1H), 8.75 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>29</sub>H<sub>33</sub>N<sub>9</sub>O<sub>2</sub>, 540.2830 [M + H]<sup>+</sup>; found, 540.2833.</div></div><div id="sec4_12_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>16a</b>)</h4><div class="NLM_p">To a solution of <b>36a</b> (4.5 mg, 0.011 mmol), DMSO (45 μL), and EtOH (90 μL), 4 M NaOH aq (2.8 μL, 0.011 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (3.7 μL, 0.033 mmol) were added under ice cooling. After being stirred for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 4 h. The reaction mixture was quenched with 10% aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (45 μL) under ice cooling and then diluted with CHCl<sub>3</sub>. The mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with 5% aqueous NaCl, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, 0–20% MeOH in EtOAc) to obtain 4.1 mg (87%) of <b>16a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 427.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.18 min. UPLC purity 96.04%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.13 (d, <i>J</i> = 6.6 Hz, 6H), 3.19 (spt, <i>J</i> = 6.8 Hz, 1H), 3.86 (s, 3H), 7.42 (br s, 1H), 7.47 (d, <i>J</i> = 5.1 Hz, 1H), 7.73 (s, 1H), 7.87 (d, <i>J</i> = 1.5 Hz, 1H), 7.97 (s, 1H), 8.02–8.12 (m, 3H), 8.18 (d, <i>J</i> = 1.1 Hz, 1H), 8.37–8.42 (m, 2H), 8.79 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>23</sub>H<sub>22</sub>N<sub>8</sub>O, 427.1989 [M + H]<sup>+</sup>; found, 427.1997.</div><div class="NLM_p last">The following compounds (<b>16b</b>) were prepared from <b>36b</b> by a method similar to that described for <b>16a</b>.</div></div><div id="sec4_12_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-(methylamino)benzamide (<b>16b</b>)</h4><div class="NLM_p last">Yield 45%, white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.30 min. UPLC purity 98.71%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.12 (d, <i>J</i> = 6.6 Hz, 6H), 2.87 (d, <i>J</i> = 5.1 Hz, 3H), 3.18 (spt, <i>J</i> = 6.7 Hz, 1H), 3.86 (s, 3H), 7.21 (br s, 1H), 7.43 (d, <i>J</i> = 5.1 Hz, 1H), 7.48 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.64 (d, <i>J</i> = 2.2 Hz, 1H), 7.73 (s, 1H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.82–7.92 (m, 2H), 7.97 (s, 1H), 8.18 (d, <i>J</i> = 1.1 Hz, 1H), 8.31 (q, <i>J</i> = 4.8 Hz, 1H), 8.77 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>24</sub>H<sub>25</sub>N<sub>9</sub>O, 456.2255 [M + H]<sup>+</sup>; found, 456.2256.</div></div><div id="sec4_12_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-3-(methylamino)benzamide (<b>16c</b>)</h4><div class="NLM_p">To a solution of <b>39</b> (18.9 mg, 0.043 mmol), DMSO (95 μL), and EtOH (189 μL), 4 M NaOH aq (5.4 μL, 0.022 mmol) and 30% H<sub>2</sub>O<sub>2</sub> aq (14.7 μL, 0.13 mmol) were added on ice. After being stirred for 2 h at 0 °C, the reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> aq (189 μL) on ice and then diluted with AcOEt. The mixture was extracted with AcOEt. The organic layer was washed with 5% NaCl aq, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 0–20% MeOH in EtOAc) to obtain 18.8 mg (96%) of <b>16c</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 456.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.10 min. UPLC purity 97.36%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25 (d, <i>J</i> = 7.0 Hz, 6H), 2.94 (d, <i>J</i> = 4.8 Hz, 3H), 3.18 (spt, <i>J</i> = 6.8 Hz, 1H), 3.98 (s, 3H), 5.33–5.44 (m, 1H), 5.64 (br s, 1H), 6.13 (br s, 1H), 7.15 (d, <i>J</i> = 4.8 Hz, 1H), 7.20 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 7.36 (d, <i>J</i> = 1.5 Hz, 1H), 7.40 (d, <i>J</i> = 1.8 Hz, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 1H), 7.80 (d, <i>J</i> = 1.5 Hz, 2H), 7.83 (d, <i>J</i> = 1.1 Hz, 1H), 8.65 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>24</sub>H<sub>25</sub>N<sub>9</sub>O, 456.2260 [M + H]<sup>+</sup>; found, 456.2253.</div><div class="NLM_p last">The following compounds (<b>16d, 16e</b>) were prepared from <b>37</b> and the corresponding benzonitriles by a method similar to that described for <b>16a</b>.</div></div><div id="sec4_12_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-3-methylbenzamide (<b>16d</b>)</h4><div class="NLM_p last">Yield 85% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 441.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.12 min. UPLC purity 98.85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.10 (d, <i>J</i> = 6.6 Hz, 6H), 2.17 (s, 3H), 3.17–3.25 (m, 1H), 3.86 (s, 3H), 7.39 (d, <i>J</i> = 5.1 Hz, 1H), 7.48 (s, 1H), 7.53 (d, <i>J</i> = 8.1 Hz, 1H), 7.73 (s, 1H), 7.86 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 7.89 (d, <i>J</i> = 1.1 Hz, 1H), 7.95–7.98 (m, 2H), 8.08 (s, 1H), 8.19 (d, <i>J</i> = 1.1 Hz, 1H), 8.63 (d, <i>J</i> = 4.8 Hz, 1H). HRMS: calcd for C<sub>24</sub>H<sub>24</sub>N<sub>8</sub>O, 441.2151 [M + H]<sup>+</sup>; found, 441.2152.</div></div><div id="sec4_12_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 3-Ethyl-4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-Pyrazol-4-yl)-1<i>H</i>-Imidazol-1-yl)-1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (<b>16e</b>)</h4><div class="NLM_p last">Yield 64% (2 steps), white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 454.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.19 min. UPLC purity 99.65%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.14 (t, <i>J</i> = 7.5 Hz, 3H), 1.25 (d, <i>J</i> = 7.0 Hz, 6H), 2.62 (q, <i>J</i> = 7.3 Hz, 2H), 3.18 (spt, <i>J</i> = 6.8 Hz, 1H), 3.98 (s, 3H), 5.88 (br s, 1H), 6.22 (br s, 1H), 7.13 (d, <i>J</i> = 5.1 Hz, 1H), 7.39 (d, <i>J</i> = 1.1 Hz, 1H), 7.58 (d, <i>J</i> = 8.1 Hz, 1H), 7.78–7.81 (m, 3H), 7.86 (d, <i>J</i> = 1.5 Hz, 1H), 7.96 (d, <i>J</i> = 1.8 Hz, 1H), 8.59 (d, <i>J</i> = 4.7 Hz, 1H). HRMS: calcd for C<sub>25</sub>H<sub>26</sub>N<sub>8</sub>O, 455.2308 [M + H]<sup>+</sup>; found, 455.2311.</div></div><div id="sec4_12_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 3-(1<i>H</i>-Indol-4-yl)quinoline (<b>18a</b>)</h4><div class="NLM_p last">The mixture of 4-bromoindole (<b>17a</b>, 3.0 g, 15.3 mmol), 3-quinoline boronic acid (2.78 g, 16.1 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.884 g, 0.77 mmol), and Na<sub>2</sub>CO<sub>3</sub> (3.41 g, 32.1 mmol) in DME (30 mL) and H<sub>2</sub>O (30 mL) was stirred at 100 °C for 14 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was extracted with CHCl<sub>3</sub>. The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (eluent, 0–15% MeOH in CHCl<sub>3</sub>) to obtain 1.87 g (50%) of <b>18a</b> as a yellow oil. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 244.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.35 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.76–6.79 (m, 1H), 7.30–7.38 (m, 3H), 7.48–7.52 (m, 1H), 7.56–7.64 (m, 1H), 7.70–7.79 (m, 1H), 7.91 (d, <i>J</i> = 8.1 Hz, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 1H), 8.39–8.52 (m, 2 H), 9.31 (d, <i>J</i> = 2.2 Hz, 1H).</div></div><div id="sec4_12_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(4-(quinolin-3-yl)-1<i>H</i>-indol-1-yl)benzonitrile (<b>20a</b>)</h4><div class="NLM_p last">The mixture of <b>18a</b> (100 mg, 0.409 mmol), <b>19</b> (154 mg, 0.45 mmol), CuI (7.8 mg, 0.041 mmol), DMEDA (8.8 μL, 0.082 mmol), Cs<sub>2</sub>CO<sub>3</sub> (267 mg, 0.82 mmol), and 1,4-dioxane (1 mL) was stirred at 110 °C for 14 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane) to obtain 178 mg (95%) of <b>20a</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 459.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.86 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.34–1.52 (m, 4H), 2.02–2.23 (m, 4H), 3.33–3.45 (m, 1H), 3.66–3.80 (m, 1H), 4.61 (d, <i>J</i> = 7.6 Hz, 1H), 6.78–6.93 (m, 3H), 7.38–7.47 (m, 3H), 7.53–7.71 (m, 3H), 7.74–7.81 (m, 1H), 7.94 (d, <i>J</i> = 8.1 Hz, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 1H), 8.44 (d, <i>J</i> = 1.7 Hz, 1H), 9.30 (br s, 1H).</div></div><div id="sec4_12_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-(1<i>H</i>-Indazol-4-yl)quinoline (<b>22a</b>)</h4><div class="NLM_p last">The mixture of <b>21a</b> (100 mg, 0.51 mmol), 3-quinoline boronic acid (141 mg, 0.81 mmol), Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (41.5 mg, 0.051 mmol), and Na<sub>2</sub>CO<sub>3</sub> (108 mg, 1.02 mmol) in 1,4-dioxane (2 mL) and H<sub>2</sub>O (1 mL) were stirred at 100 °C for 3 h. After cooling to room temperature, the reaction mixture was diluted with water and EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane) to obtain 117 mg (94%) of <b>22a</b> as a yellow amorphous solid. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 246.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.26 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39 (dd, <i>J</i> = 6.7, 1.1 Hz, 1H), 7.52–7.66 (m, 3H), 7.74–7.83 (m, 1H), 7.91–7.97 (m, 1H), 8.21 (d, <i>J</i> = 8.29 Hz, 1H), 8.30 (d, <i>J</i> = 1.0 Hz, 1H), 8.47 (d, <i>J</i> = 2.2 Hz, 1H), 9.31 (d, <i>J</i> = 2.4 Hz, 1H), 10.59 (br s, 1H).</div></div><div id="sec4_12_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(4-(quinolin-3-yl)-1<i>H</i>-indazol-1-yl)benzonitrile (<b>23a</b>)</h4><div class="NLM_p last">The mixture of <b>22a</b> (30 mg, 0.12 mmol), <b>19</b> (46 mg, 0.14 mmol), CuI (2.3 mg, 0.012 mmol), DMEDA (2.6 μL, 0.025 mmol), K<sub>3</sub>PO<sub>4</sub> (54.5 mg, 0.26 mmol), and 1,4-dioxane (0.3 mL) was stirred at 110 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane) to obtain 55 mg (98%) of <b>23a</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 460.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.78 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.35–1.54 (m, 4H), 2.01–2.13 (m, 2H), 2.21 (m, 2H), 3.41–3.56 (m, 1H), 3.69–3.79 (m, 1H), 4.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.07–7.15 (m, 2H), 7.47 (d, <i>J</i> = 7.1 Hz, 1H), 7.56–7.69 (m, 2H), 7.79–7.83 (m, 1H), 7.85 (d, <i>J</i> = 8.5 Hz, 1H), 7.96 (d, <i>J</i> = 7.8 Hz, 1H), 8.22 (d, <i>J</i> = 8.5 Hz, 1H), 8.37–8.41 (m, 1H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 9.29 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec4_12_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 4-Chloro-3-Isopropyl-1<i>H</i>-Pyrazolo[4,3-<i>c</i>]pyridine (<b>25a</b>)</h4><div class="NLM_p last">To a solution of DIPA (2.09 mL, 14.9 mmol) in THF (20 mL), <i>n</i>BuLi solution (1.58 M in hexane, 5.70 mL, 14.9 mmol) was added dropwise at 0 °C, and the mixture was stirred for 10 min. To a solution of 2,4-dichloropyridine <b>24a</b> (2.0 g, 13.5 mmol) in THF (20 mL), the LDA solution prepared as mentioned above was added dropwise at −78 °C. The reaction mixture was stirred for 15 min at that temperature and then isobutylanhydride (2.36 mL, 14.2 mmol) was added. After being stirred for 1 h at −78 °C, the reaction mixture was allowed to warm to room temperature. To the reaction mixture, hydrazine monohydrate (1.35 mL, 27.0 mmol) was added and stirred at 70 °C for 24 h. After cooling to room temperature, the reaction mixture was quenched with water and the organic materials were extracted with EtOAc. The combined organic phases were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated in vacuo and the residue was purified by silica gel column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 642 mg (24%) of <b>25a</b> and its regioisomer (186 mg, 7%) as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 196.1, 197.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.36 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.37–1.55 (m, 6H), 3.78–3.91 (m, 1H), 8.13–8.28 (m, 1H), 10.13–10.39 (m, 1H).</div></div><div id="sec4_12_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-(3-Isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-yl)quinoline (<b>26a</b>)</h4><div class="NLM_p last">The mixture of <b>25a</b> (539 mg, 2.76 mmol), 3-quinoline boronic acid (763 mg, 4.41 mmol), Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (225 mg, 0.28 mmol), and Na<sub>2</sub>CO<sub>3</sub> (584 mg, 5.51 mmol) in 1,4-dioxane (10.8 mL) and H<sub>2</sub>O (5.4 mL) was stirred at 100 °C for 3 h. After cooling to room temperature, the reaction mixture was diluted with water and EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 732 mg (92%) of <b>26a</b> as a yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 289.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.03 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.13 (d, <i>J</i> = 7.0 Hz, 6H), 3.04–3.13 (m, 1H), 7.41 (d, <i>J</i> = 5.9 Hz, 1H), 7.62–7.67 (m, 1H), 7.79–7.84 (m, 1H), 7.93 (d, <i>J</i> = 8.1 Hz, 1H), 8.23 (d, <i>J</i> = 8.8 Hz, 1H), 8.46 (d, <i>J</i> = 1.5 Hz, 1H), 8.54 (d, <i>J</i> = 6.2 Hz, 1H), 9.20 (d, <i>J</i> = 2.2 Hz, 1H), 10.35 (br s, 1H).</div></div><div id="sec4_12_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(quinolin-3-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)benzonitrile (<b>27a</b>)</h4><div class="NLM_p last">The mixture of <b>26a</b> (200 mg, 0.69 mmol), <b>19</b> (261 mg, 0.76 mmol), CuI (13.2 mg, 0.069 mmol), DMEDA (14.9 μL, 0.139 mmol), K<sub>3</sub>PO<sub>4</sub> (309 mg, 1.46 mmol), and 1,4-dioxane (2 mL) was stirred at 110 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane) to obtain 283 mg (81%) of <b>27a</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 503.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.66 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.16 (d, <i>J</i> = 7.0 Hz, 6H), 1.33–1.55 (m, 4H), 2.02–2.11 (m, 2H), 2.17–2.23 (m, 2H), 3.09 (spt, <i>J</i> = 6.8 Hz, 1H), 3.40–3.49 (m, 1H), 3.71–3.78 (m, 1H), 4.61 (d, <i>J</i> = 7.3 Hz, 1H), 7.04–7.08 (m, 2H), 7.57 (d, <i>J</i> = 8.1 Hz, 1H), 7.63–7.68 (m, 2H), 7.81–7.86 (m, 1H), 7.95 (d, <i>J</i> = 7.3 Hz, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 1H), 8.46 (d, <i>J</i> = 2.2 Hz, 1H), 8.62 (d, <i>J</i> = 5.9 Hz, 1H), 9.19 (d, <i>J</i> = 2.2 Hz, 1H).</div></div><div id="sec4_12_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 2-Fluoro-4-(4-iodo-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzonitrile (<b>28</b>)</h4><div class="NLM_p last">To a solution of <b>25c</b> (10.0 g, 34.8 mmol) in DMF (100 mL), NaH (50%, 1.84 g, 38.3 mmol) was added at 0 °C under a nitrogen atmosphere. After being stirred for 10 min at 0 °C, to the reaction mixture, 2,4-difluoro-benzonitrile (5.33 g, 38.3 mmol) was added at the same temperature. Subsequently, the reaction mixture was stirred at 60 °C for 1 h. Water was added to the mixture and the mixture was stirred at room temperature for 1 h. The resulting precipitate was collected by filtration. The precipitate was washed with water and dried under vacuum to obtain a mixture of 13.4 g (95%) of <b>28</b> and its regioisomer <b>28a</b> as a white powder. The crude product was used for the next reaction without further purification.</div></div><div id="sec4_12_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(4-iodo-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzonitrile (<b>29</b>)</h4><div class="NLM_p last">The solution of <b>29</b> (13.4 g, 33.1 mmol), <i>trans</i>-4-aminocyclohexanol (4.19 g, 36.4 mmol), DIPEA (5.76 mL, 33.1 mmol), and DMSO (81 mL) was stirred at 125 °C for 5 h under a nitrogen atmosphere. Subsequently, the reaction mixture was warmed to 150 °C and stirred for 3 h. Water (241 mL) was added to the mixture, and the mixture was stirred at room temperature for 2 h. The resulting precipitate was collected by filtration. The precipitate was washed with water and dried under vacuum to obtain crude <b>29</b> as a brown amorphous solid. The crude <b>29</b> was purified by column chromatography (eluent, 12–100% EtOAc in hexane) to obtain 2.50 g (15%) of <b>29</b> as a pale-red powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 501.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.40 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.26–1.43 (m, 4H), 1.45 (d, <i>J</i> = 6.8 Hz, 6H), 1.83–1.93 (m, 2H), 1.96–2.05 (m, 2H), 3.33–3.48 (m, 2H), 3.93 (spt, <i>J</i> = 6.8 Hz, 1H), 4.59 (br s, 1H), 5.81–5.89 (m, 1H), 7.56–7.64 (m, 2H), 7.87–7.95 (m, 2H), 8.19–8.24 (m, 1H).</div></div><div id="sec4_12_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 2-((<i>trans</i>-4-Hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(naphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzonitrile (<b>30a</b>)</h4><div class="NLM_p last">The mixture of <b>29</b> (50 mg, 0.10 mmol), 3-quinoline boronic acid (21 mg, 0.12 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (5.8 mg, 0.005 mmol), and Na<sub>2</sub>CO<sub>3</sub> (12.7 mg, 0.12 mmol) in DME (1.0 mL) and H<sub>2</sub>O (0.5 mL) was stirred at 100 °C for 4 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was quenched with 10% NaHCO<sub>3</sub> aq. The mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc, and the filtrate was washed with 5% NaCl aq and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 48 mg (96%) of <b>30a</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 502.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.53 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.10 (d, <i>J</i> = 6.6 Hz, 6H), 1.32–1.45 (m, 2H), 1.46–1.52 (m, 2H), 2.00–2.19 (m, 2H), 2.19–2.38 (m, 2H), 3.01 (spt, <i>J</i> = 6.8 Hz, 1H), 3.49–3.58 (m, 1H), 3.72–3.80 (m, 1H), 4.49 (d, <i>J</i> = 7.33 Hz, 1H), 7.17 (d, <i>J</i> = 4.8 Hz, 1H), 7.49–7.53 (m, 1H), 7.56–7.64 (m, 3H), 7.77–7.82 (m, 1H), 7.89–8.02 (m, 4H), 8.06–8.13 (m, 1H), 8.60–8.65 (m, 1H).</div></div><div id="sec4_12_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 4-(4-(1<i>H</i>-Imidazol-1-yl)-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-((<i>trans</i>-4-hydroxycyclohexyl)amino)benzonitrile (<b>31a</b>)</h4><div class="NLM_p last">The mixture of <b>29</b> (50 mg, 0.10 mmol), imidazole (8.2 mg, 0.12 mmol), CuO (4.0 mg, 0.05 mmol), K<sub>2</sub>CO<sub>3</sub> (27.6 mg, 0.20 mmol), and DMF (0.5 mL) was stirred at 120 °C for 20 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc, and the filtrate was washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 29 mg (66%) of <b>31a</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 443.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.43 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.19 (d, <i>J</i> = 6.6 Hz, 6H), 1.32–1.57 (m, 4H), 2.03–2.13 (m, 2H), 2.21–2.30 (m, 2H), 2.95–3.07 (m, 1H), 3.45–3.55 (m, 1H), 3.72–3.80 (m, 1H), 4.52 (d, <i>J</i> = 7.3 Hz, 1H), 7.14 (d, <i>J</i> = 5.1 Hz, 1H), 7.27–7.41 (m, 2H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.72 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.83 (br s, 1H), 7.97 (d, <i>J</i> = 1.5 Hz, 1H), 8.67 (d, <i>J</i> = 4.8 Hz, 1H).</div></div><div id="sec4_12_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4-Iodo-3-isopropyl-1-(4-methoxybenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>32</b>)</h4><div class="NLM_p last">To a solution of <b>25c</b> (10.0 g, 34.8 mmol) in DMF (100 mL), NaH (50%, 2.0 g, 41.8 mmol) was added at 0 °C and stirred for 10 min under a nitrogen atmosphere. To the reaction mixture, 5.2 mL of PMBCl (38.3 mmol) was added at 0 °C. After being stirred for 10 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with water and diluted with AcOEt. The organic phase was washed with brine and dried over anhydrous MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (eluent, 6–60% EtOAc in hexane) to obtain 12.8 g (91%) of <b>32</b> as a yellow oil. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 408.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.36 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.43 (d, <i>J</i> = 6.8 Hz, 6H), 3.74 (s, 3H), 3.89 (spt, <i>J</i> = 6.8 Hz, 1H), 5.58 (s, 2H), 6.78–6.83 (m, 2H), 7.24–7.31 (m, 2H), 7.52 (d, <i>J</i> = 4.9 Hz, 1H), 8.00 (d, <i>J</i> = 4.9 Hz, 1H).</div></div><div id="sec4_12_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3-Isopropyl-1-(4-methoxybenzyl)-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>34</b>)</h4><div class="NLM_p last">The mixture of <b>32</b> (1.0 g, 2.46 mmol), <b>33</b> (652 mg, 2.95 mmol), Cu<sub>2</sub>O (10.5 mg, 0.074 mmol), 4,7-dimethoxy-1,10-phenanthroline (53.1 mg, 0.221 mmol), Cs<sub>2</sub>CO<sub>3</sub> (2.4 g, 7.37 mmol), PEG (491 mg), and DMSO (10 mL) was stirred at 110 °C for 24 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc, and the filtrate was diluted with water, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 654 mg (62%) of <b>34</b> as a pale-yellow oil. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 428.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.53 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.18 (d, <i>J</i> = 6.6 Hz, 6H), 3.07 (spt, <i>J</i> = 6.9 Hz, 1H), 3.77 (s, 3H), 3.96 (s, 3H), 5.66 (s, 2H), 6.81–6.86 (m, 2H), 7.00 (d, <i>J</i> = 5.1 Hz, 1H), 7.30 (d, <i>J</i> = 1.5 Hz, 1H), 7.33–7.38 (m, 2H), 7.75–7.78 (m, 3H), 8.57 (d, <i>J</i> = 4.8 Hz, 1H).</div></div><div id="sec4_12_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>35</b>)</h4><div class="NLM_p last">To a mixture of <b>34</b> (600 mg, 1.40 mmol) and anisole (0.23 mL, 2.11 mmol), TFA (3 mL) was added and stirred at reflux for 5 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography (eluent, 0–20% MeOH in EtOAc) to obtain 379 mg (88%) of <b>35</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 308.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 0.94 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.03 (d, <i>J</i> = 6.6 Hz, 6H), 3.08 (spt, <i>J</i> = 6.8 Hz, 1H), 3.83 (s, 3H), 7.20 (d, <i>J</i> = 5.1 Hz, 1H), 7.70 (s, 1H), 7.78–7.82 (m, 1H), 7.93 (s, 1H), 8.09–8.14 (m, 1H), 8.56 (d, <i>J</i> = 4.8 Hz, 1H), 13.65 (br s, 1H).</div></div><div id="sec4_12_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzonitrile (<b>36a</b>)</h4><div class="NLM_p last">The mixture of <b>35</b> (150 mg, 0.49 mmol), 4-fluorobenzonitrile (76.8 mg, 0.63 mmol), Cs<sub>2</sub>CO<sub>3</sub> (207 mg, 0.63 mmol), and DMF (1.8 mL) was stirred at 50 °C for 30 min under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and water. The organic phase was washed with brine, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 162 mg (81%) of <b>36a</b> as a white powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 409.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.68 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25 (d, <i>J</i> = 6.6 Hz, 6H), 3.14 (spt, <i>J</i> = 6.8 Hz, 1H), 3.98 (s, 3H), 7.20 (d, <i>J</i> = 4.9 Hz, 1H), 7.34 (d, <i>J</i> = 1.2 Hz, 1H), 7.76–7.86 (m, 5H), 8.63–8.67 (m, 2H), 8.71 (d, <i>J</i> = 4.9 Hz, 1H).</div></div><div id="sec4_12_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-(methylamino)benzonitrile (<b>36b</b>)</h4><div class="NLM_p last">The mixture of <b>35</b> (200 mg, 0.65 mmol), 4-iodo-2-(methylamino)benzonitrile (<b>S1</b>) (185 mg, 0.72 mmol), CuI (12.4 mg, 0.07 mmol), DMEDA (14 μL, 0.13 mmol), K<sub>3</sub>PO<sub>4</sub> (290 mg, 1.37 mmol), and 1,4-dioxane (2.0 mL) was stirred at 110 °C for 24 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (eluent, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 103 mg (36%) of <b>36b</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 438.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.63 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.24 (d, <i>J</i> = 6.6 Hz, 6H), 3.06 (d, <i>J</i> = 5.1 Hz, 3H), 3.08–3.18 (m, 1H), 3.97 (s, 3H), 4.77 (d, <i>J</i> = 5.1 Hz, 1H), 7.16 (d, <i>J</i> = 4.8 Hz, 1H), 7.32–7.35 (m, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.78–7.86 (m, 5H), 8.68 (d, <i>J</i> = 4.8 Hz, 1H).</div></div><div id="sec4_12_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-3-nitrobenzonitrile (<b>37</b>)</h4><div class="NLM_p last">The mixture of <b>35</b> (200 mg, 0.65 mmol), 4-fluoro-3-nitrobenzonitrile (130 mg, 0.78 mmol), Cs<sub>2</sub>CO<sub>3</sub> (276 mg, 0.85 mmol), and DMF (2.0 mL) was stirred at 80 °C for 14 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and water. The organic phase was washed with brine, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 205 mg (70%) of <b>37</b> as a brown powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 454.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.56 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.05 (d, <i>J</i> = 7.0 Hz, 6H), 3.22 (spt, <i>J</i> = 6.8 Hz, 1H), 3.86 (s, 3H), 7.52 (d, <i>J</i> = 5.1 Hz, 1H), 7.72 (s, 1H), 7.91 (d, <i>J</i> = 1.5 Hz, 1H), 7.96 (s, 1H), 8.22 (d, <i>J</i> = 1.5 Hz, 1H), 8.34–8.41 (m, 2H), 8.72 (d, <i>J</i> = 4.8 Hz, 1H), 8.75 (d, <i>J</i> = 1.8 Hz, 1H).</div></div><div id="sec4_12_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 3-Amino-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzonitrile (<b>38</b>)</h4><div class="NLM_p last">The mixture of <b>37</b> (200 mg, 0.44 mmol), Fe powder (246 mg, 4.41 mmol), NH<sub>4</sub>Cl (236 mg, 4.41 mmol), THF (2.0 mL), MeOH (2.0 mL), and water (2.0 mL) was stirred at 80 °C for 4 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc, and the filtrate was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 72.2 mg (39%) of <b>38</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 424.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.38 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.23 (d, <i>J</i> = 7.0 Hz, 6H), 3.11–3.23 (m, 1H), 3.97 (s, 3H), 4.89 (br s, 2H), 7.17–7.21 (m, 3H), 7.35 (d, <i>J</i> = 1.1 Hz, 1H), 7.77–7.86 (m, 4H), 8.66 (d, <i>J</i> = 5.1 Hz, 1H).</div></div><div id="sec4_12_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 4-(3-Isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-3-(methylamino)benzonitrile (<b>39</b>)</h4><div class="NLM_p last">The mixture of <b>38</b> (58.9 mg, 0.14 mmol), Cu(OAc)<sub>2</sub> (63.2 mg, 0.35 mmol), pyridine (39.4 μL, 0.49 mmol), and 1,4-dioxane (1.6 mL) was stirred at room temperature for 15 min under a nitrogen atmosphere. To the reaction mixture, methylboronic acid (20.8 mg, 0.35 mmol) was added and stirred at 120 °C for 2 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a pad of celite. The celite pad was washed with EtOAc and concentrated in vacuo. The residue was purified by column chromatography (eluents, 12–100% EtOAc in hexane and 0–20% MeOH in EtOAc) to obtain 22.9 mg (38%) of <b>39</b> as a pale-yellow powder. UPLC–MS (ESI) <i>m</i>/<i>z</i>: 438.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 1.52 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.24 (d, <i>J</i> = 6.6 Hz, 6H), 2.89 (d, <i>J</i> = 5.1 Hz, 3H), 3.17 (spt, <i>J</i> = 6.8 Hz, 1H), 3.97 (s, 3H), 5.68–5.73 (m, 1H), 7.06–7.07 (m, 1H), 7.13–7.18 (m, 2H), 7.35 (s, 1H), 7.73 (d, <i>J</i> = 8.1 Hz, 1H), 7.78–7.82 (m, 3H), 8.65 (d, <i>J</i> = 5.1 Hz, 1H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01085" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01085" class="ext-link">10.1021/acs.jmedchem.8b01085</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General chemistry information; complete synthesis procedures and characterization of intermediates and test compounds whose procedures are not included in the main article; and X-ray crystallography data and refinement statistics (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_001.pdf">jm8b01085_si_001.pdf (185.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_002.csv">jm8b01085_si_002.csv (2.83 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of HSP90 in complex with compound <b>16d</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>) have been deposited in the Protein Data Bank. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b01085" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takao Uno</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3259-4603" title="Orcid link">http://orcid.org/0000-0002-3259-4603</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9febfef4fef0b2eaf1f0dfebfef6f7f0b1fcf0b1f5ef"><span class="__cf_email__" data-cfemail="9ce8fdf7fdf3b1e9f2f3dce8fdf5f4f3b2fff3b2f6ec">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuichi Kawai</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Yamashita</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiromi Oshiumi</span> - <span class="hlFld-Affiliation affiliation">Formulation
Research, CMC Division, Taiho Pharmaceutical
Co. Ltd., Kawauchi-cho, Tokushima 771-0194, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chihoko Yoshimura</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takashi Mizutani</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatsuya Suzuki</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khoon Tee Chong</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazuhiko Shigeno</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitsuru Ohkubo</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasuo Kodama</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiromi Muraoka</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaoru Funabashi</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Koichi Takahashi</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuichi Ohkubo</span> - <span class="hlFld-Affiliation affiliation">Discovery
and Preclinical Research Division, Taiho
Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Makoto Kitade</span> - <span class="hlFld-Affiliation affiliation">Chemical
Technology Laboratory, CMC Division, Taiho
Pharmaceutical Co. Ltd., Kamikawa-machi,
Kodama-gun, Saitama 367-0241, Japan</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All the authors contributed to draft the manuscript. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Hirokazu Ohsawa for carrying out the HRMS analysis; Atsushi Hirano for measuring the log <i>D</i> values and the solubility at pH 7.4; and Kenjiro Ito for assistance in carrying out the in vivo efficacy study. We thank Dr. Teruhiro Utsugi, Dr. Kazuhiko Yonekura, and Dr. Yoshikazu Iwasawa for their insightful discussion. We also thank all the departments at the Discovery and Preclinical Research Division of Taiho for the support they provided in this study.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">Structure–activity relationship</p></td></tr><tr><td class="NLM_term">HSR</td><td class="NLM_def"><p class="first last">heat shock response</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">UPLC–MS</td><td class="NLM_def"><p class="first last">ultra performance liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">Pd(PPh<sub>3</sub>)<sub>4</sub></td><td class="NLM_def"><p class="first last">tetrakis(triphenylphosphine)palladium (0)</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium carbonate</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">CuI</td><td class="NLM_def"><p class="first last">copper(I) iodide</p></td></tr><tr><td class="NLM_term">DMEDA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dimethylethylene diamine</p></td></tr><tr><td class="NLM_term">Cs<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">cesium carbonate</p></td></tr><tr><td class="NLM_term">NaOH</td><td class="NLM_def"><p class="first last">sodium hydroxide</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O<sub>2</sub></td><td class="NLM_def"><p class="first last">hydrogen peroxide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">K<sub>3</sub>PO<sub>4</sub></td><td class="NLM_def"><p class="first last">tripotassium phosphate</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DIPA</td><td class="NLM_def"><p class="first last">diisopropylamine</p></td></tr><tr><td class="NLM_term"><i>n</i>-BuLi</td><td class="NLM_def"><p class="first last"><i>n</i>-butyllithium</p></td></tr><tr><td class="NLM_term">NaH</td><td class="NLM_def"><p class="first last">sodium hydride</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">CuO(II)</td><td class="NLM_def"><p class="first last">copper(II) oxide</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">PMBCl</td><td class="NLM_def"><p class="first last"><i>p</i>-methoxybenzylchloride</p></td></tr><tr><td class="NLM_term">Cu<sub>2</sub>O</td><td class="NLM_def"><p class="first last">copper(I) oxide</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>Cl</td><td class="NLM_def"><p class="first last">ammonium chloride</p></td></tr><tr><td class="NLM_term">Cu(OAc)<sub>2</sub></td><td class="NLM_def"><p class="first last">copper(II) acetate</p></td></tr><tr><td class="NLM_term">CHCl<sub>3</sub></td><td class="NLM_def"><p class="first last">chloroform</p></td></tr><tr><td class="NLM_term">MgSO<sub>4</sub></td><td class="NLM_def"><p class="first last">magnesium sulfate</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium thiosulfate</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium sulfate</p></td></tr><tr><td class="NLM_term">NaCl</td><td class="NLM_def"><p class="first last">sodium chloride</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollapour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span> <span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0ljxIwBtD3_jqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S. L.</span></span> <span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0ljxIwBtD3_jqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F&doi=10.1158%2F1078-0432.ccr-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0ljxIwBtD3_jqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.ccr-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Targeting Hsp90--Who Benefits and Who Does Not</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4508</span>– <span class="NLM_lpage">4513</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-2138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-2138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22718860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4508-4513&author=M.+Scaltritiauthor=S.+Dawoodauthor=J.+Cortes&title=Molecular+Pathways%3A+Targeting+Hsp90%2D%2DWho+Benefits+and+Who+Does+Not&doi=10.1158%2F1078-0432.ccr-11-2138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Hsp90-Who Benefits and Who Does Not</span></div><div class="casAuthors">Scaltriti, Maurizio; Dawood, Shaheenah; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4508-4513</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Many kinases and hormone receptors, important for cancer cell proliferation and survival, bind to and are dependent on the Hsp90 cycle for their folding and maturation.  This provides the rationale for the development of small-mol. ATP competitors that, inhibiting Hsp90 function, lead to degrdn. of the "client" proteins.  After continual efforts to improve the pharmacol. properties and the tolerability of these mols., several Hsp90 inhibitors have exhibited activity in both preclin. models and in the clin. setting.  As is the case with many other targeted agents, patient selection seems to be the major limitation to the success of these compds.  ERBB2-pos. patients with breast cancer are exquisitely sensitive to Hsp90 inhibition.  This is because ERBB2 is indispensable for growth and survival of this subtype of cancer, and at the same time ERBB2 is a client protein strictly dependent on Hsp90 for its maturation and stability.  Extensive preclin. work identifying other ERBB-like client proteins will likely lead to the ability to enhance selection of appropriate patients for enrollment in more rational clin. trials.  Hsp90 inhibition has also been reported to synergize with other therapeutic agents.  Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance.  Clin Cancer Res; 18(17); 4508-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSf5P7B7H8bVg90H21EOLACvtfcHk0lhQrfgHz9q2oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L&md5=8274b2b8bedc14970bd02b37acb163e8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-2138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-2138%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDawood%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520Pathways%253A%2520Targeting%2520Hsp90--Who%2520Benefits%2520and%2520Who%2520Does%2520Not%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4508%26epage%3D4513%26doi%3D10.1158%2F1078-0432.ccr-11-2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heltai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugarli, C.</span></span> <span> </span><span class="NLM_article-title">Unusual expression and localization of heat-shock proteins in human tumor cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910510418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1002%2Fijc.2910510418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1601523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=613-619&author=M.+Ferrariniauthor=S.+Heltaiauthor=M.+R.+Zocchiauthor=C.+Rugarli&title=Unusual+expression+and+localization+of+heat-shock+proteins+in+human+tumor+cells&doi=10.1002%2Fijc.2910510418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual expression and localization of heat-shock proteins in human tumor cells</span></div><div class="casAuthors">Ferrarini, Marina; Heltai, Silvia; Zocchi, M. Raffaella; Rugarli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-19</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">It has been suggested that members of HSP families represent the surface target of immune responses leading to tumor rejection in mice.  The authors report that tumor cells, compared with normal cells, constitutively expressed 2- to 10-fold higher levels of intracellular HSP90.  Moreover, in the absence of environmental stress, 2 lines (out of 6) expressed the "inducible" HSP72, which was also detectable in fresh tumor cells.  HSP72 expression was not regulated during the cell cycle, in contrast with what has been obsd. with normal cells.  Both HSP90 and HSP72 proteins exhibited a heterogeneous pattern of intracellular distribution in most cells, HSP72 being confined mainly to the nuclear compartment.  Finally, both HSP90 and, to a lesser extent, HSP72 (that are generally believed to be located intracellularly) were detected at the surface of some tumor cell lines.  It is concluded that tumor cells differ from normal cells in their pattern of HSP expression; this might imply a role of HSPs in eliciting an immune response against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdlQHEKHA7jLVg90H21EOLACvtfcHk0lhQrfgHz9q2oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D&md5=4ace8651e9b125c68985102a0b3055f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910510418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910510418%26sid%3Dliteratum%253Aachs%26aulast%3DFerrarini%26aufirst%3DM.%26aulast%3DHeltai%26aufirst%3DS.%26aulast%3DZocchi%26aufirst%3DM.%2BR.%26aulast%3DRugarli%26aufirst%3DC.%26atitle%3DUnusual%2520expression%2520and%2520localization%2520of%2520heat-shock%2520proteins%2520in%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D51%26spage%3D613%26epage%3D619%26doi%3D10.1002%2Fijc.2910510418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciocca, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, S. K.</span></span> <span> </span><span class="NLM_article-title">Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications</span>. <i>Cell Stress Chaperones</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1379/csc-99r.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1379%2Fcsc-99r.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16038406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFymur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=86-103&author=D.+R.+Cioccaauthor=S.+K.+Calderwood&title=Heat+shock+proteins+in+cancer%3A+diagnostic%2C+prognostic%2C+predictive%2C+and+treatment+implications&doi=10.1379%2Fcsc-99r.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications</span></div><div class="casAuthors">Ciocca, Daniel R.; Calderwood, Stuart K.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stress & Chaperones</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-103</span>CODEN:
                <span class="NLM_cas:coden">CSCHFG</span>;
        ISSN:<span class="NLM_cas:issn">1355-8145</span>.
    
            (<span class="NLM_cas:orgname">Cell Stress Society International</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (Hsps) are overexpressed in a wide range of human cancers and are implicated in tumor cell proliferation, differentiation, invasion, metastasis, death, and recognition by the immune system.  We review the current status of the role of Hsp expression in cancer with special emphasis on the clin. setting.  Although Hsp levels are not informative at the diagnostic level, they are useful biomarkers for carcinogenesis in some tissues and signal the degree of differentiation and the aggressiveness of some cancers.  In addn., the circulating levels of Hsp and anti-Hsp antibodies in cancer patients may be useful in tumor diagnosis.  Furthermore, several Hsp are implicated with the prognosis of specific cancers, most notably Hsp27, whose expression is assocd. with poor prognosis in gastric, liver, and prostate carcinoma, and osteosarcomas, and Hsp70, which is correlated with poor prognosis in breast, endometrial, uterine cervical, and bladder carcinomas.  Increased Hsp expression may also predict the response to some anticancer treatments.  For example, Hsp27 and Hsp70 are implicated in resistance to chemotherapy in breast cancer, Hsp27 predicts a poor response to chemotherapy in leukemia patients, whereas Hsp70 expression predicts a better response to chemotherapy in osteosarcomas.  Implication of Hsp in tumor progression and response to therapy has led to its successful targeting in therapy by 2 main strategies, including: (1) pharmacol. modification of Hsp expression or mol. chaperone activity and (2) use of Hsps in anticancer vaccines, exploiting their ability to act as immunol. adjuvants.  In conclusion, the present times are of importance for the field of Hsps in cancer, with great contributions to both basic and clin. cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_88yG9rC597Vg90H21EOLACvtfcHk0lhQrfgHz9q2oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFymur4%253D&md5=d32af56d2ef8479b1bc0f13d01fcc03c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1379%2Fcsc-99r.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1379%252Fcsc-99r.1%26sid%3Dliteratum%253Aachs%26aulast%3DCiocca%26aufirst%3DD.%2BR.%26aulast%3DCalderwood%26aufirst%3DS.%2BK.%26atitle%3DHeat%2520shock%2520proteins%2520in%2520cancer%253A%2520diagnostic%252C%2520prognostic%252C%2520predictive%252C%2520and%2520treatment%2520implications%26jtitle%3DCell%2520Stress%2520Chaperones%26date%3D2005%26volume%3D10%26spage%3D86%26epage%3D103%26doi%3D10.1379%2Fcsc-99r.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span> <span> </span><span class="NLM_article-title">A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>425</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/nature01913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnature01913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=14508491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=407-410&author=A.+Kamalauthor=L.+Thaoauthor=J.+Sensintaffarauthor=L.+Zhangauthor=M.+F.+Boehmauthor=L.+C.+Fritzauthor=F.+J.+Burrows&title=A+high-affinity+conformation+of+Hsp90+confers+tumour+selectivity+on+Hsp90+inhibitors&doi=10.1038%2Fnature01913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span></div><div class="casAuthors">Kamal, Adeela; Thao, Lia; Sensintaffar, John; Zhang, Lin; Boehm, Marcus F.; Fritz, Lawrence C.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6956</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53.  Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degrdn. of Hsp90 client proteins.  Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clin. trials.  However, the mol. basis of the tumor selectivity of Hsp90 inhibitors is unknown.  Here we report that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells.  Tumor Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state.  In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity.  These results suggest that tumor cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ozo1K3wfA7Vg90H21EOLACvtfcHk0lg74KC3TtWZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D&md5=7c83fca7aaf685b589c4aef6e5f39b02</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature01913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01913%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DThao%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DA%2520high-affinity%2520conformation%2520of%2520Hsp90%2520confers%2520tumour%2520selectivity%2520on%2520Hsp90%2520inhibitors%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D407%26epage%3D410%26doi%3D10.1038%2Fnature01913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilenchik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huezo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spampinato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2004.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15217612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=787-797&author=M.+Vilenchikauthor=D.+Solitauthor=A.+Bassoauthor=H.+Huezoauthor=B.+Lucasauthor=H.+Heauthor=N.+Rosenauthor=C.+Spampinatoauthor=P.+Modrichauthor=G.+Chiosis&title=Targeting+wide-range+oncogenic+transformation+via+PU24FCl%2C+a+specific+inhibitor+of+tumor+Hsp90&doi=10.1016%2Fj.chembiol.2004.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90</span></div><div class="casAuthors">Vilenchik, Maria; Solit, David; Basso, Andrea; Huezo, Henri; Lucas, Brian; He, Huazhong; Rosen, Neal; Spampinato, Claudia; Modrich, Paul; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-797</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Agents that inhibit Hsp90 function hold significant promise in cancer therapy.  Here we present PU24FCl, a representative of the first class of designed Hsp90 inhibitors.  By specifically and potently inhibiting tumor Hsp90, PU24FCl exhibits wide-ranging anti-cancer activities that occur at similar doses in all tested tumor types.  Normal cells are 10- to 50-fold more resistant to these effects.  Its Hsp90 inhibition results in multiple antitumor-specific effects, such as degrdn. of Hsp90-client proteins involved in cell growth, survival, and specific transformation, inhibition of cancer cell growth, delay of cell cycle progression, induction of morphol. and functional changes, and apoptosis.  In concordance with its higher affinity for tumor Hsp90, in vivo PU24FCl accumulates in tumors while being rapidly cleared from normal tissue.  Concns. achieved in vivo in tumors lead to single-agent antitumor activity at non-toxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKaguPFd5FLVg90H21EOLACvtfcHk0lg74KC3TtWZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrg%253D&md5=1bf99fe18a0a212c770fa731c197e60c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DVilenchik%26aufirst%3DM.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DHuezo%26aufirst%3DH.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSpampinato%26aufirst%3DC.%26aulast%3DModrich%26aufirst%3DP.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DTargeting%2520wide-range%2520oncogenic%2520transformation%2520via%2520PU24FCl%252C%2520a%2520specific%2520inhibitor%2520of%2520tumor%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D787%26epage%3D797%26doi%3D10.1016%2Fj.chembiol.2004.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Carbonero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HSP90 molecular chaperones: moving into the clinic</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e358</span>– <span class="NLM_lpage">e369</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fs1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+HSP90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2Fs1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0lg74KC3TtWZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HSP90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2Fs1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1823</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0lhjDsgvDoUuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+heat+shock+protein+HSP90-pp60v-src+heteroprotein+complex+formation+by+benzoquinone+ansamycins%3A+essential+role+for+stress+proteins+in+oncogenic+transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0lhjDsgvDoUuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%2520HSP90-pp60v-src%2520heteroprotein%2520complex%2520formation%2520by%2520benzoquinone%2520ansamycins%253A%2520essential%2520role%2520for%2520stress%2520proteins%2520in%2520oncogenic%2520transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1007/s002800050817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1007%2Fs002800050817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=9744771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=273-279&author=T.+W.+Schulteauthor=L.+M.+Neckers&title=The+benzoquinone+ansamycin+17-allylamino-17-demethoxygeldanamycin+binds+to+HSP90+and+shares+important+biologic+activities+with+geldanamycin&doi=10.1007%2Fs002800050817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span></div><div class="casAuthors">Schulte, Theodor W.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Binding of 17-allylamino-17-demethoxygeldanamycin (17-AG) to the heat-shock protein HSP90 was studied in vitro using a geldanamycin (GA)-affinity beads competition assay.  The drug-induced destabilization was studied of p185erbB2, Raf-1, and mutant p53 in SKBR3 breast cancer cells by Western blotting.  The antiproliferative activities of 17-AG and GA were compared using the MTT assay.  The 17-AG bound specifically to HSP90 in a similar manner as GA itself.  It also led to degrdn. of the receptor Tyr kinase p185erbB2, the Ser/Thr kinase Raf-1, and mutant p53.  GA and 17-AG displayed comparable antiproliferative effects in SKBR3 and MCF7 cells.  Even though HSP90 binding with 17-AG was weaker than by GA, 17-AG and GA caused biol. effects in tumor cells at similar doses.  Since 17-AG had a better toxicity profile than GA, it was suggested as benzoquinone ansamycin candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj3pMDUB7kLVg90H21EOLACvtfcHk0lhjDsgvDoUuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D&md5=3d6ac0592b10d66b391f824272523de2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs002800050817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050817%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DThe%2520benzoquinone%2520ansamycin%252017-allylamino-17-demethoxygeldanamycin%2520binds%2520to%2520HSP90%2520and%2520shares%2520important%2520biologic%2520activities%2520with%2520geldanamycin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26spage%3D273%26epage%3D279%26doi%3D10.1007%2Fs002800050817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher-Nielson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainathan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4813</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-03-0795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-03-0795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15269157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4813-4821&author=G.+Kaurauthor=D.+Belottiauthor=A.+M.+Burgerauthor=K.+Fisher-Nielsonauthor=P.+Borsottiauthor=E.+Riccardiauthor=J.+Thillainathanauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=R.+Giavazzi&title=Antiangiogenic+properties+of+17-%28dimethylaminoethylamino%29-17-demethoxygeldanamycin%3A+an+orally+bioavailable+heat+shock+protein+90+modulator&doi=10.1158%2F1078-0432.ccr-03-0795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span></div><div class="casAuthors">Kaur, Gurmeet; Belotti, Dorina; Burger, Angelika M.; Fisher-Nielson, Kirsten; Borsotti, Patrizia; Riccardi, Elena; Thillainathan, Jagada; Hollingshead, Melinda; Sausville, Edward A.; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4813-4821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; NSC707545), a water-sol. benzoquinone ansamycin.  The activity of 17-DMAG, in vivo, was evaluated for inhibition of fibroblast growth factor (FGF)-2-induced angiogenesis in s.c. implanted Matrigel in mice.  In vitro, the activity of 17-DMAG on endothelial cells (human umbilical vein endothelial cells; HUVEC) was tested in FGF-2; and vascular endothelial growth factor (VEGF)-induced proliferation and apoptosis, motility, and extracellular matrix invasion; and on the alignment of capillary like structures in Matrigel.  The protein level of heat shock protein (Hsp)90 and client proteins was examd. by Western blot in FGF-2 and VEGF-stimulated HUVEC.  Daily oral administration of 17-DMAG affected the angiogenic response in Matrigel in a dose-dependent manner.  The Hb content in the Matrigel implants was significantly inhibited, and the histol. anal. confirmed a decrease of CD31+ endothelial cells and of structures organized in cord and erythrocyte-contg. vessels.  In vitro, the compd. inhibited dose-dependently the migration and the extracellular matrix-invasiveness of HUVEC and their capacity to form capillary like structures in Matrigel. 17-DMAG treatment also inhibited FGF-2 and VEGF-induced HUVEC proliferation and resulted in apoptosis.  Accordingly, the expression of Hsp90 direct client proteins (pAkt and c-Raf-1) or their downstream substrates including pERK was also affected. 17-DMAG consistently increased the expression of Hsp70.  Throughout the study similar results were obtained with 17-allylamino-17-demethoxygeldanamycin (17-AAG; NSC330507), the analog compd. currently undergoing clin. trials.  We show that the Hsp90 targeting agents 17-DMAG and 17-AAG inhibit angiogenesis.  The strong effects on endothelial cell functions, in vitro, indicate that the antiangiogenic activity of 17-DMAG/17-AAG could also be due to a direct effect on endothelial cells.  The oral bioavailability of 17-DMAG might be of advantage in investigating the potential of this compd. in clin. trials with antiangiogenic as well as antiproliferative endpoints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbGsLTxbCrQ7Vg90H21EOLACvtfcHk0lhjDsgvDoUuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D&md5=e78331697485d2c1948adec2d4f124e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-03-0795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-03-0795%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DFisher-Nielson%26aufirst%3DK.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DThillainathan%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DAntiangiogenic%2520properties%2520of%252017-%2528dimethylaminoethylamino%2529-17-demethoxygeldanamycin%253A%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520modulator%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4813%26epage%3D4821%26doi%3D10.1158%2F1078-0432.ccr-03-0795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4615</span>, <span class="refDoi"> DOI: 10.1021/jm0603116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbittsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+synthesis%2C+and+biological+evaluation+of+hydroquinone+derivatives+of+17-amino-17-demethoxygeldanamycin+as+potent%2C+water-soluble+inhibitors+of+Hsp90&doi=10.1021%2Fjm0603116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span></div><div class="casAuthors">Ge, Jie; Normant, Emmanuel; Porter, James R.; Ali, Janid A.; Dembski, Marlene S.; Gao, Yun; Georges, Asimina T.; Grenier, Louis; Pak, Roger H.; Patterson, Jon; Sydor, Jens R.; Tibbitts, Thomas T.; Tong, Jeffrey K.; Adams, Julian; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4606-4615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clin. trials for the treatment of cancer.  However, 17-AAG faces challenging formulation issues due to its poor soly.  Here we report the synthesis and evaluation of a highly sol. hydroquinone hydrochloride deriv. of 17-AAG, I (IPI-504), and several of the physiol. metabolites.  These compds. show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homolog, the 94 kDa glucose regulated protein (Grp94).  Furthermore, the compds. inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition.  There is a clear correlation between the measured binding affinity of the compds. and their cellular activities.  Upon the basis of its potent activity against Hsp90 and a significant improvement in soly., I is currently under evaluation in Phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9IjX75MjbULVg90H21EOLACvtfcHk0lhF-C6aVilCGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D&md5=892e372e121f75465edc6f1251e55dc6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbitts%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520hydroquinone%2520derivatives%2520of%252017-amino-17-demethoxygeldanamycin%2520as%2520potent%252C%2520water-soluble%2520inhibitors%2520of%2520Hsp90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615%26doi%3D10.1021%2Fjm0603116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pien, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penders, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayzel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span> <span> </span><span class="NLM_article-title">Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">17408</span>– <span class="NLM_lpage">17413</span>, <span class="refDoi"> DOI: 10.1073/pnas.0608372103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1073%2Fpnas.0608372103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17408-17413&author=J.+R.+Sydorauthor=E.+Normantauthor=C.+S.+Pienauthor=J.+R.+Porterauthor=J.+Geauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=J.+Hudakauthor=J.+Pattersonauthor=C.+Pendersauthor=M.+Pinkauthor=M.+A.+Readauthor=J.+Sangauthor=C.+Woodwardauthor=Y.+Zhangauthor=D.+S.+Grayzelauthor=J.+Wrightauthor=J.+A.+Barrettauthor=V.+J.+Palombellaauthor=J.+Adamsauthor=J.+K.+Tong&title=Development+of+17-allylamino-17-demethoxygeldanamycin+hydroquinone+hydrochloride+%28IPI-504%29%2C+an+anti-cancer+agent+directed+against+Hsp90&doi=10.1073%2Fpnas.0608372103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608372103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608372103%26sid%3Dliteratum%253Aachs%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPien%26aufirst%3DC.%2BS.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DHudak%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DPenders%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGrayzel%26aufirst%3DD.%2BS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%252017-allylamino-17-demethoxygeldanamycin%2520hydroquinone%2520hydrochloride%2520%2528IPI-504%2529%252C%2520an%2520anti-cancer%2520agent%2520directed%2520against%2520Hsp90%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D17408%26epage%3D17413%26doi%3D10.1073%2Fpnas.0608372103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyodo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuni, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.freeradbiomed.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20211249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=1559-1563&author=Y.+Samuniauthor=H.+Ishiiauthor=F.+Hyodoauthor=U.+Samuniauthor=M.+C.+Krishnaauthor=S.+Goldsteinauthor=J.+B.+Mitchell&title=Reactive+oxygen+species+mediate+hepatotoxicity+induced+by+the+Hsp90+inhibitor+geldanamycin+and+its+analogs&doi=10.1016%2Fj.freeradbiomed.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs</span></div><div class="casAuthors">Samuni, Yuval; Ishii, Hisanari; Hyodo, Fuminori; Samuni, Uri; Krishna, Murali C.; Goldstein, Sara; Mitchell, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1559-1563</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Geldanamycin (GM), a benzoquinone ansamycin antibiotic, is a natural product inhibitor of Hsp90 with potent and broad anti-cancer properties.  Because of its adverse effects on liver, its less toxic derivs. 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) are currently being evaluated for the treatment of cancer.  Previously, it was demonstrated that the redox cycling of GM by NADPH-cytochrome P 450 reductase leads to the formation of the GM semiquinone and superoxide radicals, the latter being identified using spin-trapping.  We hypothesized that the different hepatotoxicity induced by GM, 17-AAG, and 17-DMAG reflects the redox active properties of the quinone moiety and possibly the extent of superoxide formation, which may stimulate cellular oxidative injury.  Our data demonstrate that superoxide can be efficiently trapped during the redn. of GM, 17-AAG, and 17-DMAG by NADPH-cytochrome P 450 reductase, and that superoxide formation rate followed the order 17-DMAG > 17-AAG > GM.  In the absence of superoxide scavengers, the rate of NADPH oxidn. followed the order 17-DMAG > GM > 17-AAG.  The half-wave one-electron redn. potentials (E1/2) of GM, 17-AAG, and 17-DMAG in DMSO were detd. to be -0.37, -0.13 and -0.015 V (vs. Ag/AgCl), resp.  If the same order of E1/2 follows in neutral aq. media, thermodn. considerations imply that 17-DMAG is more readily reduced by the P 450 reductase as well as by superoxide.  The order of the drug cytotoxicity toward rat primary hepatocytes, as detd. by their effect on cell viability and on intracellular oxidant level, was opposite to the order of E1/2 of the resp. quinone/semiquinone couples.  These results suggest that hepatotoxicity exhibited by the Hsp90 inhibitors belonging to benzoquinone ansamycins could be attributed to superoxide.  The apparent discrepancy between the order of toxicity and the orders of superoxide formation rate, which is correlated with E1/2, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpruuvDYz3MwbVg90H21EOLACvtfcHk0lifbHQt7fWuKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGru7Y%253D&md5=25d6f75c0c010667a4d9d9be51f67c21</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSamuni%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DHyodo%26aufirst%3DF.%26aulast%3DSamuni%26aufirst%3DU.%26aulast%3DKrishna%26aufirst%3DM.%2BC.%26aulast%3DGoldstein%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%26atitle%3DReactive%2520oxygen%2520species%2520mediate%2520hepatotoxicity%2520induced%2520by%2520the%2520Hsp90%2520inhibitor%2520geldanamycin%2520and%2520its%2520analogs%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2010%26volume%3D48%26spage%3D1559%26epage%3D1563%26doi%3D10.1016%2Fj.freeradbiomed.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. W.</span></span> <span> </span><span class="NLM_article-title">Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer</span>. <i>Urology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.urology.2011.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.urology.2011.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=626-630&author=W.+K.+Ohauthor=M.+D.+Galskyauthor=W.+M.+Stadlerauthor=S.+Srinivasauthor=F.+Chuauthor=G.+Bubleyauthor=J.+Goddardauthor=J.+Dunbarauthor=R.+W.+Ross&title=Multicenter+Phase+II+Trial+of+the+Heat+Shock+Protein+90+Inhibitor%2C+Retaspimycin+Hydrochloride+%28IPI-504%29%2C+in+Patients+With+Castration-resistant+Prostate+Cancer&doi=10.1016%2Fj.urology.2011.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.urology.2011.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urology.2011.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBubley%26aufirst%3DG.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26atitle%3DMulticenter%2520Phase%2520II%2520Trial%2520of%2520the%2520Heat%2520Shock%2520Protein%252090%2520Inhibitor%252C%2520Retaspimycin%2520Hydrochloride%2520%2528IPI-504%2529%252C%2520in%2520Patients%2520With%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DUrology%26date%3D2011%26volume%3D78%26spage%3D626%26epage%3D630%26doi%3D10.1016%2Fj.urology.2011.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lifbHQt7fWuKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span> <span> </span><span class="NLM_article-title">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-08-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1535-7163.mct-08-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=19372565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=921-929&author=K.+Lundgrenauthor=H.+Zhangauthor=J.+Brekkenauthor=N.+Huserauthor=R.+E.+Powellauthor=N.+Timpleauthor=D.+J.+Buschauthor=L.+Neelyauthor=J.+L.+Sensintaffarauthor=Y.-c.+Yangauthor=A.+McKenzieauthor=J.+Friedmanauthor=R.+Scannevinauthor=A.+Kamalauthor=K.+Hongauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=F.+J.+Burrows&title=BIIB021%2C+an+orally+available%2C+fully+synthetic+small-molecule+inhibitor+of+the+heat+shock+protein+Hsp90&doi=10.1158%2F1535-7163.mct-08-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span></div><div class="casAuthors">Lundgren, Karen; Zhang, Hong; Brekken, John; Huser, Nanni; Powell, Rachel E.; Timple, Noel; Busch, David J.; Neely, Laura; Sensintaffar, John L.; Yang, Yong-ching; McKenzie, Andres; Friedman, Jessica; Scannevin, Robert; Kamal, Adeela; Hong, Kevin; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) results in the degrdn. of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy.  BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90.  In tumor cells, BIIB021 induced the degrdn. of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27.  BIIB021 treatment resulted in growth inhibition and cell death in cell lines from a variety of tumor types at nanomolar concns.  Oral administration of BIIB021 led to the degrdn. of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models.  Studies to investigate the antitumor effects of BIIB021 showed activity on both daily and intermittent dosing schedules, providing dose schedule flexibility for clin. studies.  Assays measuring the HER-2 protein in tumor tissue and the HER-2 extracellular domain in plasma were used to show interdiction of the Hsp90 pathway and utility as potential biomarkers in clin. trials for BIIB021.  Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclin. models.[Mol Cancer Ther 2009;8(4):921-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbI2RYG4aF7Vg90H21EOLACvtfcHk0lgcWFMtGL4FHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D&md5=271e2311ab807bc74b2ac66b81e514e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-08-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-08-0758%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DPowell%26aufirst%3DR.%2BE.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DY.-c.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DBIIB021%252C%2520an%2520orally%2520available%252C%2520fully%2520synthetic%2520small-molecule%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%2520Hsp90%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D921%26epage%3D929%26doi%3D10.1158%2F1535-7163.mct-08-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span> <span> </span><span class="NLM_article-title">A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-13-1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-13-1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=24097863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=445-455&author=M.+W.+Saifauthor=C.+Takimotoauthor=M.+Mitaauthor=U.+Banerjiauthor=N.+Lamannaauthor=J.+Castroauthor=S.+O%E2%80%99Brienauthor=C.+Stogardauthor=D.+Von+Hoff&title=A+phase+1%2C+dose-escalation%2C+pharmacokinetic+and+pharmacodynamic+study+of+BIIB021+administered+orally+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.ccr-13-1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Saif, Muhammad Wasif; Takimoto, Chris; Mita, Monica; Banerji, Udai; Lamanna, Nicole; Castro, Januario; O'Brien, Susan; Stogard, Christopher; Von Hoff, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-455</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin-based HSP90 inhibitor that showed activity in preclin. models at low nanomolar concns.  We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors.  Exptl. Design: Sixty patients received BIIB021 capsules orally on days 1, 4, 8, 11, 15, and 18 of each course in schedule 1, and on days 1, 4, 8, 11, 15, 18, 22, and 25 of each course in schedule 2.  The treatment schedules were repeated every 28 days.  In addn. to detg. the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)].  Results: The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 wk out of each 4-wk course.  The MTD for continuous dosing regimen was established at 600 mg twice weekly.  Gastrointestinal (nausea, vomiting), hot flashes, and neurol. (dizziness) events characterize the safety profile of BIIB021 dosed twice weekly, with events mostly mild or moderate.  Plasma exposure to BIIB021 was dose-dependent.  Cmax occurred at approx. 90 min and t1/2 was approx. 1 h across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.  The biol. activity of BIIB021 was demonstrated in serum, PBMCs, and tumor tissue.  Hsp70 levels were increased (>150% from baseline) and serum HER2-ECD was significantly decreased (>15% inhibition from baseline).  Conclusions: BIIB021 twice weekly, given with or without the 1 of 4-wk rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active.  Clin Cancer Res; 20(2); 445-55. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkorAuPfyrLVg90H21EOLACvtfcHk0lgcWFMtGL4FHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D&md5=48266b9da5e440eda185af9d42e9739b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-13-1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-13-1257%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DTakimoto%26aufirst%3DC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DStogard%26aufirst%3DC.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DA%2520phase%25201%252C%2520dose-escalation%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520BIIB021%2520administered%2520orally%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D445%26epage%3D455%26doi%3D10.1158%2F1078-0432.ccr-13-1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Martin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span> <span> </span><span class="NLM_article-title">Ocular toxicity of targeted therapies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3277</span>– <span class="NLM_lpage">3286</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.41.5851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1200%2Fjco.2011.41.5851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22649132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3277-3286&author=D.+J.+Renoufauthor=J.+P.+Velazquez-Martinauthor=R.+Simpsonauthor=L.+L.+Siuauthor=P.+L.+Bedard&title=Ocular+toxicity+of+targeted+therapies&doi=10.1200%2Fjco.2011.41.5851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular toxicity of targeted therapies</span></div><div class="casAuthors">Renouf, Daniel J.; Velazquez-Martin, Juan P.; Simpson, Rand; Siu, Lillian L.; Bedard, Philippe L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3277-3286</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Molecularly targeted agents are commonly used in oncol. practice, and many new targeted agents are currently being tested in clin. trials.  Although these agents are thought to be more specific and less toxic then traditional cytotoxic chemotherapy, they are assocd. with a variety of toxicities, including ocular toxicity.  Many of the mols. targeted by anticancer agents are also expressed in ocular tissues.  We reviewed the literature for described ocular toxicities assocd. with both approved and investigational molecularly targeted agents.  Ocular toxicity has been described with numerous approved targeted agents and also seems to be assocd. with several classes of agents currently being tested in early-phase clin. trials.  We discuss the proposed pathogenesis, monitoring guidelines, and management recommendations.  It is important for oncologists to be aware of the potential for ocular toxicity, with prompt recognition of symptoms that require referral to an ophthalmologist.  Ongoing collaboration between oncologists and ocular disease specialists is crit. as the use of molecularly targeted agents continues to expand and novel targeted drug combinations are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14O59XS9-sLVg90H21EOLACvtfcHk0lhozNLycj9GIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FL&md5=4eca73917ed072e92844c2695a3b2d66</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.41.5851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.41.5851%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DVelazquez-Martin%26aufirst%3DJ.%2BP.%26aulast%3DSimpson%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26atitle%3DOcular%2520toxicity%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3277%26epage%3D3286%26doi%3D10.1200%2Fjco.2011.41.5851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lhozNLycj9GIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delmotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmotte-plaquee, J.</span></span> <span> </span><span class="NLM_article-title">A new antifungal substance of fungal origin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1953</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">344</span>, <span class="refDoi"> DOI: 10.1038/171344a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2F171344a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=1953&pages=344&author=P.+Delmotteauthor=J.+Delmotte-plaquee&title=A+new+antifungal+substance+of+fungal+origin&doi=10.1038%2F171344a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F171344a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F171344a0%26sid%3Dliteratum%253Aachs%26aulast%3DDelmotte%26aufirst%3DP.%26aulast%3DDelmotte-plaquee%26aufirst%3DJ.%26atitle%3DA%2520new%2520antifungal%2520substance%2520of%2520fungal%2520origin%26jtitle%3DNature%26date%3D1953%26volume%3D171%26spage%3D344%26doi%3D10.1038%2F171344a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3680</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-12-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-12-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=23757357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3671-3680&author=C.+Sessaauthor=G.+I.+Shapiroauthor=K.+N.+Bhallaauthor=C.+Brittenauthor=K.+S.+Jacksauthor=M.+Mitaauthor=V.+Papadimitrakopoulouauthor=T.+Pluardauthor=T.+A.+Samuelauthor=M.+Akimovauthor=C.+Quadtauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Baileyauthor=S.+Chicaauthor=U.+Banerji&title=First-in-human+phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.ccr-12-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sessa, Cristiana; Shapiro, Geoffrey I.; Bhalla, Kapil N.; Britten, Carolyn; Jacks, Karen S.; Mita, Monica; Papadimitrakopoulou, Vali; Pluard, Tim; Samuel, Thomas A.; Akimov, Mikhail; Quadt, Cornelia; Fernandez-Ibarra, Cristina; Lu, Hong; Bailey, Stuart; Chica, Sandra; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3671-3680</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I study was conducted with the primary objective of detg. the max. tolerated dose (MTD) of AUY922 in patients with advanced solid tumors.  Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles.  Patients and Methods: Patients with advanced solid tumors received 1-h i.v. infusions of AUY922 once a week in a 28-day cycle.  An adaptive Bayesian logistic regression model that employed obsd. dose-limiting toxicities (DLT) in the first treatment cycle was used to guide dose-escalation decisions, with the established MTD to be used in phase II studies.  Results: One hundred and one patients were enrolled and explored at doses in the range of 2 to 70 mg/m2.  DLTs occurred in 8 patients (22-70 mg/m2) and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms.  At 70 mg/m2, the AUY922 concn. achieved was consistent with active concns. in a range of xenograft models.  There was evidence of target inhibition in peripheral blood mononuclear cells (HSP70 induction) and tumor (client protein depletion and redn. of metabolic activity by 18F-FDG PET).  The recommended phase II dose (RP2D) of 70 mg/m2 was proposed on the basis of toxicity and pharmacokinetic and pharmacodynamic profiles.  Conclusions: At the RP2D of 70 mg/m2, AUY922 exhibited acceptable tolerability, and phase II single-agent and combination studies have been initiated in patients with HER2-pos. breast, gastric, and non-small cell lung cancers.  Clin Cancer Res; 19(13); 3671-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWielpmNf9rVg90H21EOLACvtfcHk0lhozNLycj9GIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI&md5=3a428b5489b6390c84fc046945e6d575</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-12-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-12-3404%26sid%3Dliteratum%253Aachs%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DJacks%26aufirst%3DK.%2BS.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DT.%2BA.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChica%26aufirst%3DS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3671%26epage%3D3680%26doi%3D10.1158%2F1078-0432.ccr-12-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steed, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markworth, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verleysen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4288</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/jm900230j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900230j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4288-4305&author=K.+H.+Huangauthor=J.+M.+Vealauthor=R.+P.+Faddenauthor=J.+W.+Riceauthor=J.+Eavesauthor=J.-P.+Strachanauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=T.+E.+Bartaauthor=W.+Maauthor=M.+A.+Silinskiauthor=M.+Huauthor=J.+M.+Partridgeauthor=A.+Scottauthor=L.+G.+DuBoisauthor=T.+Freedauthor=P.+M.+Steedauthor=A.+J.+Ommenauthor=E.+D.+Smithauthor=P.+F.+Hughesauthor=A.+R.+Woodwardauthor=G.+J.+Hansonauthor=W.+S.+McCallauthor=C.+J.+Markworthauthor=L.+Hinkleyauthor=M.+Jenksauthor=L.+Gengauthor=M.+Lewisauthor=J.+Ottoauthor=B.+Pronkauthor=K.+Verleysenauthor=S.+E.+Hall&title=Discovery+of+novel+2-aminobenzamide+inhibitors+of+heat+shock+protein+90+as+potent%2C+selective+and+orally+active+antitumor+agents&doi=10.1021%2Fjm900230j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents</span></div><div class="casAuthors">Huang, Kenneth H.; Veal, James M.; Fadden, R. Patrick; Rice, John W.; Eaves, Jeron; Strachan, Jon-Paul; Barabasz, Amy F.; Foley, Briana E.; Barta, Thomas E.; Ma, Wei; Silinski, Melanie A.; Hu, Mei; Partridge, Jeffrey M.; Scott, Anisa; DuBois, Laura G.; Freed, Tiffany; Steed, Paul M.; Ommen, Andy J.; Smith, Emilie D.; Hughes, Philip F.; Woodward, Angela R.; Hanson, Gunnar J.; McCall, W. Stephen; Markworth, Christopher J.; Hinkley, Lindsay; Jenks, Matthew; Geng, Lifeng; Lewis, Meredith; Otto, James; Pronk, Bert; Verleysen, Katleen; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4288-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compd. library.  These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp90, and optimized analogs exhibited nanomolar antiproliferative activity across multiple cancer cell lines.  Heat shock protein 70 (Hsp70) induction and specific client protein degrdn. in cells on treatment with the inhibitors supported Hsp90 inhibition as the mechanism of action.  Computational chem. and X-ray crystallog. anal. of selected member compds. clearly defined the protein-inhibitor interaction and assisted the design of analogs. 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide (SNX-2112) (I) was identified as highly selective and potent (IC50 Her2 = 11 nM, HT-29 = 3 nM); its prodrug amino-acetic acid 4-[2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-cyclohexyl ester methanesulfonate (SNX-5422) (II)was orally bioavailable and efficacious in a broad range of xenograft tumor models (e.g. 67% growth delay in a HT-29 model) and is now in multiple phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjrhELWrFkbVg90H21EOLACvtfcHk0lgtsns85zMSJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D&md5=99e5039e1761e9099d634acd79a15a6a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900230j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900230j%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DStrachan%26aufirst%3DJ.-P.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDuBois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DOmmen%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DWoodward%26aufirst%3DA.%2BR.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DMcCall%26aufirst%3DW.%2BS.%26aulast%3DMarkworth%26aufirst%3DC.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DB.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520novel%25202-aminobenzamide%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4288%26epage%3D4305%26doi%3D10.1021%2Fjm900230j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crandon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zein, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannargudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shnaidman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6831</span>– <span class="NLM_lpage">6839</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=21908572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6831-6839&author=A.+Rajanauthor=R.+J.+Kellyauthor=J.+B.+Trepelauthor=Y.+S.+Kimauthor=S.+V.+Alarconauthor=S.+Kummarauthor=M.+Gutierrezauthor=S.+Crandonauthor=W.+M.+Zeinauthor=L.+Jainauthor=B.+Mannargudiauthor=W.+D.+Figgauthor=B.+E.+Houkauthor=M.+Shnaidmanauthor=N.+Bregaauthor=G.+Giaccone&title=A+phase+I+study+of+PF-04929113+%28SNX-5422%29%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumor+malignancies+and+lymphomas&doi=10.1158%2F1078-0432.ccr-11-0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas</span></div><div class="casAuthors">Rajan, Arun; Kelly, Ronan J.; Trepel, Jane B.; Kim, Yeong Sang; Alarcon, Sylvia V.; Kummar, Shivaani; Gutierrez, Martin; Crandon, Sonja; Zein, Wadih M.; Jain, Lokesh; Mannargudi, Baskar; Figg, William D.; Houk, Brett E.; Shnaidman, Michael; Brega, Nicoletta; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6831-6839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the max. tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.  METHODS: This was a single-institution, phase I, dose-escalation study of PF-04929113 administered twice weekly.  Endpoints included detn. of dose-limiting toxicities (DLT), MTD, the safety profile of PF-04929113, pharmacodynamic assessment of PF-04929113 on Hsp70 induction, pharmacokinetic anal. of PF-04928473 (SNX-2112) and its prodrug PF-04929113, and assessment of response.  RESULTS: Thirty-three patients with advanced malignancies were treated.  Dose escalation was continued up to 177 mg/m2 administered orally twice a week.  One DLT (nonseptic arthritis) was noted.  No grade 4 drug-related adverse events were seen; grade 3 adverse events included diarrhea (9%), nonseptic arthritis (3%), aspartate aminotransferase elevation (3%), and thrombocytopenia (3%).  No objective responses were seen in 32 evaluable patients.  Fifteen patients (47%) had stable disease; 17 patients (53%) had progressive disease.  Pharmacokinetic data revealed rapid absorption, hepatic, and extrahepatic clearance, extensive tissue binding, and almost linear pharmacokinetics of the active drug PF-04928473.  Pharmacodynamic studies confirmed inhibition of Hsp90 and a linear correlation between pharmacokinetic parameters and Hsp70 induction.  CONCLUSIONS: PF-04929113 administered orally twice a week is well tolerated and inhibits its intended target Hsp90.  No objective responses were seen, but long-lasting stabilizations were obtained.  Although no clin. significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a sep. phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQzbnkoUJnibVg90H21EOLACvtfcHk0lgtsns85zMSJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM&md5=2b10fada0eb9d1dc7e06826724edf21f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-0821%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DAlarcon%26aufirst%3DS.%2BV.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DCrandon%26aufirst%3DS.%26aulast%3DZein%26aufirst%3DW.%2BM.%26aulast%3DJain%26aufirst%3DL.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DShnaidman%26aufirst%3DM.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520PF-04929113%2520%2528SNX-5422%2529%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumor%2520malignancies%2520and%2520lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6831%26epage%3D6839%26doi%3D10.1158%2F1078-0432.ccr-11-0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the heat shock response: biology and pharmacology</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">3758</span>– <span class="NLM_lpage">3769</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2007.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.febslet.2007.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=17559840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2007&pages=3758-3769&author=M.+V.+Powersauthor=P.+Workman&title=Inhibitors+of+the+heat+shock+response%3A+biology+and+pharmacology&doi=10.1016%2Fj.febslet.2007.05.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the heat shock response: Biology and pharmacology</span></div><div class="casAuthors">Powers, Marissa V.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3758-3769</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of human diseases can be linked to aberrations in protein folding which cause an imbalance in protein homeostasis.  Mol. chaperones, including heat shock proteins, act to assist protein folding, stability and activity in the cell.  Attention has begun to focus on modulating the expression and/or activity of this group of proteins for the treatment of a wide variety of human diseases.  This review will describe the progress made to date in developing pharmacol. modulators of the heat shock response, including both agents which affect the entire heat shock response and those that specifically target the HSP70 and HSP90 chaperone families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd1XAAhY6tPLVg90H21EOLACvtfcHk0lgM41jM0DP0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlaisbo%253D&md5=3be785569e7caee11e84a8cb4ca20574</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2007.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2007.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DM.%2BV.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520the%2520heat%2520shock%2520response%253A%2520biology%2520and%2520pharmacology%26jtitle%3DFEBS%2520Lett.%26date%3D2007%26volume%3D581%26spage%3D3758%26epage%3D3769%26doi%3D10.1016%2Fj.febslet.2007.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskew, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadikot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembruff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajewski, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjarrez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vielhauer, G. A.</span></span> <span> </span><span class="NLM_article-title">Development and characeterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">468</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-11-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1186%2F1471-2407-11-468" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=468&author=J.+D.+Eskewauthor=T.+Sadikotauthor=P.+Moralesauthor=A.+Durenauthor=I.+Dunwiddieauthor=M.+Swinkauthor=X.+Zhangauthor=S.+Hembruffauthor=A.+Donnellyauthor=R.+A.+Rajewskiauthor=B.+Bladauthor=J.+R.+Manjarrezauthor=R.+L.+Mattsauthor=J.+M.+Holzbeierleinauthor=G.+A.+Vielhauer&title=Development+and+characeterization+of+a+novel+C-terminal+inhibitor+of+Hsp90+in+androgen+dependent+and+independent+prostate+cancer+cells&doi=10.1186%2F1471-2407-11-468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-468%26sid%3Dliteratum%253Aachs%26aulast%3DEskew%26aufirst%3DJ.%2BD.%26aulast%3DSadikot%26aufirst%3DT.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DDuren%26aufirst%3DA.%26aulast%3DDunwiddie%26aufirst%3DI.%26aulast%3DSwink%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHembruff%26aufirst%3DS.%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DBlad%26aufirst%3DB.%26aulast%3DManjarrez%26aufirst%3DJ.%2BR.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26atitle%3DDevelopment%2520and%2520characeterization%2520of%2520a%2520novel%2520C-terminal%2520inhibitor%2520of%2520Hsp90%2520in%2520androgen%2520dependent%2520and%2520independent%2520prostate%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D468%26doi%3D10.1186%2F1471-2407-11-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koay, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckton, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, S. R.</span></span> <span> </span><span class="NLM_article-title">Chemically accessible hsp90 inhibitor that does not induce a heat shock response</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1021/ml500114p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500114p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=771-776&author=Y.+C.+Koayauthor=J.+R.+McConnellauthor=Y.+Wangauthor=S.+J.+Kimauthor=L.+K.+Bucktonauthor=F.+Mansourauthor=S.+R.+McAlpine&title=Chemically+accessible+hsp90+inhibitor+that+does+not+induce+a+heat+shock+response&doi=10.1021%2Fml500114p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml500114p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500114p%26sid%3Dliteratum%253Aachs%26aulast%3DKoay%26aufirst%3DY.%2BC.%26aulast%3DMcConnell%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DBuckton%26aufirst%3DL.%2BK.%26aulast%3DMansour%26aufirst%3DF.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DChemically%2520accessible%2520hsp90%2520inhibitor%2520that%2520does%2520not%2520induce%2520a%2520heat%2520shock%2520response%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D771%26epage%3D776%26doi%3D10.1021%2Fml500114p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Water, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perret, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-C.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90: inhibitors in clinical trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1021/jm9004708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.-C.+Lee&title=Heat+shock+protein+90%3A+inhibitors+in+clinical+trials&doi=10.1021%2Fjm9004708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0lgM41jM0DP0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17%26doi%3D10.1021%2Fjm9004708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">How Well Can Fragments Explore Accessed Chemical Space? A Case Study from Heat Shock Protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3989</span>– <span class="NLM_lpage">4005</span>, <span class="refDoi"> DOI: 10.1021/jm200350g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200350g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3989-4005&author=S.+D.+Roughleyauthor=R.+E.+Hubbard&title=How+Well+Can+Fragments+Explore+Accessed+Chemical+Space%3F+A+Case+Study+from+Heat+Shock+Protein+90&doi=10.1021%2Fjm200350g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">How Well Can Fragments Explore Accessed Chemical Space? A Case Study from Heat Shock Protein 90</span></div><div class="casAuthors">Roughley, Stephen D.; Hubbard, Roderick E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3989-4005</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summerizes the published literature on the generation of inhibitors and design of drug against the mol. chaperone, heat shock protein 90 (Hsp90), as potential therapeutics to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocGw-54Mo8SrVg90H21EOLACvtfcHk0liajdqnHzrn4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymurs%253D&md5=90c2c8028cb460c0c6fdc956e7daae28</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm200350g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200350g%26sid%3Dliteratum%253Aachs%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DHow%2520Well%2520Can%2520Fragments%2520Explore%2520Accessed%2520Chemical%2520Space%253F%2520A%2520Case%2520Study%2520from%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3989%26epage%3D4005%26doi%3D10.1021%2Fjm200350g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzamide tetrahydro-4<i>H</i>-carbazol-4-ones as novel small molecule inhibitors of Hsp90</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3517</span>– <span class="NLM_lpage">3521</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.bmcl.2008.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=18511277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFSns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3517-3521&author=T.+E.+Bartaauthor=J.+M.+Vealauthor=J.+W.+Riceauthor=J.+M.+Partridgeauthor=R.+P.+Faddenauthor=W.+Maauthor=M.+Jenksauthor=L.+Gengauthor=G.+J.+Hansonauthor=K.+H.+Huangauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=J.+Ottoauthor=S.+E.+Hall&title=Discovery+of+benzamide+tetrahydro-4H-carbazol-4-ones+as+novel+small+molecule+inhibitors+of+Hsp90&doi=10.1016%2Fj.bmcl.2008.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90</span></div><div class="casAuthors">Barta, Thomas E.; Veal, James M.; Rice, John W.; Partridge, Jeffrey M.; Fadden, R. Patrick; Ma, Wei; Jenks, Matthew; Geng, Lifeng; Hanson, Gunnar J.; Huang, Kenneth H.; Barabasz, Amy F.; Foley, Briana E.; Otto, James; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3517-3521</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hsp90 maintains the conformational stability of multiple proteins implicated in oncogenesis and has emerged as a target for chemotherapy.  We report here the discovery of a novel small mol. scaffold that inhibits Hsp90.  X-ray data show that the scaffold binds competitively at the ATP site on Hsp90.  Cellular proliferation and client assays demonstrate that members of the series are able to inhibit Hsp90 at nanomolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Wjx_IUjKbVg90H21EOLACvtfcHk0liajdqnHzrn4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFSns74%253D&md5=f965e9a2cfd0d44a57bb1949cd87de63</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520benzamide%2520tetrahydro-4H-carbazol-4-ones%2520as%2520novel%2520small%2520molecule%2520inhibitors%2520of%2520Hsp90%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3517%26epage%3D3521%26doi%3D10.1016%2Fj.bmcl.2008.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steed, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silinski, M. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verleysen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+R.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+Hsp90&doi=10.1016%2Fj.chembiol.2010.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0liajdqnHzrn4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%2BR.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694%26doi%3D10.1016%2Fj.chembiol.2010.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span>; <span class="NLM_string-name">Mailliet, P.</span>; <span class="NLM_string-name">Ruxer, J.
M.</span>; <span class="NLM_string-name">Goulaouic, H.</span>; <span class="NLM_string-name">Vallée, F.</span>; <span class="NLM_string-name">Minoux, H.</span>; <span class="NLM_string-name">Pilorge, F.</span>; <span class="NLM_string-name">Bertin, L.</span>; <span class="NLM_string-name">Hourcade, S.</span>; <span class="NLM_string-name">Mendez-perez, M.</span>, <span class="NLM_string-name">Hamley, P.</span></span> <span> </span><span class="NLM_article-title">New Fluorine Derivatives, Compositions Containing the Same and Use Thereof as Inhibitors of the Protein Chaperone HSP 90</span>. WO <span class="NLM_patent">2008049994</span>, May 2, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=F.+Thompson&author=P.+Mailliet&author=J.%0AM.+Ruxer&author=H.+Goulaouic&author=F.+Vall%C3%A9e&author=H.+Minoux&author=F.+Pilorge&author=L.+Bertin&author=S.+Hourcade&author=M.+Mendez-perez&author=P.+Hamley&title=New+Fluorine+Derivatives%2C+Compositions+Containing+the+Same+and+Use+Thereof+as+Inhibitors+of+the+Protein+Chaperone+HSP+90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DF.%26atitle%3DNew%2520Fluorine%2520Derivatives%252C%2520Compositions%2520Containing%2520the%2520Same%2520and%2520Use%2520Thereof%2520as%2520Inhibitors%2520of%2520the%2520Protein%2520Chaperone%2520HSP%252090%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span>; <span class="NLM_string-name">Minoux, H.</span>; <span class="NLM_string-name">Ruxer, J.
M.</span></span> <span> </span><span class="NLM_article-title">Novel HSP90-Inhibiting Indole Derivatives, Compositions Containing Said Derivatives, and Use Thereof</span>. WO <span class="NLM_patent">2011004132</span>, Jan 13, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Mailliet&author=H.+Minoux&author=J.%0AM.+Ruxer&title=Novel+HSP90-Inhibiting+Indole+Derivatives%2C+Compositions+Containing+Said+Derivatives%2C+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMailliet%26aufirst%3DP.%26atitle%3DNovel%2520HSP90-Inhibiting%2520Indole%2520Derivatives%252C%2520Compositions%2520Containing%2520Said%2520Derivatives%252C%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span> <span> </span><span class="NLM_article-title">Improvement of the high-speed log<i>D</i> assay using an injection marker for the water plug aspiration/injection method</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1216</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2009.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chroma.2009.02.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1216&publication_year=2009&pages=2984-2988&author=I.+Nishimuraauthor=A.+Hiranoauthor=T.+Yamashitaauthor=T.+Fukami&title=Improvement+of+the+high-speed+logD+assay+using+an+injection+marker+for+the+water+plug+aspiration%2Finjection+method&doi=10.1016%2Fj.chroma.2009.02.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2009.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2009.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DI.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26atitle%3DImprovement%2520of%2520the%2520high-speed%2520logD%2520assay%2520using%2520an%2520injection%2520marker%2520for%2520the%2520water%2520plug%2520aspiration%252Finjection%2520method%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2009%26volume%3D1216%26spage%3D2984%26epage%3D2988%26doi%3D10.1016%2Fj.chroma.2009.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span> <span> </span><span class="NLM_article-title">High-speed solubility screening assay using ultra-performance liquid chromatography/mass spectrometry in drug discovery</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1182</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2007.12.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chroma.2007.12.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=2008&pages=72-76&author=T.+Yamashitaauthor=Y.+Dohtaauthor=T.+Nakamuraauthor=T.+Fukami&title=High-speed+solubility+screening+assay+using+ultra-performance+liquid+chromatography%2Fmass+spectrometry+in+drug+discovery&doi=10.1016%2Fj.chroma.2007.12.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2007.12.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2007.12.086%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DDohta%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26atitle%3DHigh-speed%2520solubility%2520screening%2520assay%2520using%2520ultra-performance%2520liquid%2520chromatography%252Fmass%2520spectrometry%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2008%26volume%3D1182%26spage%3D72%26epage%3D76%26doi%3D10.1016%2Fj.chroma.2007.12.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span>; <span class="NLM_string-name">Okubo, S.</span>; <span class="NLM_string-name">Yoshimura, C.</span>; <span class="NLM_string-name">Yamashita, S.</span>; <span class="NLM_string-name">Osiumi, H.</span>; <span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Kawai, Y.</span></span> <span> </span><span class="NLM_article-title">Azabicyclo Compound and Salt Thereof</span>. WO <span class="NLM_patent">2011004610</span>, Jan 13, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Kitade&author=S.+Okubo&author=C.+Yoshimura&author=S.+Yamashita&author=H.+Osiumi&author=T.+Uno&author=Y.+Kawai&title=Azabicyclo+Compound+and+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKitade%26aufirst%3DM.%26atitle%3DAzabicyclo%2520Compound%2520and%2520Salt%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2004.03.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=776-785&author=L.+Wrightauthor=X.+Barrilauthor=B.+Dymockauthor=L.+Sheridanauthor=A.+Surgenorauthor=M.+Beswickauthor=M.+Drysdaleauthor=A.+Collierauthor=A.+Masseyauthor=N.+Daviesauthor=A.+Finkauthor=C.+Fromontauthor=W.+Aherneauthor=K.+Boxallauthor=S.+Sharpauthor=P.+Workmanauthor=R.+E.+Hubbard&title=Structure-activity+relationships+in+purine-based+inhibitor+binding+to+HSP90+isoforms&doi=10.1016%2Fj.chembiol.2004.03.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DL.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DBeswick%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DFromont%26aufirst%3DC.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DStructure-activity%2520relationships%2520in%2520purine-based%2520inhibitor%2520binding%2520to%2520HSP90%2520isoforms%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D776%26epage%3D785%26doi%3D10.1016%2Fj.chembiol.2004.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrebola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohaut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruxer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouanen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grépin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulaouic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dereu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoux, H.</span></span> <span> </span><span class="NLM_article-title">Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: Discovery of tricyclic imidazo[4,5-<i>c</i>]pyridines as potent inhibitors of the Hsp90 molecular chaperone</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7219</span>, <span class="refDoi"> DOI: 10.1021/jm200784m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200784m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7206-7219&author=F.+Vall%C3%A9eauthor=C.+Carrezauthor=F.+Pilorgeauthor=A.+Dupuyauthor=A.+Parentauthor=L.+Bertinauthor=F.+Thompsonauthor=P.+Ferrariauthor=F.+Fassyauthor=A.+Lambertonauthor=A.+Thomasauthor=R.+Arrebolaauthor=S.+Guerifauthor=A.+Rohautauthor=V.+Certalauthor=J.+M.+Ruxerauthor=C.+Delormeauthor=A.+Jouanenauthor=J.+Dumasauthor=C.+Gr%C3%A9pinauthor=C.+Combeauauthor=H.+Goulaouicauthor=N.+Dereuauthor=V.+Mikolauthor=P.+Maillietauthor=H.+Minoux&title=Tricyclic+series+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+part+I%3A+Discovery+of+tricyclic+imidazo%5B4%2C5-c%5Dpyridines+as+potent+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1021%2Fjm200784m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm200784m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200784m%26sid%3Dliteratum%253Aachs%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DCarrez%26aufirst%3DC.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFerrari%26aufirst%3DP.%26aulast%3DFassy%26aufirst%3DF.%26aulast%3DLamberton%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DArrebola%26aufirst%3DR.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DRohaut%26aufirst%3DA.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DRuxer%26aufirst%3DJ.%2BM.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DJouanen%26aufirst%3DA.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DGr%25C3%25A9pin%26aufirst%3DC.%26aulast%3DCombeau%26aufirst%3DC.%26aulast%3DGoulaouic%26aufirst%3DH.%26aulast%3DDereu%26aufirst%3DN.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMinoux%26aufirst%3DH.%26atitle%3DTricyclic%2520series%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520part%2520I%253A%2520Discovery%2520of%2520tricyclic%2520imidazo%255B4%252C5-c%255Dpyridines%2520as%2520potent%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7206%26epage%3D7219%26doi%3D10.1021%2Fjm200784m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 and, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1535-7163.mct-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+Highly+Selective+Inhibitor+of+Heat+Shock+Protein+90+and%2C+Demonstrates+Potent+Antitumor+Activity+and+Minimal+Ocular+Toxicity+in+Preclinical+Models&doi=10.1158%2F1535-7163.mct-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0lh4j5nN0CHsNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520Highly%2520Selective%2520Inhibitor%2520of%2520Heat%2520Shock%2520Protein%252090%2520and%252C%2520Demonstrates%2520Potent%2520Antitumor%2520Activity%2520and%2520Minimal%2520Ocular%2520Toxicity%2520in%2520Preclinical%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.mct-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span> <span> </span><span class="NLM_article-title">A fluorescence polarization assay for inhibitors of Hsp90</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2005.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.ab.2005.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16460658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVeht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2006&pages=202-213&author=R.+Howesauthor=X.+Barrilauthor=B.+W.+Dymockauthor=K.+Grantauthor=C.+J.+Northfieldauthor=A.+G.+S.+Robertsonauthor=A.+Surgenorauthor=J.+Wayneauthor=L.+Wrightauthor=K.+Jamesauthor=T.+Matthewsauthor=K.-M.+Cheungauthor=E.+McDonaldauthor=P.+Workmanauthor=M.+J.+Drysdale&title=A+fluorescence+polarization+assay+for+inhibitors+of+Hsp90&doi=10.1016%2Fj.ab.2005.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescence polarization assay for inhibitors of Hsp90</span></div><div class="casAuthors">Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G. S.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K.-M.; McDonald, E.; Workman, P.; Drysdale, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-213</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hsp90 encodes a ubiquitous mol. chaperone protein conserved among species which acts on multiple substrates, many of which are important cell-signaling proteins.  Inhibition of Hsp90 function has been promoted as a mechanism to degrade client proteins involved in tumorigenesis and disease progression.  Several assays to monitor inhibition of Hsp90 function currently exist but are limited in their use for a drug discovery campaign.  Using data from the crystal structure of an initial hit compd., we have synthesized a fluorescent probe to be used in a fluorescence polarization assay to monitor binding of compds. to the ATP-binding site of Hsp90.  This assay is very robust (Z' > 0.9) and can detect affinity of compds. with IC50s to 40 nM.  We have used this assay in conjunction with cocrystal structures of small mols. to drive a structure-based design program aimed at the discovery and optimization of a novel class of potent Hsp90 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoag8hYDpa7BrVg90H21EOLACvtfcHk0lh4j5nN0CHsNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVeht74%253D&md5=59b8bce204a19c6618f9bce225eeb7df</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2005.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2005.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DRobertson%26aufirst%3DA.%2BG.%2BS.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWayne%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DMatthews%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26atitle%3DA%2520fluorescence%2520polarization%2520assay%2520for%2520inhibitors%2520of%2520Hsp90%26jtitle%3DAnal.%2520Biochem.%26date%3D2006%26volume%3D350%26spage%3D202%26epage%3D213%26doi%3D10.1016%2Fj.ab.2005.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lea, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span> <span> </span><span class="NLM_article-title">fluorescence polarization assays in small molecule screening</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1517/17460441.2011.537322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1517%2F17460441.2011.537322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22328899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=17-32&author=W.+A.+Leaauthor=A.+Simeonov&title=fluorescence+polarization+assays+in+small+molecule+screening&doi=10.1517%2F17460441.2011.537322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence polarization assays in small molecule screening</span></div><div class="casAuthors">Lea, Wendy A.; Simeonov, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Fluorescence polarization (FP) is a homogeneous method that allows rapid and quant. anal. of diverse mol. interactions and enzyme activities.  This technique has been widely utilized in clin. and biomedical settings, including the diagnosis of certain diseases and monitoring therapeutic drug levels in body fluids.  Recent developments in the field have been symbolized by the facile adoption of FP in high-throughput screening and small mol. drug discovery of an increasing range of target classes.  Areas covered in this review: The article provides a brief overview of the theor. foundation of FP, followed by updates on recent advancements in its application for various drug target classes, including GPCRs, enzymes and protein-protein interactions.  The strengths and weaknesses of this method, practical considerations in assay design, novel applications and future directions are also discussed.  What the reader will gain: The reader is informed of the most recent advancements and future directions of FP application to small mol. screening.  Take home message: In addn. to its continued utilization in high-throughput screening, FP has expanded into new disease and target areas and has been marked by increased use of labeled small mol. ligands for receptor-binding studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqudLso-a4wR7Vg90H21EOLACvtfcHk0lhnni1F0evLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvP&md5=6f102f40b56fd7a13c4fb59b64a3f883</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.537322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.537322%26sid%3Dliteratum%253Aachs%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DSimeonov%26aufirst%3DA.%26atitle%3Dfluorescence%2520polarization%2520assays%2520in%2520small%2520molecule%2520screening%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D17%26epage%3D32%26doi%3D10.1517%2F17460441.2011.537322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fleu.2014.300" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=510-514&author=R.+Suzukiauthor=T.+Hideshimaauthor=N.+Mimuraauthor=J.+Minamiauthor=H.+Ohguchiauthor=S.+Kikuchiauthor=Y.+Yoshidaauthor=G.+Gorgunauthor=D.+Cirsteaauthor=F.+Cottiniauthor=J.+Jakubikovaauthor=Y.-T.+Taiauthor=D.+Chauhanauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=T.+Utsugiauthor=K.+C.+Anderson&title=Anti-tumor+activities+of+selective+HSP90%CE%B1%2F%CE%B2+inhibitor%2C+TAS-116%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1038%2Fleu.2014.300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.300%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DMinami%26aufirst%3DJ.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DJakubikova%26aufirst%3DJ.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DAnti-tumor%2520activities%2520of%2520selective%2520HSP90%25CE%25B1%252F%25CE%25B2%2520inhibitor%252C%2520TAS-116%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D510%26epage%3D514%26doi%3D10.1038%2Fleu.2014.300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e73</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3Dresistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lhnni1F0evLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antilla, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">The Copper-Catalyzed N-Arylation of Indoles</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">11684</span>– <span class="NLM_lpage">11688</span>, <span class="refDoi"> DOI: 10.1021/ja027433h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja027433h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms12rtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=11684-11688&author=J.+C.+Antillaauthor=A.+Klaparsauthor=S.+L.+Buchwald&title=The+Copper-Catalyzed+N-Arylation+of+Indoles&doi=10.1021%2Fja027433h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Copper-Catalyzed N-Arylation of Indoles</span></div><div class="casAuthors">Antilla, Jon C.; Klapars, Artis; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">11684-11688</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general method for the N-arylation of indoles using catalysts derived from CuI and trans-1,2-cyclohexanediamine, trans-N,N'-dimethyl-1,2-cyclohexanediamine, or N,N'-dimethylethylenediamine is reported.  N-Arylindoles can be produced in high yield from the coupling of an aryl iodide or aryl bromide with a variety of indoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6AFBSNUIjerVg90H21EOLACvtfcHk0lhnni1F0evLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms12rtb8%253D&md5=6f6f920e679db7512c645208c772c975</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja027433h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja027433h%26sid%3Dliteratum%253Aachs%26aulast%3DAntilla%26aufirst%3DJ.%2BC.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DThe%2520Copper-Catalyzed%2520N-Arylation%2520of%2520Indoles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D11684%26epage%3D11688%26doi%3D10.1021%2Fja027433h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antilla, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barder, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Copper–Diamine-CatalyzedN-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">5578</span>– <span class="NLM_lpage">5587</span>, <span class="refDoi"> DOI: 10.1021/jo049658b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo049658b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFemu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=5578-5587&author=J.+C.+Antillaauthor=J.+M.+Baskinauthor=T.+E.+Barderauthor=S.+L.+Buchwald&title=Copper%E2%80%93Diamine-CatalyzedN-Arylation+of+Pyrroles%2C+Pyrazoles%2C+Indazoles%2C+Imidazoles%2C+and+Triazoles&doi=10.1021%2Fjo049658b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles</span></div><div class="casAuthors">Antilla, Jon C.; Baskin, Jeremy M.; Barder, Timothy E.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5578-5587</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A copper-catalyzed N-arylation reaction of π-excessive nitrogen heterocycles is presented.  The coupling of either aryl iodides or aryl bromides with common nitrogen heterocycles (pyrroles, pyrazoles, indazoles, imidazoles, and triazoles) was successfully performed in good yield with catalysts derived from diamine ligands and CuI.  General conditions that tolerate functional groups such as aldehydes, ketones, alcs., primary amines, and nitriles on the aryl halide or heterocycle, were found.  Hindered aryl halides or heterocycles were also found to be suitable substrates using the conditions reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRNBpOn5bH6rVg90H21EOLACvtfcHk0ljOz3hi2Jlbog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFemu7s%253D&md5=aba4bc16c9e4cf2d4c8688b42667a581</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo049658b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049658b%26sid%3Dliteratum%253Aachs%26aulast%3DAntilla%26aufirst%3DJ.%2BC.%26aulast%3DBaskin%26aufirst%3DJ.%2BM.%26aulast%3DBarder%26aufirst%3DT.%2BE.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper%25E2%2580%2593Diamine-CatalyzedN-Arylation%2520of%2520Pyrroles%252C%2520Pyrazoles%252C%2520Indazoles%252C%2520Imidazoles%252C%2520and%2520Triazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D5578%26epage%3D5587%26doi%3D10.1021%2Fjo049658b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urogdi, L.</span></span> <span> </span><span class="NLM_article-title">Efficient Conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1055/s-1989-27441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1055%2Fs-1989-27441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK3cXktVGrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&pages=949-950&author=A.+R.+Katritzkyauthor=B.+Pilarskiauthor=L.+Urogdi&title=Efficient+Conversion+of+nitriles+to+amides+with+basic+hydrogen+peroxide+in+dimethyl+sulfoxide&doi=10.1055%2Fs-1989-27441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide</span></div><div class="casAuthors">Katritzky, Alan R.; Pilarski, Boguslaw; Urogdi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-50</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">Hydrolysis of RCN [R = Ph, 4-ClC6H4, 2-pyridyl, 2-benzimidazolylmethyl, H(CH2)8, PhCH2O2CNHCHPh, etc.] with 30% H2O2 in DMSO contg. K2CO3 gave 65-99% RCONH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPMBmBssp3MrVg90H21EOLACvtfcHk0ljOz3hi2Jlbog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVGrtrY%253D&md5=16cddca5856116a7674dfec60f18398b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1055%2Fs-1989-27441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1989-27441%26sid%3Dliteratum%253Aachs%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26aulast%3DPilarski%26aufirst%3DB.%26aulast%3DUrogdi%26aufirst%3DL.%26atitle%3DEfficient%2520Conversion%2520of%2520nitriles%2520to%2520amides%2520with%2520basic%2520hydrogen%2520peroxide%2520in%2520dimethyl%2520sulfoxide%26jtitle%3DSynthesis%26date%3D1989%26spage%3D949%26epage%3D950%26doi%3D10.1055%2Fs-1989-27441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of the reaction of nitriles with alkaline hydrogen peroxide. reactivity of peroxycarboximidic acid and application to superoxide ion reaction</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1246/bcsj.54.793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1246%2Fbcsj.54.793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaL3MXks1Wjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1981&pages=793-799&author=Y.+Sawakiauthor=Y.+Ogata&title=Mechanism+of+the+reaction+of+nitriles+with+alkaline+hydrogen+peroxide.+reactivity+of+peroxycarboximidic+acid+and+application+to+superoxide+ion+reaction&doi=10.1246%2Fbcsj.54.793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of the reaction of nitriles with alkaline hydrogen peroxide.  Reactivity of peroxycarboximidic acid and application to superoxide ion reaction</span></div><div class="casAuthors">Sawaki, Yasuhiko; Ogata, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">793-9</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">Formation of peroxycarboximidic acid (I) is not rate-detg. in the reaction of nitrile with alk. H2O2 to form amide and oxygen; the yield of amide based on H2O2 varies from 20 to 60%.  When Me2SO, a reactive substrate, is added, the rate is independent of its concn. and governed in turn by a rate-detg. addn. of HOO- to nitrile.  This reaction gives a reliable α-value of kHOO-/kHO-, which is 10000 for PhCN.  A facile conversion of nitrile to amide may be achieved by the reaction in the presence of MeSO, unaccompanied by side reactions such as the epoxyamide formation from α,β-unsatd. nitrile.  Kinetics and product anal. suggest that a predominant reaction is a radical decompn. of H2O2 which is induced by the homolysis of anion of I.  The reaction of superoxide ion, O2, with acetonitrile is analogous to that of HOO-; the decompn. of O2- is fast in the presence of MeCN and Me2SO in C6H6, affording acetamide and Me2SO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4ijDOd7BFVbVg90H21EOLACvtfcHk0ljOz3hi2Jlbog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXks1Wjsb4%253D&md5=ff0be923eb97bcd8d1a0d52595de1a43</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.54.793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.54.793%26sid%3Dliteratum%253Aachs%26aulast%3DSawaki%26aufirst%3DY.%26aulast%3DOgata%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520the%2520reaction%2520of%2520nitriles%2520with%2520alkaline%2520hydrogen%2520peroxide.%2520reactivity%2520of%2520peroxycarboximidic%2520acid%2520and%2520application%2520to%2520superoxide%2520ion%2520reaction%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1981%26volume%3D54%26spage%3D793%26epage%3D799%26doi%3D10.1246%2Fbcsj.54.793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasamatsu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohuchida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span> <span> </span><span class="NLM_article-title">A New process for synthesis of the astrocyte activation suppressor, ONO-2506</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1021/op0500988</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0500988" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=774-781&author=T.+Hasegawaauthor=Y.+Kawanakaauthor=E.+Kasamatsuauthor=C.+Ohtaauthor=K.+Nakabayashiauthor=M.+Okamotoauthor=M.+Hamanoauthor=K.+Takahashiauthor=S.+Ohuchidaauthor=Y.+Hamada&title=A+New+process+for+synthesis+of+the+astrocyte+activation+suppressor%2C+ONO-2506&doi=10.1021%2Fop0500988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A new process for synthesis of the astrocyte activation suppressor, ONO-2506</span></div><div class="casAuthors">Hasegawa, Tomoyuki; Kawanaka, Yasufumi; Kasamatsu, Eichi; Ohta, Chisa; Nakabayashi, Kazuhiro; Okamoto, Masaki; Hamano, Masaya; Takahashi, Keiji; Ohuchida, Shuichi; Hamada, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">774-781</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of a new process for the synthesis of ONO-2506, an agent that suppresses astrocyte activation, is described.  Previous processes that involved asym. synthesis with a chiral auxiliary were unsatisfactory from a cost perspective because the relatively expensive chiral auxiliaries were not recyclable.  To develop a more cost-effective process, the authors designed a new process starting from chiral 1,2-epoxyoctane, which was readily prepd. catalytically by Jacobsen's method.  The new five-step process was developed with the establishment of a modified cyanation condition, in which lithium cyanide was prepd. in situ by combining lithium hydroxide with acetone cyanohydrin.  Then the mechanisms for racemization and the side reaction until the cyanation step were clarified, and these problems were solved.  The main features of this process are crystn. of the amide intermediate, since its optical purity is readily improved by recrystn. up to 100% ee in addn. to formation of the dibenzylamine salt with ONO-2506 that leads to improved chem. and optical purity of the final product.  The shorter synthesis, including a one-pot reaction was ruled out because of the hazardous nature of the Katritzky hydrolysis conditions for the conversion of nitrile to amide in the presence of sodium cyanide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcY9CneNUWULVg90H21EOLACvtfcHk0li5yC6JDE5FpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslWrtL0%253D&md5=6ffc717de08a3d78b124310fe2088006</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fop0500988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0500988%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DKawanaka%26aufirst%3DY.%26aulast%3DKasamatsu%26aufirst%3DE.%26aulast%3DOhta%26aufirst%3DC.%26aulast%3DNakabayashi%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DHamano%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DOhuchida%26aufirst%3DS.%26aulast%3DHamada%26aufirst%3DY.%26atitle%3DA%2520New%2520process%2520for%2520synthesis%2520of%2520the%2520astrocyte%2520activation%2520suppressor%252C%2520ONO-2506%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D774%26epage%3D781%26doi%3D10.1021%2Fop0500988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnürch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihovilovic, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanetty, P.</span></span> <span> </span><span class="NLM_article-title">Halogen dance reactions-A review</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1039/b607701n</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1039%2Fb607701n" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=17576473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=1046-1057&author=M.+Schn%C3%BCrchauthor=M.+Spinaauthor=A.+F.+Khanauthor=M.+D.+Mihovilovicauthor=P.+Stanetty&title=Halogen+dance+reactions-A+review&doi=10.1039%2Fb607701n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen dance reactions - A review</span></div><div class="casAuthors">Schnuerch, Michael; Spina, Markus; Khan, Ather Farooq; Mihovilovic, Marko D.; Stanetty, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1046-1057</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Halogen Dance (HD) reactions are a useful tool for synthetic chemists as they enable access to positions in arom. and heteroarom. systems for subsequent functionalization which are often difficult to address by other methods, hence, allowing entry to versatile scaffolds.  While the method can be extremely useful, this transformation is often neglected upon designing synthetic sequences.  This may be largely attributed to the lack of comprehensive ref. works covering the general principles and outlining the versatility and limitations of the technique.  The following review tries to present HD reactions in a clear and concise manner in order to convince more chemists of its advantages.  It covers the field of HD reactions from their first observation in 1951 until the present.  The important contributions leading to the elucidation of the mechanism are briefly outlined followed by a detailed mechanistic section and a discussion of factors which influence HD reactions.  Finally, an overview of HD reactions on various carbocyclic and heterocyclic ring systems and its applications in the synthesis of complex compds. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcr1jxTRMi3bVg90H21EOLACvtfcHk0li5yC6JDE5FpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFantLs%253D&md5=72ee905f7657190172d195dd8ca326e7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fb607701n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb607701n%26sid%3Dliteratum%253Aachs%26aulast%3DSchn%25C3%25BCrch%26aufirst%3DM.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DA.%2BF.%26aulast%3DMihovilovic%26aufirst%3DM.%2BD.%26aulast%3DStanetty%26aufirst%3DP.%26atitle%3DHalogen%2520dance%2520reactions-A%2520review%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2007%26volume%3D36%26spage%3D1046%26epage%3D1057%26doi%3D10.1039%2Fb607701n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantam, M.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreedhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-arylation of heterocycles with activated chloro- and fluoroarenes using nanocrystalline copper(II) oxide</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1002/adsc.200600483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1002%2Fadsc.200600483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=1938-1942&author=M.%0AL.+Kantamauthor=J.+Yadavauthor=S.+Lahaauthor=B.+Sreedharauthor=S.+Jha&title=N-arylation+of+heterocycles+with+activated+chloro-+and+fluoroarenes+using+nanocrystalline+copper%28II%29+oxide&doi=10.1002%2Fadsc.200600483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200600483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200600483%26sid%3Dliteratum%253Aachs%26aulast%3DKantam%26aufirst%3DM.%2BL.%26aulast%3DYadav%26aufirst%3DJ.%26aulast%3DLaha%26aufirst%3DS.%26aulast%3DSreedhar%26aufirst%3DB.%26aulast%3DJha%26aufirst%3DS.%26atitle%3DN-arylation%2520of%2520heterocycles%2520with%2520activated%2520chloro-%2520and%2520fluoroarenes%2520using%2520nanocrystalline%2520copper%2528II%2529%2520oxide%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D1938%26epage%3D1942%26doi%3D10.1002%2Fadsc.200600483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koval, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Copper-catalyzed <i>N</i>-arylation of imidazoles and benzimidazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">6190</span>– <span class="NLM_lpage">6199</span>, <span class="refDoi"> DOI: 10.1021/jo070807a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070807a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1CktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=6190-6199&author=R.+A.+Altmanauthor=E.+D.+Kovalauthor=S.+L.+Buchwald&title=Copper-catalyzed+N-arylation+of+imidazoles+and+benzimidazoles&doi=10.1021%2Fjo070807a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Catalyzed N-Arylation of Imidazoles and Benzimidazoles</span></div><div class="casAuthors">Altman, Ryan A.; Koval, Erica D.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6190-6199</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4,7-Dimethoxy-1,10-phenanthroline (L1c) was found to be an efficient ligand for the copper-catalyzed N-arylation of imidazoles and benzimidazoles with both aryl iodides and bromides under mild conditions.  Further optimization of the system has revealed that the addn. of poly(ethylene glycol) accelerates this reaction.  A variety of hindered and functionalized imidazoles, benzimidazoles, and aryl halides were transformed in good to excellent yields.  Heteroaryl halides were also coupled in moderate to good yields.  We also present the results obtained from a series of coupling reactions, which directly compare the use of L1c with other recently reported ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnJAu6gmqUF7Vg90H21EOLACvtfcHk0li5yC6JDE5FpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1CktLY%253D&md5=26329baaf70d9f9a1fa318330e47b0b5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo070807a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070807a%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DKoval%26aufirst%3DE.%2BD.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper-catalyzed%2520N-arylation%2520of%2520imidazoles%2520and%2520benzimidazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D6190%26epage%3D6199%26doi%3D10.1021%2Fjo070807a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid, high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">6382</span>– <span class="NLM_lpage">6394</span>, <span class="refDoi"> DOI: 10.1021/ja994192d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja994192d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=6382-6394&author=D.+L.+Bogerauthor=B.+E.+Finkauthor=M.+P.+Hedrick&title=Total+synthesis+of+distamycin+A+and+2640+analogues%3A+A+solution-phase+combinatorial+approach+to+the+discovery+of+new%2C+bioactive+DNA+binding+agents+and+development+of+a+rapid%2C+high-throughput+screen+for+determining+relative+DNA+binding+affinity+or+DNA+binding+sequence+selectivity&doi=10.1021%2Fja994192d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Distamycin A and 2640 Analogs: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity</span></div><div class="casAuthors">Boger, Dale L.; Fink, Brian E.; Hedrick, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6382-6394</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a soln.-phase synthesis of distamycin A and its extension to the prepn. of 2640 analogs are described.  Thus, soln.-phase synthesis techniques with reaction workup and purifn. employing acid/base liq.-liq. extns. were used in the multistep prepn. of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogs providing intermediates and final products that are ≥95% pure on conventional reaction scales.  The complementary development of a simple, rapid, and high-throughput screen for DNA binding affinity based on the loss of fluorescence derived from displacement of prebound ethidium bromide is disclosed which is applicable for assessing relative or abs. binding affinity to DNA homopolymers or specific sequences (hairpin oligonucleotides).  Using hairpin oligonucleotides, this method permits the screening of a library of compds. against a single predefined sequence to identify high affinity binders, or the screening of a single compd. against a full library of individual hairpin oligonucleotides to define its sequence selectivity.  The combination permits the establishment of the complete DNA binding profile of each member of a library of compds.  Screening the prototypical library provided compds. that are 1000 times more potent than distamycin A in cytotoxic assays (I, Boc = tert-butoxycarbonyl; IC50 = 29 nM, L1210), that bind to poly[dA]-poly[dT] with comparable affinity, and that exhibit an altered DNA binding sequence selectivity.  Several candidates were identified which bound the five-base-pair AT-rich site of the PSA-ARE-3 sequence, and one (II, R = 4-dimethylaminobutyryl; K = 3.2 × 106 M-1) maintained the high affinity binding (K = 4.5 × 106 M-1) to the ARE-consensus sequence contg. a GC base-pair interrupted five-base-pair AT-rich site suitable for inhibition of gene transcription initiated by hormone insensitive androgen receptor dimerization and DNA binding characteristic of therapeutic resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeiV3cg0jix7Vg90H21EOLACvtfcHk0lhuMljRPMpiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGltL0%253D&md5=fe06cf76512cd2970fe28d611a4b25d7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja994192d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja994192d%26sid%3Dliteratum%253Aachs%26aulast%3DBoger%26aufirst%3DD.%2BL.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26atitle%3DTotal%2520synthesis%2520of%2520distamycin%2520A%2520and%25202640%2520analogues%253A%2520A%2520solution-phase%2520combinatorial%2520approach%2520to%2520the%2520discovery%2520of%2520new%252C%2520bioactive%2520DNA%2520binding%2520agents%2520and%2520development%2520of%2520a%2520rapid%252C%2520high-throughput%2520screen%2520for%2520determining%2520relative%2520DNA%2520binding%2520affinity%2520or%2520DNA%2520binding%2520sequence%2520selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D6382%26epage%3D6394%26doi%3D10.1021%2Fja994192d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramadas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, N.</span></span> <span> </span><span class="NLM_article-title">Iron-Ammonium Chloride—A Convenient and Inexpensive Reductant</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3189</span>– <span class="NLM_lpage">3195</span>, <span class="refDoi"> DOI: 10.1080/00397919208021132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1080%2F00397919208021132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=3189-3195&author=K.+Ramadasauthor=N.+Srinivasan&title=Iron-Ammonium+Chloride%E2%80%94A+Convenient+and+Inexpensive+Reductant&doi=10.1080%2F00397919208021132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Iron-ammonium chloride - a convenient and inexpensive reductant</span></div><div class="casAuthors">Ramadas, Krishnamurthy; Srinivasan, Natarajan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3189-95</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">The redn. of nitro arom. compds., I (R1 = H, NH2, Me, Cl, R2 = H, NH2, NO2, R3 = H, CH2CN, CH2CO2H, Me, OH, NHAc, Br, Cl, NH2, R4 = NO2), contg. other susceptible groups is reinvestigated to provide a viable economic route from the point of view of quant. transformation, reduced reaction times, and simple work up using iron powder and ammonium chloride soln. in neutral medium.  Thus, using Fe/NH4Cl on I gave I (R4 = NH2) in 67-90% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_QX8c0Gcx7Vg90H21EOLACvtfcHk0lhuMljRPMpiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D&md5=7b3830ad2efaf09a30cbff04b89eb32a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1080%2F00397919208021132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021132%26sid%3Dliteratum%253Aachs%26aulast%3DRamadas%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DIron-Ammonium%2520Chloride%25E2%2580%2594A%2520Convenient%2520and%2520Inexpensive%2520Reductant%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D3189%26epage%3D3195%26doi%3D10.1080%2F00397919208021132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosquera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, J.</span></span> <span> </span><span class="NLM_article-title">Selective monomethylation of anilines by Cu(OAc)<sub>2</sub>-promoted cross-coupling with MeB(OH)<sub>2</sub></span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1677</span>– <span class="NLM_lpage">1680</span>, <span class="refDoi"> DOI: 10.1021/ol802882k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol802882k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFegtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1677-1680&author=I.+Gonz%C3%A1lezauthor=J.+Mosqueraauthor=C.+Guerreroauthor=R.+Rodr%C3%ADguezauthor=J.+Cruces&title=Selective+monomethylation+of+anilines+by+Cu%28OAc%292-promoted+cross-coupling+with+MeB%28OH%292&doi=10.1021%2Fol802882k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Monomethylation of Anilines by Cu(OAc)2-Promoted Cross-Coupling with MeB(OH)2</span></div><div class="casAuthors">Gonzalez, Israel; Mosquera, Jesus; Guerrero, Cesar; Rodriguez, Ramon; Cruces, Jacobo</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1677-1680</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Methylanilines are readily synthesized in high yields through the copper(II)-promoted coupling of anilines and methylboronic acid.  This method represents a new approach for the selective monomethylation of anilines, and it is the first reported example of a Chan-Lam coupling involving the use of methylboronic acid.  An incubation period of the substrate with the copper reagent is needed before addn. of the methylboronic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfxOiIczUGx7Vg90H21EOLACvtfcHk0lhuMljRPMpiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFegtb8%253D&md5=3d05bb2320a2276c740fffabe9ad7346</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fol802882k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol802882k%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DI.%26aulast%3DMosquera%26aufirst%3DJ.%26aulast%3DGuerrero%26aufirst%3DC.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DR.%26aulast%3DCruces%26aufirst%3DJ.%26atitle%3DSelective%2520monomethylation%2520of%2520anilines%2520by%2520Cu%2528OAc%25292-promoted%2520cross-coupling%2520with%2520MeB%2528OH%25292%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1677%26epage%3D1680%26doi%3D10.1021%2Fol802882k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span> <span> </span><span class="NLM_article-title">Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx387.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1093%2Fannonc%2Fmdx387.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=522-523&author=Y.+Kurokawaauthor=T.+Doiauthor=A.+Sawakiauthor=Y.+Komatsuauthor=M.+Ozakaauthor=T.+Takahashiauthor=Y.+Naitoauthor=S.+Okuboauthor=T.+Nishida&title=Phase+II+study+of+TAS-116%2C+an+oral+inhibitor+of+heat+shock+protein+90+%28HSP90%29%2C+in+metastatic+or+unresectable+gastrointestinal+stromal+tumor+refractory+to+imatinib%2C+sunitinib+and+regorafenib&doi=10.1093%2Fannonc%2Fmdx387.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx387.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx387.006%26sid%3Dliteratum%253Aachs%26aulast%3DKurokawa%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DSawaki%26aufirst%3DA.%26aulast%3DKomatsu%26aufirst%3DY.%26aulast%3DOzaka%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DNishida%26aufirst%3DT.%26atitle%3DPhase%2520II%2520study%2520of%2520TAS-116%252C%2520an%2520oral%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%252C%2520in%2520metastatic%2520or%2520unresectable%2520gastrointestinal%2520stromal%2520tumor%2520refractory%2520to%2520imatinib%252C%2520sunitinib%2520and%2520regorafenib%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D522%26epage%3D523%26doi%3D10.1093%2Fannonc%2Fmdx387.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battye, T. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiannis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span> <span> </span><span class="NLM_article-title">iMOSFLM: a new graphical interface for diffraction-image processing withMOSFLM</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1107/s0907444910048675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2Fs0907444910048675" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=271-281&author=T.+G.+G.+Battyeauthor=L.+Kontogiannisauthor=O.+Johnsonauthor=H.+R.+Powellauthor=A.+G.+W.+Leslie&title=iMOSFLM%3A+a+new+graphical+interface+for+diffraction-image+processing+withMOSFLM&doi=10.1107%2Fs0907444910048675"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2Fs0907444910048675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444910048675%26sid%3Dliteratum%253Aachs%26aulast%3DBattye%26aufirst%3DT.%2BG.%2BG.%26aulast%3DKontogiannis%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DO.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DiMOSFLM%253A%2520a%2520new%2520graphical%2520interface%2520for%2520diffraction-image%2520processing%2520withMOSFLM%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D271%26epage%3D281%26doi%3D10.1107%2Fs0907444910048675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Collaborative
Computational
Project No. 4</span>. <span> </span><span class="NLM_article-title">The CCP4 suite:
programs for protein crystallography</span>.  <i>Acta
Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume">50</span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>.<span class="refDoi"> DOI: 10.1107/s0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2Fs0907444994003112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative%0AComputational%0AProject+No.+4&title=The+CCP4+suite%3A%0Aprograms+for+protein+crystallography&doi=10.1107%2Fs0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1107%2Fs0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%250Aprograms%2520for%2520protein%2520crystallography%26jtitle%3DActa%250ACrystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2Fs0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplyakov, A.</span></span> <span> </span><span class="NLM_article-title">MOLREP: an automated program for molecular replacement</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1107/s0021889897006766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+automated+program+for+molecular+replacement&doi=10.1107%2Fs0021889897006766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0ljTtJi8YYWCXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520automated%2520program%2520for%2520molecular%2520replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025%26doi%3D10.1107%2Fs0021889897006766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/s0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2Fs0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0ljTtJi8YYWCXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2Fs0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0ljTtJi8YYWCXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chihoko Yoshimura, Satoru Nagatoishi, Daisuke Kuroda, Yasuo Kodama, Takao Uno, Makoto Kitade, Khoontee Chong-Takata, Hiromi Oshiumi, Hiromi Muraoka, Satoshi Yamashita, Yuichi Kawai, Shuichi Ohkubo, <span class="NLM_string-name hlFld-ContribAuthor">Kouhei Tsumoto</span>. </span><span class="cited-content_cbyCitation_article-title">Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2669-2677. <a href="https://doi.org/10.1021/acs.jmedchem.0c01715" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01715%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThermodynamic%252BDissection%252Bof%252BPotency%252Band%252BSelectivity%252Bof%252BCytosolic%252BHsp90%252BInhibitors%26aulast%3DYoshimura%26aufirst%3DChihoko%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29102020%26date%3D23022021%26volume%3D64%26issue%3D5%26spage%3D2669%26epage%3D2677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shulei Zhu, Qianqian Shen, Yinglei Gao, Lei Wang, Yanfen Fang, Yi Chen, <span class="NLM_string-name hlFld-ContribAuthor">Wei Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5421-5441. <a href="https://doi.org/10.1021/acs.jmedchem.0c00305" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00305%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BHSP90%252BInhibitor%2525E2%252580%252593SN38%252BConjugates%252Bfor%252BTargeted%252BDrug%252BAccumulation%26aulast%3DZhu%26aufirst%3DShulei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20022020%26date%3D11052020%26date%3D30042020%26volume%3D63%26issue%3D10%26spage%3D5421%26epage%3D5441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicolas Brach, Vincent Le Fouler, Vincent Bizet, Marian Lanz, Fabrice Gallou, Corinne Bailly, Pascale Hoehn, Michael Parmentier, <span class="NLM_string-name hlFld-ContribAuthor">Nicolas Blanchard</span>. </span><span class="cited-content_cbyCitation_article-title">Optimized Synthesis of 7-Azaindazole by a Diels–Alder Cascade and Associated Process Safety. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (5)
                                     , 776-786. <a href="https://doi.org/10.1021/acs.oprd.0c00184" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00184%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DOptimized%252BSynthesis%252Bof%252B7-Azaindazole%252Bby%252Ba%252BDiels%2525E2%252580%252593Alder%252BCascade%252Band%252BAssociated%252BProcess%252BSafety%26aulast%3DBrach%26aufirst%3DNicolas%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14042020%26date%3D01052020%26date%3D29042020%26volume%3D24%26issue%3D5%26spage%3D776%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lin Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jin He</span>. </span><span class="cited-content_cbyCitation_article-title">DABCO-Catalyzed Michael/Alkylation Cascade Reactions Involving α-Substituted Ammonium Ylides for the Construction of Spirocyclopropyl Oxindoles: Access to the Powerful Chemical Leads against HIV-1. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (8)
                                     , 5203-5219. <a href="https://doi.org/10.1021/acs.joc.9b03164" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03164%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDABCO-Catalyzed%252BMichael%25252FAlkylation%252BCascade%252BReactions%252BInvolving%252B%2525CE%2525B1-Substituted%252BAmmonium%252BYlides%252Bfor%252Bthe%252BConstruction%252Bof%252BSpirocyclopropyl%252BOxindoles%25253A%252BAccess%252Bto%252Bthe%252BPowerful%252BChemical%252BLeads%252Bagainst%252BHIV-1%26aulast%3DChen%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03122019%26date%3D03042020%26date%3D23032020%26volume%3D85%26issue%3D8%26spage%3D5203%26epage%3D5219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj  Sharma</span>, <span class="hlFld-ContribAuthor ">Chris  LaRosa</span>, <span class="hlFld-ContribAuthor ">Janet  Antwi</span>, <span class="hlFld-ContribAuthor ">Rajgopal  Govindarajan</span>, <span class="hlFld-ContribAuthor ">Karl A.  Werbovetz</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4213. <a href="https://doi.org/10.3390/molecules26144213" title="DOI URL">https://doi.org/10.3390/molecules26144213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144213%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImidazoles%252Bas%252BPotential%252BAnticancer%252BAgents%25253A%252BAn%252BUpdate%252Bon%252BRecent%252BStudies%26aulast%3DSharma%26aufirst%3DPankaj%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.J.  Blagg</span>, <span class="hlFld-ContribAuthor ">Matthew Kyle  Hadden</span>, <span class="hlFld-ContribAuthor ">Reid S.  Tarpley</span>. </span><span class="cited-content_cbyCitation_article-title">Hsp90 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-88. <a href="https://doi.org/10.1002/0471266949.bmc212.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc212.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc212.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc212.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DHsp90%252BInhibitors%26aulast%3DBlagg%26aufirst%3DBrian%2BS.J.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D88%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting-jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin-yang  Li</span>, <span class="hlFld-ContribAuthor ">Jing-wei  Liang</span>, <span class="hlFld-ContribAuthor ">Shun  Tu</span>, <span class="hlFld-ContribAuthor ">Hai-li  Xu</span>, <span class="hlFld-ContribAuthor ">Wen-han  Xue</span>, <span class="hlFld-ContribAuthor ">Xin-hua  Qian</span>, <span class="hlFld-ContribAuthor ">Zhen-hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Fan-hao  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112988. <a href="https://doi.org/10.1016/j.ejmech.2020.112988" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112988%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-%252528%2525281-Phenyl-1H-1%25252C2%25252C3-triazol-4-yl%252529methyl%252529-2-azabicyclo%25255B3.2.1%25255Doctan-3-one%252Bderivatives%25253A%252BSimplification%252Band%252Bmodification%252Bof%252Baconitine%252Bscaffold%252Bfor%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Banticancer%252Bagents%26aulast%3DZhang%26aufirst%3DYi%26date%3D2021%26volume%3D210%26spage%3D112988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Elkina</span>, <span class="hlFld-ContribAuthor ">Yanina V.  Burgart</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shchegolkov</span>, <span class="hlFld-ContribAuthor ">Olga P.  Krasnykh</span>, <span class="hlFld-ContribAuthor ">Vera V.  Maslova</span>, <span class="hlFld-ContribAuthor ">Galina A.  Triandafilova</span>, <span class="hlFld-ContribAuthor ">Sergey S.  Solodnikov</span>, <span class="hlFld-ContribAuthor ">Anna A.  Muryleva</span>, <span class="hlFld-ContribAuthor ">Maria A.  Misiurina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Slita</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zarubaev</span>, <span class="hlFld-ContribAuthor ">Victor I.  Saloutin</span>. </span><span class="cited-content_cbyCitation_article-title">Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2020,</strong> <em>240 </em>, 109648. <a href="https://doi.org/10.1016/j.jfluchem.2020.109648" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2020.109648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2020.109648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2020.109648%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DCompetitive%252Broutes%252Bto%252Bcyclizations%252Bof%252Bpolyfluoroalkyl-containing%252B2-tolylhydrazinylidene-1%25252C3-diketones%252Bwith%252B3-aminopyrazoles%252Binto%252Bbioactive%252Bpyrazoloazines%26aulast%3DElkina%26aufirst%3DNatalia%2BA.%26date%3D2020%26volume%3D240%26spage%3D109648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Furen  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunmei  Li</span>, <span class="hlFld-ContribAuthor ">Chenze  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">A one-pot three-component strategy for highly diastereoselective synthesis of spirocycloalkane fused pyrazolo[3,4-
              b
              ]pyridine derivatives using recyclable solid acid as a catalyst. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (17)
                                     , 2456-2466. <a href="https://doi.org/10.1039/D0QO00591F" title="DOI URL">https://doi.org/10.1039/D0QO00591F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO00591F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO00591F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DA%252Bone-pot%252Bthree-component%252Bstrategy%252Bfor%252Bhighly%252Bdiastereoselective%252Bsynthesis%252Bof%252Bspirocycloalkane%252Bfused%252Bpyrazolo%25255B3%25252C4-%252Bb%252B%25255Dpyridine%252Bderivatives%252Busing%252Brecyclable%252Bsolid%252Bacid%252Bas%252Ba%252Bcatalyst%26aulast%3DZhang%26aufirst%3DFuren%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D17%26spage%3D2456%26epage%3D2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulei  Zhu</span>, <span class="hlFld-ContribAuthor ">Yalei  Li</span>, <span class="hlFld-ContribAuthor ">Yushu  Huang</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Gu</span>, <span class="hlFld-ContribAuthor ">Yang  He</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Mingliang  Ma</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2020,</strong> <em>8 </em>
                                    (9)
                                     , 1878-1896. <a href="https://doi.org/10.1039/C9TB02505G" title="DOI URL">https://doi.org/10.1039/C9TB02505G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9TB02505G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9TB02505G%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DOptimized%252BHSP90%252Bmediated%252Bfluorescent%252Bprobes%252Bfor%252Bcancer-specific%252Bbioimaging%26aulast%3DZhu%26aufirst%3DShulei%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D9%26spage%3D1878%26epage%3D1896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen-Hua  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Meng  Sun</span>, <span class="hlFld-ContribAuthor ">Jin-Jing  Qin</span>, <span class="hlFld-ContribAuthor ">Zhi-Yong  Tan</span>, <span class="hlFld-ContribAuthor ">Wen-Biao  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent strategy for the chemoselective synthesis of N-Arylbenzimidazoles and N-Arylindazoles from arylamino oximes. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (8)
                                     , 130945. <a href="https://doi.org/10.1016/j.tet.2020.130945" title="DOI URL">https://doi.org/10.1016/j.tet.2020.130945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.130945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.130945%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDivergent%252Bstrategy%252Bfor%252Bthe%252Bchemoselective%252Bsynthesis%252Bof%252BN-Arylbenzimidazoles%252Band%252BN-Arylindazoles%252Bfrom%252Barylamino%252Boximes%26aulast%3DLi%26aufirst%3DZhen-Hua%26date%3D2020%26volume%3D76%26issue%3D8%26spage%3D130945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems: Three Heteroatoms 2:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00021-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00021-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00021-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00021-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%25253A%252BThree%252BHeteroatoms%252B2%25253A1%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of selected small-molecular HSP90 inhibitors <b>1–10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Superposition of the speculated binding mode of <b>8</b> and <b>10</b>, a hybridization strategy used to design novel HSP90 inhibitors. (B) Structure and HSP90 binding inhibitory activity of 4-(1<i>H</i>-indol-1-yl)benzamide hit <b>11a</b>. (C) Drug design strategies to enhance the HSP90 binding inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Cocrystal structure of compound <b>16d</b> bound to the N-terminal ATP binding site of human HSP90. (B) Molecular surface representation of the cocrystal structure of compound <b>16d</b> in hydrophobic (red) to nonhydrophobic (white) gradient (PDB:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Antitumor efficacy of <b>16e</b> (TAS-116) in athymic nude mice bearing NCI-H1975 human lung cancer xenografts. (B) BWC of the tumor-bearing mice administered <b>16e</b> (TAS-116). (C) Pharmacodynamic activity of <b>16e</b> (TAS-116) in the NCI-H1975 tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Indole Derivatives <b>11a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-quinolineboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, 100 °C, 14 h, <b>18a</b>: 50%, <b>18b</b>: 87%; (b) <b>19</b>, CuI, DMEDA, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 14 h, <b>20a</b>: 95%, <b>20b</b>: 96%; and (c) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C-rt, 2.5 h, <b>11a</b>: 65%, <b>11b</b>: 97%.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Indazole Derivatives <b>12a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-quinolineboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C, 3 h, 56%–94%.; (b) <b>19</b>, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 64%–98%; and (c) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 66–84%.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrazolopyridine Derivatives <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <b>24a–c</b>, DIPA, <i>n</i>-BuLi, THF, −78 °C, 15 min; (2) isobutylanhydride, −78 °C, 1 h; (3) N<sub>2</sub>H<sub>4</sub> aq, 60–110 °C, 1–24 h, 17–42%; (d) 3-quinolineboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C, 3 h, 76–97%; (d) <b>19</b>, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 81%–95%; (e) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 28–91%.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of pyrazolo[3,4-<i>b</i>]pyridine Derivatives <b>14a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,4-difluorobenzonitrile, NaH, DMF, 60 °C, 1 h; (b) <i>trans</i>-4-aminocyclohexanol, DIPEA, DMSO, 125–150 °C, 8 h, 15%, 2 steps; (c) boronic acids or boronic acid pinacol esters, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, 100 °C, 4 h, 82%-quant.; and (d) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, rt, 30 min, 75–97%.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Imidazole Derivatives <b>15a–k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) imidazoles, CuO nanopowder, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 20 h, 45–90% and (b) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 50%-quant. The synthesis of the 4-aryl-1<i>H</i>-imidazole derivatives <b>15a–k</b> is shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Copper-mediated cross-coupling reaction of the obtained intermediate <b>29</b> with various 4-aryl-1<i>H</i>-imidazoles mediated by copper(II) oxide (CuO) nanopowder under basic conditions using potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) in DMF was carried out at 120 °C for 20 h<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> to obtain 4-substituted benzonitriles <b>31a–k</b> (45–90%). Finally, the hydrolysis of the obtained benzonitriles <b>31a–k</b> with 4 M NaOH and 30% H<sub>2</sub>O<sub>2</sub> in a mixture of DMSO<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> and EtOH resulted in the desired benzamide compounds <b>15a–k</b> (50%-quant.).</p></p></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Introduction of Various Benzamide Groups to the 1<i>H</i>-imidazole-1-yl-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine Scaffold <b>16a</b>, <b>16b</b>, <b>16d</b>, and <b>16e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PMBCl, NaH, DMF, 0 °C to rt, 2 h, 91%; (b) <b>33</b>, Cu<sub>2</sub>O, 4,7-dimethoxy-1,10-phenanthroline, Cs<sub>2</sub>CO<sub>3</sub>, PEG, DMSO, 110 °C, 24 h, 62%; (c) TFA, anisole, reflux, 5 h, 88%; (d) benzonitriles, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50–120 °C, 0.5–14 h, 81–91%; (e) 4-iodo-2-(methylamino)benzonitrile, CuI, DMEDA, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 °C, 24 h, 36%; and (f) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C to rt, 2.5 h, 45–95%.</p></p></figure><figure data-id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/medium/jm-2018-01085h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Introduction of the 3-(Methylamino)benzamide Group to the 1<i>H</i>-Imidazole-1-yl-3-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine Scaffold <b>16c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01085/20190116/images/large/jm-2018-01085h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01085&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-3-nitrobenzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 14 h, 70%; (b) Fe, NH<sub>4</sub>Cl, THF, EtOH, H<sub>2</sub>O, 80 °C, 4 h, 39%; (c) methylboronic acid, Cu(OAc)<sub>2</sub>(II), pyridine, 1,4-dioxane, 120 °C, 2 h, 38%; and (d) 4 M NaOH aq, 30% H<sub>2</sub>O<sub>2</sub> aq, DMSO, EtOH, 0 °C, 2 h, 83%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollapour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span> <span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0ljKqBOrV8_gNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S. L.</span></span> <span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lhS9QyndkiWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F&doi=10.1158%2F1078-0432.ccr-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lhS9QyndkiWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.ccr-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Targeting Hsp90--Who Benefits and Who Does Not</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4508</span>– <span class="NLM_lpage">4513</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-2138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-2138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22718860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4508-4513&author=M.+Scaltritiauthor=S.+Dawoodauthor=J.+Cortes&title=Molecular+Pathways%3A+Targeting+Hsp90%2D%2DWho+Benefits+and+Who+Does+Not&doi=10.1158%2F1078-0432.ccr-11-2138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Hsp90-Who Benefits and Who Does Not</span></div><div class="casAuthors">Scaltriti, Maurizio; Dawood, Shaheenah; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4508-4513</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Many kinases and hormone receptors, important for cancer cell proliferation and survival, bind to and are dependent on the Hsp90 cycle for their folding and maturation.  This provides the rationale for the development of small-mol. ATP competitors that, inhibiting Hsp90 function, lead to degrdn. of the "client" proteins.  After continual efforts to improve the pharmacol. properties and the tolerability of these mols., several Hsp90 inhibitors have exhibited activity in both preclin. models and in the clin. setting.  As is the case with many other targeted agents, patient selection seems to be the major limitation to the success of these compds.  ERBB2-pos. patients with breast cancer are exquisitely sensitive to Hsp90 inhibition.  This is because ERBB2 is indispensable for growth and survival of this subtype of cancer, and at the same time ERBB2 is a client protein strictly dependent on Hsp90 for its maturation and stability.  Extensive preclin. work identifying other ERBB-like client proteins will likely lead to the ability to enhance selection of appropriate patients for enrollment in more rational clin. trials.  Hsp90 inhibition has also been reported to synergize with other therapeutic agents.  Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance.  Clin Cancer Res; 18(17); 4508-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSf5P7B7H8bVg90H21EOLACvtfcHk0lhS9QyndkiWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L&md5=8274b2b8bedc14970bd02b37acb163e8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-2138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-2138%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDawood%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520Pathways%253A%2520Targeting%2520Hsp90--Who%2520Benefits%2520and%2520Who%2520Does%2520Not%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4508%26epage%3D4513%26doi%3D10.1158%2F1078-0432.ccr-11-2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heltai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugarli, C.</span></span> <span> </span><span class="NLM_article-title">Unusual expression and localization of heat-shock proteins in human tumor cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1002/ijc.2910510418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1002%2Fijc.2910510418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1601523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=613-619&author=M.+Ferrariniauthor=S.+Heltaiauthor=M.+R.+Zocchiauthor=C.+Rugarli&title=Unusual+expression+and+localization+of+heat-shock+proteins+in+human+tumor+cells&doi=10.1002%2Fijc.2910510418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual expression and localization of heat-shock proteins in human tumor cells</span></div><div class="casAuthors">Ferrarini, Marina; Heltai, Silvia; Zocchi, M. Raffaella; Rugarli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-19</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">It has been suggested that members of HSP families represent the surface target of immune responses leading to tumor rejection in mice.  The authors report that tumor cells, compared with normal cells, constitutively expressed 2- to 10-fold higher levels of intracellular HSP90.  Moreover, in the absence of environmental stress, 2 lines (out of 6) expressed the "inducible" HSP72, which was also detectable in fresh tumor cells.  HSP72 expression was not regulated during the cell cycle, in contrast with what has been obsd. with normal cells.  Both HSP90 and HSP72 proteins exhibited a heterogeneous pattern of intracellular distribution in most cells, HSP72 being confined mainly to the nuclear compartment.  Finally, both HSP90 and, to a lesser extent, HSP72 (that are generally believed to be located intracellularly) were detected at the surface of some tumor cell lines.  It is concluded that tumor cells differ from normal cells in their pattern of HSP expression; this might imply a role of HSPs in eliciting an immune response against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdlQHEKHA7jLVg90H21EOLACvtfcHk0lhOcScOZ7vJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D&md5=4ace8651e9b125c68985102a0b3055f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910510418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910510418%26sid%3Dliteratum%253Aachs%26aulast%3DFerrarini%26aufirst%3DM.%26aulast%3DHeltai%26aufirst%3DS.%26aulast%3DZocchi%26aufirst%3DM.%2BR.%26aulast%3DRugarli%26aufirst%3DC.%26atitle%3DUnusual%2520expression%2520and%2520localization%2520of%2520heat-shock%2520proteins%2520in%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D51%26spage%3D613%26epage%3D619%26doi%3D10.1002%2Fijc.2910510418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciocca, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, S. K.</span></span> <span> </span><span class="NLM_article-title">Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications</span>. <i>Cell Stress Chaperones</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1379/csc-99r.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1379%2Fcsc-99r.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16038406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFymur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=86-103&author=D.+R.+Cioccaauthor=S.+K.+Calderwood&title=Heat+shock+proteins+in+cancer%3A+diagnostic%2C+prognostic%2C+predictive%2C+and+treatment+implications&doi=10.1379%2Fcsc-99r.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications</span></div><div class="casAuthors">Ciocca, Daniel R.; Calderwood, Stuart K.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stress & Chaperones</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-103</span>CODEN:
                <span class="NLM_cas:coden">CSCHFG</span>;
        ISSN:<span class="NLM_cas:issn">1355-8145</span>.
    
            (<span class="NLM_cas:orgname">Cell Stress Society International</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (Hsps) are overexpressed in a wide range of human cancers and are implicated in tumor cell proliferation, differentiation, invasion, metastasis, death, and recognition by the immune system.  We review the current status of the role of Hsp expression in cancer with special emphasis on the clin. setting.  Although Hsp levels are not informative at the diagnostic level, they are useful biomarkers for carcinogenesis in some tissues and signal the degree of differentiation and the aggressiveness of some cancers.  In addn., the circulating levels of Hsp and anti-Hsp antibodies in cancer patients may be useful in tumor diagnosis.  Furthermore, several Hsp are implicated with the prognosis of specific cancers, most notably Hsp27, whose expression is assocd. with poor prognosis in gastric, liver, and prostate carcinoma, and osteosarcomas, and Hsp70, which is correlated with poor prognosis in breast, endometrial, uterine cervical, and bladder carcinomas.  Increased Hsp expression may also predict the response to some anticancer treatments.  For example, Hsp27 and Hsp70 are implicated in resistance to chemotherapy in breast cancer, Hsp27 predicts a poor response to chemotherapy in leukemia patients, whereas Hsp70 expression predicts a better response to chemotherapy in osteosarcomas.  Implication of Hsp in tumor progression and response to therapy has led to its successful targeting in therapy by 2 main strategies, including: (1) pharmacol. modification of Hsp expression or mol. chaperone activity and (2) use of Hsps in anticancer vaccines, exploiting their ability to act as immunol. adjuvants.  In conclusion, the present times are of importance for the field of Hsps in cancer, with great contributions to both basic and clin. cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_88yG9rC597Vg90H21EOLACvtfcHk0lhOcScOZ7vJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFymur4%253D&md5=d32af56d2ef8479b1bc0f13d01fcc03c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1379%2Fcsc-99r.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1379%252Fcsc-99r.1%26sid%3Dliteratum%253Aachs%26aulast%3DCiocca%26aufirst%3DD.%2BR.%26aulast%3DCalderwood%26aufirst%3DS.%2BK.%26atitle%3DHeat%2520shock%2520proteins%2520in%2520cancer%253A%2520diagnostic%252C%2520prognostic%252C%2520predictive%252C%2520and%2520treatment%2520implications%26jtitle%3DCell%2520Stress%2520Chaperones%26date%3D2005%26volume%3D10%26spage%3D86%26epage%3D103%26doi%3D10.1379%2Fcsc-99r.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span> <span> </span><span class="NLM_article-title">A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>425</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/nature01913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fnature01913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=14508491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=407-410&author=A.+Kamalauthor=L.+Thaoauthor=J.+Sensintaffarauthor=L.+Zhangauthor=M.+F.+Boehmauthor=L.+C.+Fritzauthor=F.+J.+Burrows&title=A+high-affinity+conformation+of+Hsp90+confers+tumour+selectivity+on+Hsp90+inhibitors&doi=10.1038%2Fnature01913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span></div><div class="casAuthors">Kamal, Adeela; Thao, Lia; Sensintaffar, John; Zhang, Lin; Boehm, Marcus F.; Fritz, Lawrence C.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6956</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53.  Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degrdn. of Hsp90 client proteins.  Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clin. trials.  However, the mol. basis of the tumor selectivity of Hsp90 inhibitors is unknown.  Here we report that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells.  Tumor Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state.  In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity.  These results suggest that tumor cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ozo1K3wfA7Vg90H21EOLACvtfcHk0lhOcScOZ7vJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D&md5=7c83fca7aaf685b589c4aef6e5f39b02</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature01913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01913%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DThao%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DA%2520high-affinity%2520conformation%2520of%2520Hsp90%2520confers%2520tumour%2520selectivity%2520on%2520Hsp90%2520inhibitors%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D407%26epage%3D410%26doi%3D10.1038%2Fnature01913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilenchik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huezo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spampinato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2004.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15217612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=787-797&author=M.+Vilenchikauthor=D.+Solitauthor=A.+Bassoauthor=H.+Huezoauthor=B.+Lucasauthor=H.+Heauthor=N.+Rosenauthor=C.+Spampinatoauthor=P.+Modrichauthor=G.+Chiosis&title=Targeting+wide-range+oncogenic+transformation+via+PU24FCl%2C+a+specific+inhibitor+of+tumor+Hsp90&doi=10.1016%2Fj.chembiol.2004.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90</span></div><div class="casAuthors">Vilenchik, Maria; Solit, David; Basso, Andrea; Huezo, Henri; Lucas, Brian; He, Huazhong; Rosen, Neal; Spampinato, Claudia; Modrich, Paul; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-797</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Agents that inhibit Hsp90 function hold significant promise in cancer therapy.  Here we present PU24FCl, a representative of the first class of designed Hsp90 inhibitors.  By specifically and potently inhibiting tumor Hsp90, PU24FCl exhibits wide-ranging anti-cancer activities that occur at similar doses in all tested tumor types.  Normal cells are 10- to 50-fold more resistant to these effects.  Its Hsp90 inhibition results in multiple antitumor-specific effects, such as degrdn. of Hsp90-client proteins involved in cell growth, survival, and specific transformation, inhibition of cancer cell growth, delay of cell cycle progression, induction of morphol. and functional changes, and apoptosis.  In concordance with its higher affinity for tumor Hsp90, in vivo PU24FCl accumulates in tumors while being rapidly cleared from normal tissue.  Concns. achieved in vivo in tumors lead to single-agent antitumor activity at non-toxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKaguPFd5FLVg90H21EOLACvtfcHk0lhOcScOZ7vJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrg%253D&md5=1bf99fe18a0a212c770fa731c197e60c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DVilenchik%26aufirst%3DM.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DHuezo%26aufirst%3DH.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSpampinato%26aufirst%3DC.%26aulast%3DModrich%26aufirst%3DP.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DTargeting%2520wide-range%2520oncogenic%2520transformation%2520via%2520PU24FCl%252C%2520a%2520specific%2520inhibitor%2520of%2520tumor%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D787%26epage%3D797%26doi%3D10.1016%2Fj.chembiol.2004.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Carbonero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HSP90 molecular chaperones: moving into the clinic</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e358</span>– <span class="NLM_lpage">e369</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fs1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+HSP90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2Fs1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0ljq9BpyBz27Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HSP90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2Fs1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1823</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0ljq9BpyBz27Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+heat+shock+protein+HSP90-pp60v-src+heteroprotein+complex+formation+by+benzoquinone+ansamycins%3A+essential+role+for+stress+proteins+in+oncogenic+transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0ljq9BpyBz27Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%2520HSP90-pp60v-src%2520heteroprotein%2520complex%2520formation%2520by%2520benzoquinone%2520ansamycins%253A%2520essential%2520role%2520for%2520stress%2520proteins%2520in%2520oncogenic%2520transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1007/s002800050817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1007%2Fs002800050817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=9744771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=273-279&author=T.+W.+Schulteauthor=L.+M.+Neckers&title=The+benzoquinone+ansamycin+17-allylamino-17-demethoxygeldanamycin+binds+to+HSP90+and+shares+important+biologic+activities+with+geldanamycin&doi=10.1007%2Fs002800050817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span></div><div class="casAuthors">Schulte, Theodor W.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Binding of 17-allylamino-17-demethoxygeldanamycin (17-AG) to the heat-shock protein HSP90 was studied in vitro using a geldanamycin (GA)-affinity beads competition assay.  The drug-induced destabilization was studied of p185erbB2, Raf-1, and mutant p53 in SKBR3 breast cancer cells by Western blotting.  The antiproliferative activities of 17-AG and GA were compared using the MTT assay.  The 17-AG bound specifically to HSP90 in a similar manner as GA itself.  It also led to degrdn. of the receptor Tyr kinase p185erbB2, the Ser/Thr kinase Raf-1, and mutant p53.  GA and 17-AG displayed comparable antiproliferative effects in SKBR3 and MCF7 cells.  Even though HSP90 binding with 17-AG was weaker than by GA, 17-AG and GA caused biol. effects in tumor cells at similar doses.  Since 17-AG had a better toxicity profile than GA, it was suggested as benzoquinone ansamycin candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj3pMDUB7kLVg90H21EOLACvtfcHk0lhBXKKT4Ipwnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D&md5=3d6ac0592b10d66b391f824272523de2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs002800050817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050817%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DThe%2520benzoquinone%2520ansamycin%252017-allylamino-17-demethoxygeldanamycin%2520binds%2520to%2520HSP90%2520and%2520shares%2520important%2520biologic%2520activities%2520with%2520geldanamycin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26spage%3D273%26epage%3D279%26doi%3D10.1007%2Fs002800050817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher-Nielson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainathan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4813</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-03-0795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-03-0795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15269157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4813-4821&author=G.+Kaurauthor=D.+Belottiauthor=A.+M.+Burgerauthor=K.+Fisher-Nielsonauthor=P.+Borsottiauthor=E.+Riccardiauthor=J.+Thillainathanauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=R.+Giavazzi&title=Antiangiogenic+properties+of+17-%28dimethylaminoethylamino%29-17-demethoxygeldanamycin%3A+an+orally+bioavailable+heat+shock+protein+90+modulator&doi=10.1158%2F1078-0432.ccr-03-0795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span></div><div class="casAuthors">Kaur, Gurmeet; Belotti, Dorina; Burger, Angelika M.; Fisher-Nielson, Kirsten; Borsotti, Patrizia; Riccardi, Elena; Thillainathan, Jagada; Hollingshead, Melinda; Sausville, Edward A.; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4813-4821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; NSC707545), a water-sol. benzoquinone ansamycin.  The activity of 17-DMAG, in vivo, was evaluated for inhibition of fibroblast growth factor (FGF)-2-induced angiogenesis in s.c. implanted Matrigel in mice.  In vitro, the activity of 17-DMAG on endothelial cells (human umbilical vein endothelial cells; HUVEC) was tested in FGF-2; and vascular endothelial growth factor (VEGF)-induced proliferation and apoptosis, motility, and extracellular matrix invasion; and on the alignment of capillary like structures in Matrigel.  The protein level of heat shock protein (Hsp)90 and client proteins was examd. by Western blot in FGF-2 and VEGF-stimulated HUVEC.  Daily oral administration of 17-DMAG affected the angiogenic response in Matrigel in a dose-dependent manner.  The Hb content in the Matrigel implants was significantly inhibited, and the histol. anal. confirmed a decrease of CD31+ endothelial cells and of structures organized in cord and erythrocyte-contg. vessels.  In vitro, the compd. inhibited dose-dependently the migration and the extracellular matrix-invasiveness of HUVEC and their capacity to form capillary like structures in Matrigel. 17-DMAG treatment also inhibited FGF-2 and VEGF-induced HUVEC proliferation and resulted in apoptosis.  Accordingly, the expression of Hsp90 direct client proteins (pAkt and c-Raf-1) or their downstream substrates including pERK was also affected. 17-DMAG consistently increased the expression of Hsp70.  Throughout the study similar results were obtained with 17-allylamino-17-demethoxygeldanamycin (17-AAG; NSC330507), the analog compd. currently undergoing clin. trials.  We show that the Hsp90 targeting agents 17-DMAG and 17-AAG inhibit angiogenesis.  The strong effects on endothelial cell functions, in vitro, indicate that the antiangiogenic activity of 17-DMAG/17-AAG could also be due to a direct effect on endothelial cells.  The oral bioavailability of 17-DMAG might be of advantage in investigating the potential of this compd. in clin. trials with antiangiogenic as well as antiproliferative endpoints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbGsLTxbCrQ7Vg90H21EOLACvtfcHk0lhBXKKT4Ipwnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D&md5=e78331697485d2c1948adec2d4f124e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-03-0795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-03-0795%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DFisher-Nielson%26aufirst%3DK.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DThillainathan%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DAntiangiogenic%2520properties%2520of%252017-%2528dimethylaminoethylamino%2529-17-demethoxygeldanamycin%253A%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520modulator%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4813%26epage%3D4821%26doi%3D10.1158%2F1078-0432.ccr-03-0795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4615</span>, <span class="refDoi"> DOI: 10.1021/jm0603116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbittsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+synthesis%2C+and+biological+evaluation+of+hydroquinone+derivatives+of+17-amino-17-demethoxygeldanamycin+as+potent%2C+water-soluble+inhibitors+of+Hsp90&doi=10.1021%2Fjm0603116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span></div><div class="casAuthors">Ge, Jie; Normant, Emmanuel; Porter, James R.; Ali, Janid A.; Dembski, Marlene S.; Gao, Yun; Georges, Asimina T.; Grenier, Louis; Pak, Roger H.; Patterson, Jon; Sydor, Jens R.; Tibbitts, Thomas T.; Tong, Jeffrey K.; Adams, Julian; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4606-4615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clin. trials for the treatment of cancer.  However, 17-AAG faces challenging formulation issues due to its poor soly.  Here we report the synthesis and evaluation of a highly sol. hydroquinone hydrochloride deriv. of 17-AAG, I (IPI-504), and several of the physiol. metabolites.  These compds. show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homolog, the 94 kDa glucose regulated protein (Grp94).  Furthermore, the compds. inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition.  There is a clear correlation between the measured binding affinity of the compds. and their cellular activities.  Upon the basis of its potent activity against Hsp90 and a significant improvement in soly., I is currently under evaluation in Phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9IjX75MjbULVg90H21EOLACvtfcHk0lhBXKKT4Ipwnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D&md5=892e372e121f75465edc6f1251e55dc6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbitts%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520hydroquinone%2520derivatives%2520of%252017-amino-17-demethoxygeldanamycin%2520as%2520potent%252C%2520water-soluble%2520inhibitors%2520of%2520Hsp90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615%26doi%3D10.1021%2Fjm0603116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pien, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penders, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayzel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span> <span> </span><span class="NLM_article-title">Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">17408</span>– <span class="NLM_lpage">17413</span>, <span class="refDoi"> DOI: 10.1073/pnas.0608372103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1073%2Fpnas.0608372103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17408-17413&author=J.+R.+Sydorauthor=E.+Normantauthor=C.+S.+Pienauthor=J.+R.+Porterauthor=J.+Geauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=J.+Hudakauthor=J.+Pattersonauthor=C.+Pendersauthor=M.+Pinkauthor=M.+A.+Readauthor=J.+Sangauthor=C.+Woodwardauthor=Y.+Zhangauthor=D.+S.+Grayzelauthor=J.+Wrightauthor=J.+A.+Barrettauthor=V.+J.+Palombellaauthor=J.+Adamsauthor=J.+K.+Tong&title=Development+of+17-allylamino-17-demethoxygeldanamycin+hydroquinone+hydrochloride+%28IPI-504%29%2C+an+anti-cancer+agent+directed+against+Hsp90&doi=10.1073%2Fpnas.0608372103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608372103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608372103%26sid%3Dliteratum%253Aachs%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPien%26aufirst%3DC.%2BS.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DHudak%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DPenders%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGrayzel%26aufirst%3DD.%2BS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%252017-allylamino-17-demethoxygeldanamycin%2520hydroquinone%2520hydrochloride%2520%2528IPI-504%2529%252C%2520an%2520anti-cancer%2520agent%2520directed%2520against%2520Hsp90%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D17408%26epage%3D17413%26doi%3D10.1073%2Fpnas.0608372103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyodo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuni, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.freeradbiomed.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20211249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=1559-1563&author=Y.+Samuniauthor=H.+Ishiiauthor=F.+Hyodoauthor=U.+Samuniauthor=M.+C.+Krishnaauthor=S.+Goldsteinauthor=J.+B.+Mitchell&title=Reactive+oxygen+species+mediate+hepatotoxicity+induced+by+the+Hsp90+inhibitor+geldanamycin+and+its+analogs&doi=10.1016%2Fj.freeradbiomed.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs</span></div><div class="casAuthors">Samuni, Yuval; Ishii, Hisanari; Hyodo, Fuminori; Samuni, Uri; Krishna, Murali C.; Goldstein, Sara; Mitchell, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1559-1563</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Geldanamycin (GM), a benzoquinone ansamycin antibiotic, is a natural product inhibitor of Hsp90 with potent and broad anti-cancer properties.  Because of its adverse effects on liver, its less toxic derivs. 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) are currently being evaluated for the treatment of cancer.  Previously, it was demonstrated that the redox cycling of GM by NADPH-cytochrome P 450 reductase leads to the formation of the GM semiquinone and superoxide radicals, the latter being identified using spin-trapping.  We hypothesized that the different hepatotoxicity induced by GM, 17-AAG, and 17-DMAG reflects the redox active properties of the quinone moiety and possibly the extent of superoxide formation, which may stimulate cellular oxidative injury.  Our data demonstrate that superoxide can be efficiently trapped during the redn. of GM, 17-AAG, and 17-DMAG by NADPH-cytochrome P 450 reductase, and that superoxide formation rate followed the order 17-DMAG > 17-AAG > GM.  In the absence of superoxide scavengers, the rate of NADPH oxidn. followed the order 17-DMAG > GM > 17-AAG.  The half-wave one-electron redn. potentials (E1/2) of GM, 17-AAG, and 17-DMAG in DMSO were detd. to be -0.37, -0.13 and -0.015 V (vs. Ag/AgCl), resp.  If the same order of E1/2 follows in neutral aq. media, thermodn. considerations imply that 17-DMAG is more readily reduced by the P 450 reductase as well as by superoxide.  The order of the drug cytotoxicity toward rat primary hepatocytes, as detd. by their effect on cell viability and on intracellular oxidant level, was opposite to the order of E1/2 of the resp. quinone/semiquinone couples.  These results suggest that hepatotoxicity exhibited by the Hsp90 inhibitors belonging to benzoquinone ansamycins could be attributed to superoxide.  The apparent discrepancy between the order of toxicity and the orders of superoxide formation rate, which is correlated with E1/2, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpruuvDYz3MwbVg90H21EOLACvtfcHk0lgz_3Q45nz_TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGru7Y%253D&md5=25d6f75c0c010667a4d9d9be51f67c21</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSamuni%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DHyodo%26aufirst%3DF.%26aulast%3DSamuni%26aufirst%3DU.%26aulast%3DKrishna%26aufirst%3DM.%2BC.%26aulast%3DGoldstein%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%26atitle%3DReactive%2520oxygen%2520species%2520mediate%2520hepatotoxicity%2520induced%2520by%2520the%2520Hsp90%2520inhibitor%2520geldanamycin%2520and%2520its%2520analogs%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2010%26volume%3D48%26spage%3D1559%26epage%3D1563%26doi%3D10.1016%2Fj.freeradbiomed.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. W.</span></span> <span> </span><span class="NLM_article-title">Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer</span>. <i>Urology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.urology.2011.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.urology.2011.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=626-630&author=W.+K.+Ohauthor=M.+D.+Galskyauthor=W.+M.+Stadlerauthor=S.+Srinivasauthor=F.+Chuauthor=G.+Bubleyauthor=J.+Goddardauthor=J.+Dunbarauthor=R.+W.+Ross&title=Multicenter+Phase+II+Trial+of+the+Heat+Shock+Protein+90+Inhibitor%2C+Retaspimycin+Hydrochloride+%28IPI-504%29%2C+in+Patients+With+Castration-resistant+Prostate+Cancer&doi=10.1016%2Fj.urology.2011.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.urology.2011.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urology.2011.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBubley%26aufirst%3DG.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26atitle%3DMulticenter%2520Phase%2520II%2520Trial%2520of%2520the%2520Heat%2520Shock%2520Protein%252090%2520Inhibitor%252C%2520Retaspimycin%2520Hydrochloride%2520%2528IPI-504%2529%252C%2520in%2520Patients%2520With%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DUrology%26date%3D2011%26volume%3D78%26spage%3D626%26epage%3D630%26doi%3D10.1016%2Fj.urology.2011.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lhVzB3VJB5yyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span> <span> </span><span class="NLM_article-title">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-08-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1535-7163.mct-08-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=19372565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=921-929&author=K.+Lundgrenauthor=H.+Zhangauthor=J.+Brekkenauthor=N.+Huserauthor=R.+E.+Powellauthor=N.+Timpleauthor=D.+J.+Buschauthor=L.+Neelyauthor=J.+L.+Sensintaffarauthor=Y.-c.+Yangauthor=A.+McKenzieauthor=J.+Friedmanauthor=R.+Scannevinauthor=A.+Kamalauthor=K.+Hongauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=F.+J.+Burrows&title=BIIB021%2C+an+orally+available%2C+fully+synthetic+small-molecule+inhibitor+of+the+heat+shock+protein+Hsp90&doi=10.1158%2F1535-7163.mct-08-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90</span></div><div class="casAuthors">Lundgren, Karen; Zhang, Hong; Brekken, John; Huser, Nanni; Powell, Rachel E.; Timple, Noel; Busch, David J.; Neely, Laura; Sensintaffar, John L.; Yang, Yong-ching; McKenzie, Andres; Friedman, Jessica; Scannevin, Robert; Kamal, Adeela; Hong, Kevin; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) results in the degrdn. of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy.  BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90.  In tumor cells, BIIB021 induced the degrdn. of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27.  BIIB021 treatment resulted in growth inhibition and cell death in cell lines from a variety of tumor types at nanomolar concns.  Oral administration of BIIB021 led to the degrdn. of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models.  Studies to investigate the antitumor effects of BIIB021 showed activity on both daily and intermittent dosing schedules, providing dose schedule flexibility for clin. studies.  Assays measuring the HER-2 protein in tumor tissue and the HER-2 extracellular domain in plasma were used to show interdiction of the Hsp90 pathway and utility as potential biomarkers in clin. trials for BIIB021.  Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclin. models.[Mol Cancer Ther 2009;8(4):921-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbI2RYG4aF7Vg90H21EOLACvtfcHk0lhVzB3VJB5yyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amt74%253D&md5=271e2311ab807bc74b2ac66b81e514e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-08-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-08-0758%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DPowell%26aufirst%3DR.%2BE.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DNeely%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DY.-c.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DBIIB021%252C%2520an%2520orally%2520available%252C%2520fully%2520synthetic%2520small-molecule%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%2520Hsp90%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D921%26epage%3D929%26doi%3D10.1158%2F1535-7163.mct-08-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span> <span> </span><span class="NLM_article-title">A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-13-1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-13-1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=24097863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=445-455&author=M.+W.+Saifauthor=C.+Takimotoauthor=M.+Mitaauthor=U.+Banerjiauthor=N.+Lamannaauthor=J.+Castroauthor=S.+O%E2%80%99Brienauthor=C.+Stogardauthor=D.+Von+Hoff&title=A+phase+1%2C+dose-escalation%2C+pharmacokinetic+and+pharmacodynamic+study+of+BIIB021+administered+orally+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.ccr-13-1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Saif, Muhammad Wasif; Takimoto, Chris; Mita, Monica; Banerji, Udai; Lamanna, Nicole; Castro, Januario; O'Brien, Susan; Stogard, Christopher; Von Hoff, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-455</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin-based HSP90 inhibitor that showed activity in preclin. models at low nanomolar concns.  We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors.  Exptl. Design: Sixty patients received BIIB021 capsules orally on days 1, 4, 8, 11, 15, and 18 of each course in schedule 1, and on days 1, 4, 8, 11, 15, 18, 22, and 25 of each course in schedule 2.  The treatment schedules were repeated every 28 days.  In addn. to detg. the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)].  Results: The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 wk out of each 4-wk course.  The MTD for continuous dosing regimen was established at 600 mg twice weekly.  Gastrointestinal (nausea, vomiting), hot flashes, and neurol. (dizziness) events characterize the safety profile of BIIB021 dosed twice weekly, with events mostly mild or moderate.  Plasma exposure to BIIB021 was dose-dependent.  Cmax occurred at approx. 90 min and t1/2 was approx. 1 h across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.  The biol. activity of BIIB021 was demonstrated in serum, PBMCs, and tumor tissue.  Hsp70 levels were increased (>150% from baseline) and serum HER2-ECD was significantly decreased (>15% inhibition from baseline).  Conclusions: BIIB021 twice weekly, given with or without the 1 of 4-wk rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active.  Clin Cancer Res; 20(2); 445-55. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkorAuPfyrLVg90H21EOLACvtfcHk0lhVzB3VJB5yyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D&md5=48266b9da5e440eda185af9d42e9739b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-13-1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-13-1257%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DTakimoto%26aufirst%3DC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DStogard%26aufirst%3DC.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DA%2520phase%25201%252C%2520dose-escalation%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520BIIB021%2520administered%2520orally%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D445%26epage%3D455%26doi%3D10.1158%2F1078-0432.ccr-13-1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Martin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span> <span> </span><span class="NLM_article-title">Ocular toxicity of targeted therapies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3277</span>– <span class="NLM_lpage">3286</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.41.5851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1200%2Fjco.2011.41.5851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22649132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3277-3286&author=D.+J.+Renoufauthor=J.+P.+Velazquez-Martinauthor=R.+Simpsonauthor=L.+L.+Siuauthor=P.+L.+Bedard&title=Ocular+toxicity+of+targeted+therapies&doi=10.1200%2Fjco.2011.41.5851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular toxicity of targeted therapies</span></div><div class="casAuthors">Renouf, Daniel J.; Velazquez-Martin, Juan P.; Simpson, Rand; Siu, Lillian L.; Bedard, Philippe L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3277-3286</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Molecularly targeted agents are commonly used in oncol. practice, and many new targeted agents are currently being tested in clin. trials.  Although these agents are thought to be more specific and less toxic then traditional cytotoxic chemotherapy, they are assocd. with a variety of toxicities, including ocular toxicity.  Many of the mols. targeted by anticancer agents are also expressed in ocular tissues.  We reviewed the literature for described ocular toxicities assocd. with both approved and investigational molecularly targeted agents.  Ocular toxicity has been described with numerous approved targeted agents and also seems to be assocd. with several classes of agents currently being tested in early-phase clin. trials.  We discuss the proposed pathogenesis, monitoring guidelines, and management recommendations.  It is important for oncologists to be aware of the potential for ocular toxicity, with prompt recognition of symptoms that require referral to an ophthalmologist.  Ongoing collaboration between oncologists and ocular disease specialists is crit. as the use of molecularly targeted agents continues to expand and novel targeted drug combinations are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14O59XS9-sLVg90H21EOLACvtfcHk0livTs67cLUKgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FL&md5=4eca73917ed072e92844c2695a3b2d66</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.41.5851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.41.5851%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DVelazquez-Martin%26aufirst%3DJ.%2BP.%26aulast%3DSimpson%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26atitle%3DOcular%2520toxicity%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3277%26epage%3D3286%26doi%3D10.1200%2Fjco.2011.41.5851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0livTs67cLUKgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delmotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmotte-plaquee, J.</span></span> <span> </span><span class="NLM_article-title">A new antifungal substance of fungal origin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1953</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">344</span>, <span class="refDoi"> DOI: 10.1038/171344a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2F171344a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=1953&pages=344&author=P.+Delmotteauthor=J.+Delmotte-plaquee&title=A+new+antifungal+substance+of+fungal+origin&doi=10.1038%2F171344a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F171344a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F171344a0%26sid%3Dliteratum%253Aachs%26aulast%3DDelmotte%26aufirst%3DP.%26aulast%3DDelmotte-plaquee%26aufirst%3DJ.%26atitle%3DA%2520new%2520antifungal%2520substance%2520of%2520fungal%2520origin%26jtitle%3DNature%26date%3D1953%26volume%3D171%26spage%3D344%26doi%3D10.1038%2F171344a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3680</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-12-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-12-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=23757357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3671-3680&author=C.+Sessaauthor=G.+I.+Shapiroauthor=K.+N.+Bhallaauthor=C.+Brittenauthor=K.+S.+Jacksauthor=M.+Mitaauthor=V.+Papadimitrakopoulouauthor=T.+Pluardauthor=T.+A.+Samuelauthor=M.+Akimovauthor=C.+Quadtauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Baileyauthor=S.+Chicaauthor=U.+Banerji&title=First-in-human+phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.ccr-12-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sessa, Cristiana; Shapiro, Geoffrey I.; Bhalla, Kapil N.; Britten, Carolyn; Jacks, Karen S.; Mita, Monica; Papadimitrakopoulou, Vali; Pluard, Tim; Samuel, Thomas A.; Akimov, Mikhail; Quadt, Cornelia; Fernandez-Ibarra, Cristina; Lu, Hong; Bailey, Stuart; Chica, Sandra; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3671-3680</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I study was conducted with the primary objective of detg. the max. tolerated dose (MTD) of AUY922 in patients with advanced solid tumors.  Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles.  Patients and Methods: Patients with advanced solid tumors received 1-h i.v. infusions of AUY922 once a week in a 28-day cycle.  An adaptive Bayesian logistic regression model that employed obsd. dose-limiting toxicities (DLT) in the first treatment cycle was used to guide dose-escalation decisions, with the established MTD to be used in phase II studies.  Results: One hundred and one patients were enrolled and explored at doses in the range of 2 to 70 mg/m2.  DLTs occurred in 8 patients (22-70 mg/m2) and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms.  At 70 mg/m2, the AUY922 concn. achieved was consistent with active concns. in a range of xenograft models.  There was evidence of target inhibition in peripheral blood mononuclear cells (HSP70 induction) and tumor (client protein depletion and redn. of metabolic activity by 18F-FDG PET).  The recommended phase II dose (RP2D) of 70 mg/m2 was proposed on the basis of toxicity and pharmacokinetic and pharmacodynamic profiles.  Conclusions: At the RP2D of 70 mg/m2, AUY922 exhibited acceptable tolerability, and phase II single-agent and combination studies have been initiated in patients with HER2-pos. breast, gastric, and non-small cell lung cancers.  Clin Cancer Res; 19(13); 3671-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWielpmNf9rVg90H21EOLACvtfcHk0ljo2DyYPAEykg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI&md5=3a428b5489b6390c84fc046945e6d575</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-12-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-12-3404%26sid%3Dliteratum%253Aachs%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DJacks%26aufirst%3DK.%2BS.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DT.%2BA.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChica%26aufirst%3DS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3671%26epage%3D3680%26doi%3D10.1158%2F1078-0432.ccr-12-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steed, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markworth, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verleysen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4288</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/jm900230j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900230j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4288-4305&author=K.+H.+Huangauthor=J.+M.+Vealauthor=R.+P.+Faddenauthor=J.+W.+Riceauthor=J.+Eavesauthor=J.-P.+Strachanauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=T.+E.+Bartaauthor=W.+Maauthor=M.+A.+Silinskiauthor=M.+Huauthor=J.+M.+Partridgeauthor=A.+Scottauthor=L.+G.+DuBoisauthor=T.+Freedauthor=P.+M.+Steedauthor=A.+J.+Ommenauthor=E.+D.+Smithauthor=P.+F.+Hughesauthor=A.+R.+Woodwardauthor=G.+J.+Hansonauthor=W.+S.+McCallauthor=C.+J.+Markworthauthor=L.+Hinkleyauthor=M.+Jenksauthor=L.+Gengauthor=M.+Lewisauthor=J.+Ottoauthor=B.+Pronkauthor=K.+Verleysenauthor=S.+E.+Hall&title=Discovery+of+novel+2-aminobenzamide+inhibitors+of+heat+shock+protein+90+as+potent%2C+selective+and+orally+active+antitumor+agents&doi=10.1021%2Fjm900230j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents</span></div><div class="casAuthors">Huang, Kenneth H.; Veal, James M.; Fadden, R. Patrick; Rice, John W.; Eaves, Jeron; Strachan, Jon-Paul; Barabasz, Amy F.; Foley, Briana E.; Barta, Thomas E.; Ma, Wei; Silinski, Melanie A.; Hu, Mei; Partridge, Jeffrey M.; Scott, Anisa; DuBois, Laura G.; Freed, Tiffany; Steed, Paul M.; Ommen, Andy J.; Smith, Emilie D.; Hughes, Philip F.; Woodward, Angela R.; Hanson, Gunnar J.; McCall, W. Stephen; Markworth, Christopher J.; Hinkley, Lindsay; Jenks, Matthew; Geng, Lifeng; Lewis, Meredith; Otto, James; Pronk, Bert; Verleysen, Katleen; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4288-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compd. library.  These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp90, and optimized analogs exhibited nanomolar antiproliferative activity across multiple cancer cell lines.  Heat shock protein 70 (Hsp70) induction and specific client protein degrdn. in cells on treatment with the inhibitors supported Hsp90 inhibition as the mechanism of action.  Computational chem. and X-ray crystallog. anal. of selected member compds. clearly defined the protein-inhibitor interaction and assisted the design of analogs. 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide (SNX-2112) (I) was identified as highly selective and potent (IC50 Her2 = 11 nM, HT-29 = 3 nM); its prodrug amino-acetic acid 4-[2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-cyclohexyl ester methanesulfonate (SNX-5422) (II)was orally bioavailable and efficacious in a broad range of xenograft tumor models (e.g. 67% growth delay in a HT-29 model) and is now in multiple phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjrhELWrFkbVg90H21EOLACvtfcHk0ljo2DyYPAEykg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D&md5=99e5039e1761e9099d634acd79a15a6a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900230j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900230j%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DStrachan%26aufirst%3DJ.-P.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDuBois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DOmmen%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DWoodward%26aufirst%3DA.%2BR.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DMcCall%26aufirst%3DW.%2BS.%26aulast%3DMarkworth%26aufirst%3DC.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DB.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520novel%25202-aminobenzamide%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4288%26epage%3D4305%26doi%3D10.1021%2Fjm900230j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crandon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zein, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannargudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shnaidman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6831</span>– <span class="NLM_lpage">6839</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1078-0432.ccr-11-0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=21908572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6831-6839&author=A.+Rajanauthor=R.+J.+Kellyauthor=J.+B.+Trepelauthor=Y.+S.+Kimauthor=S.+V.+Alarconauthor=S.+Kummarauthor=M.+Gutierrezauthor=S.+Crandonauthor=W.+M.+Zeinauthor=L.+Jainauthor=B.+Mannargudiauthor=W.+D.+Figgauthor=B.+E.+Houkauthor=M.+Shnaidmanauthor=N.+Bregaauthor=G.+Giaccone&title=A+phase+I+study+of+PF-04929113+%28SNX-5422%29%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumor+malignancies+and+lymphomas&doi=10.1158%2F1078-0432.ccr-11-0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas</span></div><div class="casAuthors">Rajan, Arun; Kelly, Ronan J.; Trepel, Jane B.; Kim, Yeong Sang; Alarcon, Sylvia V.; Kummar, Shivaani; Gutierrez, Martin; Crandon, Sonja; Zein, Wadih M.; Jain, Lokesh; Mannargudi, Baskar; Figg, William D.; Houk, Brett E.; Shnaidman, Michael; Brega, Nicoletta; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6831-6839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the max. tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.  METHODS: This was a single-institution, phase I, dose-escalation study of PF-04929113 administered twice weekly.  Endpoints included detn. of dose-limiting toxicities (DLT), MTD, the safety profile of PF-04929113, pharmacodynamic assessment of PF-04929113 on Hsp70 induction, pharmacokinetic anal. of PF-04928473 (SNX-2112) and its prodrug PF-04929113, and assessment of response.  RESULTS: Thirty-three patients with advanced malignancies were treated.  Dose escalation was continued up to 177 mg/m2 administered orally twice a week.  One DLT (nonseptic arthritis) was noted.  No grade 4 drug-related adverse events were seen; grade 3 adverse events included diarrhea (9%), nonseptic arthritis (3%), aspartate aminotransferase elevation (3%), and thrombocytopenia (3%).  No objective responses were seen in 32 evaluable patients.  Fifteen patients (47%) had stable disease; 17 patients (53%) had progressive disease.  Pharmacokinetic data revealed rapid absorption, hepatic, and extrahepatic clearance, extensive tissue binding, and almost linear pharmacokinetics of the active drug PF-04928473.  Pharmacodynamic studies confirmed inhibition of Hsp90 and a linear correlation between pharmacokinetic parameters and Hsp70 induction.  CONCLUSIONS: PF-04929113 administered orally twice a week is well tolerated and inhibits its intended target Hsp90.  No objective responses were seen, but long-lasting stabilizations were obtained.  Although no clin. significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a sep. phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQzbnkoUJnibVg90H21EOLACvtfcHk0liOUTNo0swK1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM&md5=2b10fada0eb9d1dc7e06826724edf21f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-0821%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DAlarcon%26aufirst%3DS.%2BV.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DCrandon%26aufirst%3DS.%26aulast%3DZein%26aufirst%3DW.%2BM.%26aulast%3DJain%26aufirst%3DL.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DShnaidman%26aufirst%3DM.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520PF-04929113%2520%2528SNX-5422%2529%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumor%2520malignancies%2520and%2520lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6831%26epage%3D6839%26doi%3D10.1158%2F1078-0432.ccr-11-0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the heat shock response: biology and pharmacology</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">3758</span>– <span class="NLM_lpage">3769</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2007.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.febslet.2007.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=17559840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2007&pages=3758-3769&author=M.+V.+Powersauthor=P.+Workman&title=Inhibitors+of+the+heat+shock+response%3A+biology+and+pharmacology&doi=10.1016%2Fj.febslet.2007.05.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the heat shock response: Biology and pharmacology</span></div><div class="casAuthors">Powers, Marissa V.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3758-3769</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of human diseases can be linked to aberrations in protein folding which cause an imbalance in protein homeostasis.  Mol. chaperones, including heat shock proteins, act to assist protein folding, stability and activity in the cell.  Attention has begun to focus on modulating the expression and/or activity of this group of proteins for the treatment of a wide variety of human diseases.  This review will describe the progress made to date in developing pharmacol. modulators of the heat shock response, including both agents which affect the entire heat shock response and those that specifically target the HSP70 and HSP90 chaperone families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd1XAAhY6tPLVg90H21EOLACvtfcHk0liOUTNo0swK1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlaisbo%253D&md5=3be785569e7caee11e84a8cb4ca20574</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2007.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2007.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DM.%2BV.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520the%2520heat%2520shock%2520response%253A%2520biology%2520and%2520pharmacology%26jtitle%3DFEBS%2520Lett.%26date%3D2007%26volume%3D581%26spage%3D3758%26epage%3D3769%26doi%3D10.1016%2Fj.febslet.2007.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskew, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadikot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembruff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajewski, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjarrez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vielhauer, G. A.</span></span> <span> </span><span class="NLM_article-title">Development and characeterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">468</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-11-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1186%2F1471-2407-11-468" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=468&author=J.+D.+Eskewauthor=T.+Sadikotauthor=P.+Moralesauthor=A.+Durenauthor=I.+Dunwiddieauthor=M.+Swinkauthor=X.+Zhangauthor=S.+Hembruffauthor=A.+Donnellyauthor=R.+A.+Rajewskiauthor=B.+Bladauthor=J.+R.+Manjarrezauthor=R.+L.+Mattsauthor=J.+M.+Holzbeierleinauthor=G.+A.+Vielhauer&title=Development+and+characeterization+of+a+novel+C-terminal+inhibitor+of+Hsp90+in+androgen+dependent+and+independent+prostate+cancer+cells&doi=10.1186%2F1471-2407-11-468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-468%26sid%3Dliteratum%253Aachs%26aulast%3DEskew%26aufirst%3DJ.%2BD.%26aulast%3DSadikot%26aufirst%3DT.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DDuren%26aufirst%3DA.%26aulast%3DDunwiddie%26aufirst%3DI.%26aulast%3DSwink%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHembruff%26aufirst%3DS.%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DBlad%26aufirst%3DB.%26aulast%3DManjarrez%26aufirst%3DJ.%2BR.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26atitle%3DDevelopment%2520and%2520characeterization%2520of%2520a%2520novel%2520C-terminal%2520inhibitor%2520of%2520Hsp90%2520in%2520androgen%2520dependent%2520and%2520independent%2520prostate%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D468%26doi%3D10.1186%2F1471-2407-11-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koay, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckton, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, S. R.</span></span> <span> </span><span class="NLM_article-title">Chemically accessible hsp90 inhibitor that does not induce a heat shock response</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1021/ml500114p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500114p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=771-776&author=Y.+C.+Koayauthor=J.+R.+McConnellauthor=Y.+Wangauthor=S.+J.+Kimauthor=L.+K.+Bucktonauthor=F.+Mansourauthor=S.+R.+McAlpine&title=Chemically+accessible+hsp90+inhibitor+that+does+not+induce+a+heat+shock+response&doi=10.1021%2Fml500114p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml500114p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500114p%26sid%3Dliteratum%253Aachs%26aulast%3DKoay%26aufirst%3DY.%2BC.%26aulast%3DMcConnell%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DBuckton%26aufirst%3DL.%2BK.%26aulast%3DMansour%26aufirst%3DF.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DChemically%2520accessible%2520hsp90%2520inhibitor%2520that%2520does%2520not%2520induce%2520a%2520heat%2520shock%2520response%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D771%26epage%3D776%26doi%3D10.1021%2Fml500114p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Water, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perret, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-C.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90: inhibitors in clinical trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1021/jm9004708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.-C.+Lee&title=Heat+shock+protein+90%3A+inhibitors+in+clinical+trials&doi=10.1021%2Fjm9004708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0liy7apJ_esF5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17%26doi%3D10.1021%2Fjm9004708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">How Well Can Fragments Explore Accessed Chemical Space? A Case Study from Heat Shock Protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3989</span>– <span class="NLM_lpage">4005</span>, <span class="refDoi"> DOI: 10.1021/jm200350g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200350g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3989-4005&author=S.+D.+Roughleyauthor=R.+E.+Hubbard&title=How+Well+Can+Fragments+Explore+Accessed+Chemical+Space%3F+A+Case+Study+from+Heat+Shock+Protein+90&doi=10.1021%2Fjm200350g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">How Well Can Fragments Explore Accessed Chemical Space? A Case Study from Heat Shock Protein 90</span></div><div class="casAuthors">Roughley, Stephen D.; Hubbard, Roderick E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3989-4005</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summerizes the published literature on the generation of inhibitors and design of drug against the mol. chaperone, heat shock protein 90 (Hsp90), as potential therapeutics to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocGw-54Mo8SrVg90H21EOLACvtfcHk0liy7apJ_esF5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymurs%253D&md5=90c2c8028cb460c0c6fdc956e7daae28</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm200350g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200350g%26sid%3Dliteratum%253Aachs%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DHow%2520Well%2520Can%2520Fragments%2520Explore%2520Accessed%2520Chemical%2520Space%253F%2520A%2520Case%2520Study%2520from%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3989%26epage%3D4005%26doi%3D10.1021%2Fjm200350g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzamide tetrahydro-4<i>H</i>-carbazol-4-ones as novel small molecule inhibitors of Hsp90</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3517</span>– <span class="NLM_lpage">3521</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.bmcl.2008.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=18511277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFSns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3517-3521&author=T.+E.+Bartaauthor=J.+M.+Vealauthor=J.+W.+Riceauthor=J.+M.+Partridgeauthor=R.+P.+Faddenauthor=W.+Maauthor=M.+Jenksauthor=L.+Gengauthor=G.+J.+Hansonauthor=K.+H.+Huangauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=J.+Ottoauthor=S.+E.+Hall&title=Discovery+of+benzamide+tetrahydro-4H-carbazol-4-ones+as+novel+small+molecule+inhibitors+of+Hsp90&doi=10.1016%2Fj.bmcl.2008.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90</span></div><div class="casAuthors">Barta, Thomas E.; Veal, James M.; Rice, John W.; Partridge, Jeffrey M.; Fadden, R. Patrick; Ma, Wei; Jenks, Matthew; Geng, Lifeng; Hanson, Gunnar J.; Huang, Kenneth H.; Barabasz, Amy F.; Foley, Briana E.; Otto, James; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3517-3521</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hsp90 maintains the conformational stability of multiple proteins implicated in oncogenesis and has emerged as a target for chemotherapy.  We report here the discovery of a novel small mol. scaffold that inhibits Hsp90.  X-ray data show that the scaffold binds competitively at the ATP site on Hsp90.  Cellular proliferation and client assays demonstrate that members of the series are able to inhibit Hsp90 at nanomolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Wjx_IUjKbVg90H21EOLACvtfcHk0liy7apJ_esF5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFSns74%253D&md5=f965e9a2cfd0d44a57bb1949cd87de63</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520benzamide%2520tetrahydro-4H-carbazol-4-ones%2520as%2520novel%2520small%2520molecule%2520inhibitors%2520of%2520Hsp90%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3517%26epage%3D3521%26doi%3D10.1016%2Fj.bmcl.2008.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fadden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steed, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barabasz, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silinski, M. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verleysen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span> <span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+R.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+Hsp90&doi=10.1016%2Fj.chembiol.2010.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0lgg5yBskhKYMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%2BR.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694%26doi%3D10.1016%2Fj.chembiol.2010.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span>; <span class="NLM_string-name">Mailliet, P.</span>; <span class="NLM_string-name">Ruxer, J.
M.</span>; <span class="NLM_string-name">Goulaouic, H.</span>; <span class="NLM_string-name">Vallée, F.</span>; <span class="NLM_string-name">Minoux, H.</span>; <span class="NLM_string-name">Pilorge, F.</span>; <span class="NLM_string-name">Bertin, L.</span>; <span class="NLM_string-name">Hourcade, S.</span>; <span class="NLM_string-name">Mendez-perez, M.</span>, <span class="NLM_string-name">Hamley, P.</span></span> <span> </span><span class="NLM_article-title">New Fluorine Derivatives, Compositions Containing the Same and Use Thereof as Inhibitors of the Protein Chaperone HSP 90</span>. WO <span class="NLM_patent">2008049994</span>, May 2, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=F.+Thompson&author=P.+Mailliet&author=J.%0AM.+Ruxer&author=H.+Goulaouic&author=F.+Vall%C3%A9e&author=H.+Minoux&author=F.+Pilorge&author=L.+Bertin&author=S.+Hourcade&author=M.+Mendez-perez&author=P.+Hamley&title=New+Fluorine+Derivatives%2C+Compositions+Containing+the+Same+and+Use+Thereof+as+Inhibitors+of+the+Protein+Chaperone+HSP+90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DF.%26atitle%3DNew%2520Fluorine%2520Derivatives%252C%2520Compositions%2520Containing%2520the%2520Same%2520and%2520Use%2520Thereof%2520as%2520Inhibitors%2520of%2520the%2520Protein%2520Chaperone%2520HSP%252090%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span>; <span class="NLM_string-name">Minoux, H.</span>; <span class="NLM_string-name">Ruxer, J.
M.</span></span> <span> </span><span class="NLM_article-title">Novel HSP90-Inhibiting Indole Derivatives, Compositions Containing Said Derivatives, and Use Thereof</span>. WO <span class="NLM_patent">2011004132</span>, Jan 13, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Mailliet&author=H.+Minoux&author=J.%0AM.+Ruxer&title=Novel+HSP90-Inhibiting+Indole+Derivatives%2C+Compositions+Containing+Said+Derivatives%2C+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMailliet%26aufirst%3DP.%26atitle%3DNovel%2520HSP90-Inhibiting%2520Indole%2520Derivatives%252C%2520Compositions%2520Containing%2520Said%2520Derivatives%252C%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span> <span> </span><span class="NLM_article-title">Improvement of the high-speed log<i>D</i> assay using an injection marker for the water plug aspiration/injection method</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1216</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2009.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chroma.2009.02.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1216&publication_year=2009&pages=2984-2988&author=I.+Nishimuraauthor=A.+Hiranoauthor=T.+Yamashitaauthor=T.+Fukami&title=Improvement+of+the+high-speed+logD+assay+using+an+injection+marker+for+the+water+plug+aspiration%2Finjection+method&doi=10.1016%2Fj.chroma.2009.02.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2009.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2009.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DI.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26atitle%3DImprovement%2520of%2520the%2520high-speed%2520logD%2520assay%2520using%2520an%2520injection%2520marker%2520for%2520the%2520water%2520plug%2520aspiration%252Finjection%2520method%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2009%26volume%3D1216%26spage%3D2984%26epage%3D2988%26doi%3D10.1016%2Fj.chroma.2009.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span> <span> </span><span class="NLM_article-title">High-speed solubility screening assay using ultra-performance liquid chromatography/mass spectrometry in drug discovery</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1182</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2007.12.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chroma.2007.12.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=2008&pages=72-76&author=T.+Yamashitaauthor=Y.+Dohtaauthor=T.+Nakamuraauthor=T.+Fukami&title=High-speed+solubility+screening+assay+using+ultra-performance+liquid+chromatography%2Fmass+spectrometry+in+drug+discovery&doi=10.1016%2Fj.chroma.2007.12.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2007.12.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2007.12.086%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DDohta%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26atitle%3DHigh-speed%2520solubility%2520screening%2520assay%2520using%2520ultra-performance%2520liquid%2520chromatography%252Fmass%2520spectrometry%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2008%26volume%3D1182%26spage%3D72%26epage%3D76%26doi%3D10.1016%2Fj.chroma.2007.12.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span>; <span class="NLM_string-name">Okubo, S.</span>; <span class="NLM_string-name">Yoshimura, C.</span>; <span class="NLM_string-name">Yamashita, S.</span>; <span class="NLM_string-name">Osiumi, H.</span>; <span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Kawai, Y.</span></span> <span> </span><span class="NLM_article-title">Azabicyclo Compound and Salt Thereof</span>. WO <span class="NLM_patent">2011004610</span>, Jan 13, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Kitade&author=S.+Okubo&author=C.+Yoshimura&author=S.+Yamashita&author=H.+Osiumi&author=T.+Uno&author=Y.+Kawai&title=Azabicyclo+Compound+and+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKitade%26aufirst%3DM.%26atitle%3DAzabicyclo%2520Compound%2520and%2520Salt%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.chembiol.2004.03.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=776-785&author=L.+Wrightauthor=X.+Barrilauthor=B.+Dymockauthor=L.+Sheridanauthor=A.+Surgenorauthor=M.+Beswickauthor=M.+Drysdaleauthor=A.+Collierauthor=A.+Masseyauthor=N.+Daviesauthor=A.+Finkauthor=C.+Fromontauthor=W.+Aherneauthor=K.+Boxallauthor=S.+Sharpauthor=P.+Workmanauthor=R.+E.+Hubbard&title=Structure-activity+relationships+in+purine-based+inhibitor+binding+to+HSP90+isoforms&doi=10.1016%2Fj.chembiol.2004.03.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DL.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DBeswick%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DFromont%26aufirst%3DC.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DStructure-activity%2520relationships%2520in%2520purine-based%2520inhibitor%2520binding%2520to%2520HSP90%2520isoforms%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D776%26epage%3D785%26doi%3D10.1016%2Fj.chembiol.2004.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrebola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohaut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruxer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouanen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grépin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulaouic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dereu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoux, H.</span></span> <span> </span><span class="NLM_article-title">Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: Discovery of tricyclic imidazo[4,5-<i>c</i>]pyridines as potent inhibitors of the Hsp90 molecular chaperone</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7219</span>, <span class="refDoi"> DOI: 10.1021/jm200784m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200784m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7206-7219&author=F.+Vall%C3%A9eauthor=C.+Carrezauthor=F.+Pilorgeauthor=A.+Dupuyauthor=A.+Parentauthor=L.+Bertinauthor=F.+Thompsonauthor=P.+Ferrariauthor=F.+Fassyauthor=A.+Lambertonauthor=A.+Thomasauthor=R.+Arrebolaauthor=S.+Guerifauthor=A.+Rohautauthor=V.+Certalauthor=J.+M.+Ruxerauthor=C.+Delormeauthor=A.+Jouanenauthor=J.+Dumasauthor=C.+Gr%C3%A9pinauthor=C.+Combeauauthor=H.+Goulaouicauthor=N.+Dereuauthor=V.+Mikolauthor=P.+Maillietauthor=H.+Minoux&title=Tricyclic+series+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+part+I%3A+Discovery+of+tricyclic+imidazo%5B4%2C5-c%5Dpyridines+as+potent+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1021%2Fjm200784m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm200784m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200784m%26sid%3Dliteratum%253Aachs%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DCarrez%26aufirst%3DC.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFerrari%26aufirst%3DP.%26aulast%3DFassy%26aufirst%3DF.%26aulast%3DLamberton%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DArrebola%26aufirst%3DR.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DRohaut%26aufirst%3DA.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DRuxer%26aufirst%3DJ.%2BM.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DJouanen%26aufirst%3DA.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DGr%25C3%25A9pin%26aufirst%3DC.%26aulast%3DCombeau%26aufirst%3DC.%26aulast%3DGoulaouic%26aufirst%3DH.%26aulast%3DDereu%26aufirst%3DN.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMinoux%26aufirst%3DH.%26atitle%3DTricyclic%2520series%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520part%2520I%253A%2520Discovery%2520of%2520tricyclic%2520imidazo%255B4%252C5-c%255Dpyridines%2520as%2520potent%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7206%26epage%3D7219%26doi%3D10.1021%2Fjm200784m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 and, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1158%2F1535-7163.mct-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+Highly+Selective+Inhibitor+of+Heat+Shock+Protein+90+and%2C+Demonstrates+Potent+Antitumor+Activity+and+Minimal+Ocular+Toxicity+in+Preclinical+Models&doi=10.1158%2F1535-7163.mct-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0ljYlHN-Wth9jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520Highly%2520Selective%2520Inhibitor%2520of%2520Heat%2520Shock%2520Protein%252090%2520and%252C%2520Demonstrates%2520Potent%2520Antitumor%2520Activity%2520and%2520Minimal%2520Ocular%2520Toxicity%2520in%2520Preclinical%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.mct-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span> <span> </span><span class="NLM_article-title">A fluorescence polarization assay for inhibitors of Hsp90</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2005.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1016%2Fj.ab.2005.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=16460658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVeht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2006&pages=202-213&author=R.+Howesauthor=X.+Barrilauthor=B.+W.+Dymockauthor=K.+Grantauthor=C.+J.+Northfieldauthor=A.+G.+S.+Robertsonauthor=A.+Surgenorauthor=J.+Wayneauthor=L.+Wrightauthor=K.+Jamesauthor=T.+Matthewsauthor=K.-M.+Cheungauthor=E.+McDonaldauthor=P.+Workmanauthor=M.+J.+Drysdale&title=A+fluorescence+polarization+assay+for+inhibitors+of+Hsp90&doi=10.1016%2Fj.ab.2005.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescence polarization assay for inhibitors of Hsp90</span></div><div class="casAuthors">Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G. S.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K.-M.; McDonald, E.; Workman, P.; Drysdale, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-213</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hsp90 encodes a ubiquitous mol. chaperone protein conserved among species which acts on multiple substrates, many of which are important cell-signaling proteins.  Inhibition of Hsp90 function has been promoted as a mechanism to degrade client proteins involved in tumorigenesis and disease progression.  Several assays to monitor inhibition of Hsp90 function currently exist but are limited in their use for a drug discovery campaign.  Using data from the crystal structure of an initial hit compd., we have synthesized a fluorescent probe to be used in a fluorescence polarization assay to monitor binding of compds. to the ATP-binding site of Hsp90.  This assay is very robust (Z' > 0.9) and can detect affinity of compds. with IC50s to 40 nM.  We have used this assay in conjunction with cocrystal structures of small mols. to drive a structure-based design program aimed at the discovery and optimization of a novel class of potent Hsp90 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoag8hYDpa7BrVg90H21EOLACvtfcHk0ljYlHN-Wth9jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVeht74%253D&md5=59b8bce204a19c6618f9bce225eeb7df</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2005.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2005.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DRobertson%26aufirst%3DA.%2BG.%2BS.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWayne%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DMatthews%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26atitle%3DA%2520fluorescence%2520polarization%2520assay%2520for%2520inhibitors%2520of%2520Hsp90%26jtitle%3DAnal.%2520Biochem.%26date%3D2006%26volume%3D350%26spage%3D202%26epage%3D213%26doi%3D10.1016%2Fj.ab.2005.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lea, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span> <span> </span><span class="NLM_article-title">fluorescence polarization assays in small molecule screening</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1517/17460441.2011.537322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1517%2F17460441.2011.537322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=22328899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=17-32&author=W.+A.+Leaauthor=A.+Simeonov&title=fluorescence+polarization+assays+in+small+molecule+screening&doi=10.1517%2F17460441.2011.537322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence polarization assays in small molecule screening</span></div><div class="casAuthors">Lea, Wendy A.; Simeonov, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Fluorescence polarization (FP) is a homogeneous method that allows rapid and quant. anal. of diverse mol. interactions and enzyme activities.  This technique has been widely utilized in clin. and biomedical settings, including the diagnosis of certain diseases and monitoring therapeutic drug levels in body fluids.  Recent developments in the field have been symbolized by the facile adoption of FP in high-throughput screening and small mol. drug discovery of an increasing range of target classes.  Areas covered in this review: The article provides a brief overview of the theor. foundation of FP, followed by updates on recent advancements in its application for various drug target classes, including GPCRs, enzymes and protein-protein interactions.  The strengths and weaknesses of this method, practical considerations in assay design, novel applications and future directions are also discussed.  What the reader will gain: The reader is informed of the most recent advancements and future directions of FP application to small mol. screening.  Take home message: In addn. to its continued utilization in high-throughput screening, FP has expanded into new disease and target areas and has been marked by increased use of labeled small mol. ligands for receptor-binding studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqudLso-a4wR7Vg90H21EOLACvtfcHk0lhDYwnChmRmOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvP&md5=6f102f40b56fd7a13c4fb59b64a3f883</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.537322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.537322%26sid%3Dliteratum%253Aachs%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DSimeonov%26aufirst%3DA.%26atitle%3Dfluorescence%2520polarization%2520assays%2520in%2520small%2520molecule%2520screening%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D17%26epage%3D32%26doi%3D10.1517%2F17460441.2011.537322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1038%2Fleu.2014.300" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=510-514&author=R.+Suzukiauthor=T.+Hideshimaauthor=N.+Mimuraauthor=J.+Minamiauthor=H.+Ohguchiauthor=S.+Kikuchiauthor=Y.+Yoshidaauthor=G.+Gorgunauthor=D.+Cirsteaauthor=F.+Cottiniauthor=J.+Jakubikovaauthor=Y.-T.+Taiauthor=D.+Chauhanauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=T.+Utsugiauthor=K.+C.+Anderson&title=Anti-tumor+activities+of+selective+HSP90%CE%B1%2F%CE%B2+inhibitor%2C+TAS-116%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1038%2Fleu.2014.300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.300%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DMinami%26aufirst%3DJ.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DJakubikova%26aufirst%3DJ.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DAnti-tumor%2520activities%2520of%2520selective%2520HSP90%25CE%25B1%252F%25CE%25B2%2520inhibitor%252C%2520TAS-116%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D510%26epage%3D514%26doi%3D10.1038%2Fleu.2014.300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e73</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3Dresistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lhDYwnChmRmOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antilla, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">The Copper-Catalyzed N-Arylation of Indoles</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">11684</span>– <span class="NLM_lpage">11688</span>, <span class="refDoi"> DOI: 10.1021/ja027433h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja027433h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms12rtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=11684-11688&author=J.+C.+Antillaauthor=A.+Klaparsauthor=S.+L.+Buchwald&title=The+Copper-Catalyzed+N-Arylation+of+Indoles&doi=10.1021%2Fja027433h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Copper-Catalyzed N-Arylation of Indoles</span></div><div class="casAuthors">Antilla, Jon C.; Klapars, Artis; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">11684-11688</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general method for the N-arylation of indoles using catalysts derived from CuI and trans-1,2-cyclohexanediamine, trans-N,N'-dimethyl-1,2-cyclohexanediamine, or N,N'-dimethylethylenediamine is reported.  N-Arylindoles can be produced in high yield from the coupling of an aryl iodide or aryl bromide with a variety of indoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6AFBSNUIjerVg90H21EOLACvtfcHk0liJ_siPVZlucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms12rtb8%253D&md5=6f6f920e679db7512c645208c772c975</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja027433h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja027433h%26sid%3Dliteratum%253Aachs%26aulast%3DAntilla%26aufirst%3DJ.%2BC.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DThe%2520Copper-Catalyzed%2520N-Arylation%2520of%2520Indoles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D11684%26epage%3D11688%26doi%3D10.1021%2Fja027433h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antilla, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barder, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Copper–Diamine-CatalyzedN-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">5578</span>– <span class="NLM_lpage">5587</span>, <span class="refDoi"> DOI: 10.1021/jo049658b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo049658b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFemu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=5578-5587&author=J.+C.+Antillaauthor=J.+M.+Baskinauthor=T.+E.+Barderauthor=S.+L.+Buchwald&title=Copper%E2%80%93Diamine-CatalyzedN-Arylation+of+Pyrroles%2C+Pyrazoles%2C+Indazoles%2C+Imidazoles%2C+and+Triazoles&doi=10.1021%2Fjo049658b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles</span></div><div class="casAuthors">Antilla, Jon C.; Baskin, Jeremy M.; Barder, Timothy E.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5578-5587</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A copper-catalyzed N-arylation reaction of π-excessive nitrogen heterocycles is presented.  The coupling of either aryl iodides or aryl bromides with common nitrogen heterocycles (pyrroles, pyrazoles, indazoles, imidazoles, and triazoles) was successfully performed in good yield with catalysts derived from diamine ligands and CuI.  General conditions that tolerate functional groups such as aldehydes, ketones, alcs., primary amines, and nitriles on the aryl halide or heterocycle, were found.  Hindered aryl halides or heterocycles were also found to be suitable substrates using the conditions reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRNBpOn5bH6rVg90H21EOLACvtfcHk0liJ_siPVZlucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFemu7s%253D&md5=aba4bc16c9e4cf2d4c8688b42667a581</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo049658b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049658b%26sid%3Dliteratum%253Aachs%26aulast%3DAntilla%26aufirst%3DJ.%2BC.%26aulast%3DBaskin%26aufirst%3DJ.%2BM.%26aulast%3DBarder%26aufirst%3DT.%2BE.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper%25E2%2580%2593Diamine-CatalyzedN-Arylation%2520of%2520Pyrroles%252C%2520Pyrazoles%252C%2520Indazoles%252C%2520Imidazoles%252C%2520and%2520Triazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D5578%26epage%3D5587%26doi%3D10.1021%2Fjo049658b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urogdi, L.</span></span> <span> </span><span class="NLM_article-title">Efficient Conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1055/s-1989-27441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1055%2Fs-1989-27441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK3cXktVGrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&pages=949-950&author=A.+R.+Katritzkyauthor=B.+Pilarskiauthor=L.+Urogdi&title=Efficient+Conversion+of+nitriles+to+amides+with+basic+hydrogen+peroxide+in+dimethyl+sulfoxide&doi=10.1055%2Fs-1989-27441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide</span></div><div class="casAuthors">Katritzky, Alan R.; Pilarski, Boguslaw; Urogdi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-50</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">Hydrolysis of RCN [R = Ph, 4-ClC6H4, 2-pyridyl, 2-benzimidazolylmethyl, H(CH2)8, PhCH2O2CNHCHPh, etc.] with 30% H2O2 in DMSO contg. K2CO3 gave 65-99% RCONH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPMBmBssp3MrVg90H21EOLACvtfcHk0liJ_siPVZlucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVGrtrY%253D&md5=16cddca5856116a7674dfec60f18398b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1055%2Fs-1989-27441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1989-27441%26sid%3Dliteratum%253Aachs%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26aulast%3DPilarski%26aufirst%3DB.%26aulast%3DUrogdi%26aufirst%3DL.%26atitle%3DEfficient%2520Conversion%2520of%2520nitriles%2520to%2520amides%2520with%2520basic%2520hydrogen%2520peroxide%2520in%2520dimethyl%2520sulfoxide%26jtitle%3DSynthesis%26date%3D1989%26spage%3D949%26epage%3D950%26doi%3D10.1055%2Fs-1989-27441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of the reaction of nitriles with alkaline hydrogen peroxide. reactivity of peroxycarboximidic acid and application to superoxide ion reaction</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1246/bcsj.54.793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1246%2Fbcsj.54.793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaL3MXks1Wjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1981&pages=793-799&author=Y.+Sawakiauthor=Y.+Ogata&title=Mechanism+of+the+reaction+of+nitriles+with+alkaline+hydrogen+peroxide.+reactivity+of+peroxycarboximidic+acid+and+application+to+superoxide+ion+reaction&doi=10.1246%2Fbcsj.54.793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of the reaction of nitriles with alkaline hydrogen peroxide.  Reactivity of peroxycarboximidic acid and application to superoxide ion reaction</span></div><div class="casAuthors">Sawaki, Yasuhiko; Ogata, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">793-9</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">Formation of peroxycarboximidic acid (I) is not rate-detg. in the reaction of nitrile with alk. H2O2 to form amide and oxygen; the yield of amide based on H2O2 varies from 20 to 60%.  When Me2SO, a reactive substrate, is added, the rate is independent of its concn. and governed in turn by a rate-detg. addn. of HOO- to nitrile.  This reaction gives a reliable α-value of kHOO-/kHO-, which is 10000 for PhCN.  A facile conversion of nitrile to amide may be achieved by the reaction in the presence of MeSO, unaccompanied by side reactions such as the epoxyamide formation from α,β-unsatd. nitrile.  Kinetics and product anal. suggest that a predominant reaction is a radical decompn. of H2O2 which is induced by the homolysis of anion of I.  The reaction of superoxide ion, O2, with acetonitrile is analogous to that of HOO-; the decompn. of O2- is fast in the presence of MeCN and Me2SO in C6H6, affording acetamide and Me2SO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4ijDOd7BFVbVg90H21EOLACvtfcHk0lgWbHh0DISqMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXks1Wjsb4%253D&md5=ff0be923eb97bcd8d1a0d52595de1a43</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.54.793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.54.793%26sid%3Dliteratum%253Aachs%26aulast%3DSawaki%26aufirst%3DY.%26aulast%3DOgata%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520the%2520reaction%2520of%2520nitriles%2520with%2520alkaline%2520hydrogen%2520peroxide.%2520reactivity%2520of%2520peroxycarboximidic%2520acid%2520and%2520application%2520to%2520superoxide%2520ion%2520reaction%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1981%26volume%3D54%26spage%3D793%26epage%3D799%26doi%3D10.1246%2Fbcsj.54.793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasamatsu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohuchida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span> <span> </span><span class="NLM_article-title">A New process for synthesis of the astrocyte activation suppressor, ONO-2506</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1021/op0500988</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0500988" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=774-781&author=T.+Hasegawaauthor=Y.+Kawanakaauthor=E.+Kasamatsuauthor=C.+Ohtaauthor=K.+Nakabayashiauthor=M.+Okamotoauthor=M.+Hamanoauthor=K.+Takahashiauthor=S.+Ohuchidaauthor=Y.+Hamada&title=A+New+process+for+synthesis+of+the+astrocyte+activation+suppressor%2C+ONO-2506&doi=10.1021%2Fop0500988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A new process for synthesis of the astrocyte activation suppressor, ONO-2506</span></div><div class="casAuthors">Hasegawa, Tomoyuki; Kawanaka, Yasufumi; Kasamatsu, Eichi; Ohta, Chisa; Nakabayashi, Kazuhiro; Okamoto, Masaki; Hamano, Masaya; Takahashi, Keiji; Ohuchida, Shuichi; Hamada, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">774-781</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of a new process for the synthesis of ONO-2506, an agent that suppresses astrocyte activation, is described.  Previous processes that involved asym. synthesis with a chiral auxiliary were unsatisfactory from a cost perspective because the relatively expensive chiral auxiliaries were not recyclable.  To develop a more cost-effective process, the authors designed a new process starting from chiral 1,2-epoxyoctane, which was readily prepd. catalytically by Jacobsen's method.  The new five-step process was developed with the establishment of a modified cyanation condition, in which lithium cyanide was prepd. in situ by combining lithium hydroxide with acetone cyanohydrin.  Then the mechanisms for racemization and the side reaction until the cyanation step were clarified, and these problems were solved.  The main features of this process are crystn. of the amide intermediate, since its optical purity is readily improved by recrystn. up to 100% ee in addn. to formation of the dibenzylamine salt with ONO-2506 that leads to improved chem. and optical purity of the final product.  The shorter synthesis, including a one-pot reaction was ruled out because of the hazardous nature of the Katritzky hydrolysis conditions for the conversion of nitrile to amide in the presence of sodium cyanide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcY9CneNUWULVg90H21EOLACvtfcHk0lgWbHh0DISqMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslWrtL0%253D&md5=6ffc717de08a3d78b124310fe2088006</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fop0500988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0500988%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DKawanaka%26aufirst%3DY.%26aulast%3DKasamatsu%26aufirst%3DE.%26aulast%3DOhta%26aufirst%3DC.%26aulast%3DNakabayashi%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DHamano%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DOhuchida%26aufirst%3DS.%26aulast%3DHamada%26aufirst%3DY.%26atitle%3DA%2520New%2520process%2520for%2520synthesis%2520of%2520the%2520astrocyte%2520activation%2520suppressor%252C%2520ONO-2506%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D774%26epage%3D781%26doi%3D10.1021%2Fop0500988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnürch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihovilovic, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanetty, P.</span></span> <span> </span><span class="NLM_article-title">Halogen dance reactions-A review</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1039/b607701n</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1039%2Fb607701n" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=17576473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=1046-1057&author=M.+Schn%C3%BCrchauthor=M.+Spinaauthor=A.+F.+Khanauthor=M.+D.+Mihovilovicauthor=P.+Stanetty&title=Halogen+dance+reactions-A+review&doi=10.1039%2Fb607701n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen dance reactions - A review</span></div><div class="casAuthors">Schnuerch, Michael; Spina, Markus; Khan, Ather Farooq; Mihovilovic, Marko D.; Stanetty, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1046-1057</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Halogen Dance (HD) reactions are a useful tool for synthetic chemists as they enable access to positions in arom. and heteroarom. systems for subsequent functionalization which are often difficult to address by other methods, hence, allowing entry to versatile scaffolds.  While the method can be extremely useful, this transformation is often neglected upon designing synthetic sequences.  This may be largely attributed to the lack of comprehensive ref. works covering the general principles and outlining the versatility and limitations of the technique.  The following review tries to present HD reactions in a clear and concise manner in order to convince more chemists of its advantages.  It covers the field of HD reactions from their first observation in 1951 until the present.  The important contributions leading to the elucidation of the mechanism are briefly outlined followed by a detailed mechanistic section and a discussion of factors which influence HD reactions.  Finally, an overview of HD reactions on various carbocyclic and heterocyclic ring systems and its applications in the synthesis of complex compds. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcr1jxTRMi3bVg90H21EOLACvtfcHk0lgWbHh0DISqMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFantLs%253D&md5=72ee905f7657190172d195dd8ca326e7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fb607701n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb607701n%26sid%3Dliteratum%253Aachs%26aulast%3DSchn%25C3%25BCrch%26aufirst%3DM.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DA.%2BF.%26aulast%3DMihovilovic%26aufirst%3DM.%2BD.%26aulast%3DStanetty%26aufirst%3DP.%26atitle%3DHalogen%2520dance%2520reactions-A%2520review%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2007%26volume%3D36%26spage%3D1046%26epage%3D1057%26doi%3D10.1039%2Fb607701n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantam, M.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreedhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-arylation of heterocycles with activated chloro- and fluoroarenes using nanocrystalline copper(II) oxide</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1002/adsc.200600483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1002%2Fadsc.200600483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=1938-1942&author=M.%0AL.+Kantamauthor=J.+Yadavauthor=S.+Lahaauthor=B.+Sreedharauthor=S.+Jha&title=N-arylation+of+heterocycles+with+activated+chloro-+and+fluoroarenes+using+nanocrystalline+copper%28II%29+oxide&doi=10.1002%2Fadsc.200600483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200600483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200600483%26sid%3Dliteratum%253Aachs%26aulast%3DKantam%26aufirst%3DM.%2BL.%26aulast%3DYadav%26aufirst%3DJ.%26aulast%3DLaha%26aufirst%3DS.%26aulast%3DSreedhar%26aufirst%3DB.%26aulast%3DJha%26aufirst%3DS.%26atitle%3DN-arylation%2520of%2520heterocycles%2520with%2520activated%2520chloro-%2520and%2520fluoroarenes%2520using%2520nanocrystalline%2520copper%2528II%2529%2520oxide%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D1938%26epage%3D1942%26doi%3D10.1002%2Fadsc.200600483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koval, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Copper-catalyzed <i>N</i>-arylation of imidazoles and benzimidazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">6190</span>– <span class="NLM_lpage">6199</span>, <span class="refDoi"> DOI: 10.1021/jo070807a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070807a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1CktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=6190-6199&author=R.+A.+Altmanauthor=E.+D.+Kovalauthor=S.+L.+Buchwald&title=Copper-catalyzed+N-arylation+of+imidazoles+and+benzimidazoles&doi=10.1021%2Fjo070807a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Catalyzed N-Arylation of Imidazoles and Benzimidazoles</span></div><div class="casAuthors">Altman, Ryan A.; Koval, Erica D.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6190-6199</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4,7-Dimethoxy-1,10-phenanthroline (L1c) was found to be an efficient ligand for the copper-catalyzed N-arylation of imidazoles and benzimidazoles with both aryl iodides and bromides under mild conditions.  Further optimization of the system has revealed that the addn. of poly(ethylene glycol) accelerates this reaction.  A variety of hindered and functionalized imidazoles, benzimidazoles, and aryl halides were transformed in good to excellent yields.  Heteroaryl halides were also coupled in moderate to good yields.  We also present the results obtained from a series of coupling reactions, which directly compare the use of L1c with other recently reported ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnJAu6gmqUF7Vg90H21EOLACvtfcHk0lhY7IAJLN0YNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1CktLY%253D&md5=26329baaf70d9f9a1fa318330e47b0b5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo070807a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070807a%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DKoval%26aufirst%3DE.%2BD.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper-catalyzed%2520N-arylation%2520of%2520imidazoles%2520and%2520benzimidazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D6190%26epage%3D6199%26doi%3D10.1021%2Fjo070807a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid, high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">6382</span>– <span class="NLM_lpage">6394</span>, <span class="refDoi"> DOI: 10.1021/ja994192d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja994192d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=6382-6394&author=D.+L.+Bogerauthor=B.+E.+Finkauthor=M.+P.+Hedrick&title=Total+synthesis+of+distamycin+A+and+2640+analogues%3A+A+solution-phase+combinatorial+approach+to+the+discovery+of+new%2C+bioactive+DNA+binding+agents+and+development+of+a+rapid%2C+high-throughput+screen+for+determining+relative+DNA+binding+affinity+or+DNA+binding+sequence+selectivity&doi=10.1021%2Fja994192d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Distamycin A and 2640 Analogs: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity</span></div><div class="casAuthors">Boger, Dale L.; Fink, Brian E.; Hedrick, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6382-6394</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a soln.-phase synthesis of distamycin A and its extension to the prepn. of 2640 analogs are described.  Thus, soln.-phase synthesis techniques with reaction workup and purifn. employing acid/base liq.-liq. extns. were used in the multistep prepn. of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogs providing intermediates and final products that are ≥95% pure on conventional reaction scales.  The complementary development of a simple, rapid, and high-throughput screen for DNA binding affinity based on the loss of fluorescence derived from displacement of prebound ethidium bromide is disclosed which is applicable for assessing relative or abs. binding affinity to DNA homopolymers or specific sequences (hairpin oligonucleotides).  Using hairpin oligonucleotides, this method permits the screening of a library of compds. against a single predefined sequence to identify high affinity binders, or the screening of a single compd. against a full library of individual hairpin oligonucleotides to define its sequence selectivity.  The combination permits the establishment of the complete DNA binding profile of each member of a library of compds.  Screening the prototypical library provided compds. that are 1000 times more potent than distamycin A in cytotoxic assays (I, Boc = tert-butoxycarbonyl; IC50 = 29 nM, L1210), that bind to poly[dA]-poly[dT] with comparable affinity, and that exhibit an altered DNA binding sequence selectivity.  Several candidates were identified which bound the five-base-pair AT-rich site of the PSA-ARE-3 sequence, and one (II, R = 4-dimethylaminobutyryl; K = 3.2 × 106 M-1) maintained the high affinity binding (K = 4.5 × 106 M-1) to the ARE-consensus sequence contg. a GC base-pair interrupted five-base-pair AT-rich site suitable for inhibition of gene transcription initiated by hormone insensitive androgen receptor dimerization and DNA binding characteristic of therapeutic resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeiV3cg0jix7Vg90H21EOLACvtfcHk0lhY7IAJLN0YNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGltL0%253D&md5=fe06cf76512cd2970fe28d611a4b25d7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja994192d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja994192d%26sid%3Dliteratum%253Aachs%26aulast%3DBoger%26aufirst%3DD.%2BL.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26atitle%3DTotal%2520synthesis%2520of%2520distamycin%2520A%2520and%25202640%2520analogues%253A%2520A%2520solution-phase%2520combinatorial%2520approach%2520to%2520the%2520discovery%2520of%2520new%252C%2520bioactive%2520DNA%2520binding%2520agents%2520and%2520development%2520of%2520a%2520rapid%252C%2520high-throughput%2520screen%2520for%2520determining%2520relative%2520DNA%2520binding%2520affinity%2520or%2520DNA%2520binding%2520sequence%2520selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D6382%26epage%3D6394%26doi%3D10.1021%2Fja994192d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramadas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, N.</span></span> <span> </span><span class="NLM_article-title">Iron-Ammonium Chloride—A Convenient and Inexpensive Reductant</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3189</span>– <span class="NLM_lpage">3195</span>, <span class="refDoi"> DOI: 10.1080/00397919208021132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1080%2F00397919208021132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=3189-3195&author=K.+Ramadasauthor=N.+Srinivasan&title=Iron-Ammonium+Chloride%E2%80%94A+Convenient+and+Inexpensive+Reductant&doi=10.1080%2F00397919208021132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Iron-ammonium chloride - a convenient and inexpensive reductant</span></div><div class="casAuthors">Ramadas, Krishnamurthy; Srinivasan, Natarajan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3189-95</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">The redn. of nitro arom. compds., I (R1 = H, NH2, Me, Cl, R2 = H, NH2, NO2, R3 = H, CH2CN, CH2CO2H, Me, OH, NHAc, Br, Cl, NH2, R4 = NO2), contg. other susceptible groups is reinvestigated to provide a viable economic route from the point of view of quant. transformation, reduced reaction times, and simple work up using iron powder and ammonium chloride soln. in neutral medium.  Thus, using Fe/NH4Cl on I gave I (R4 = NH2) in 67-90% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_QX8c0Gcx7Vg90H21EOLACvtfcHk0lhY7IAJLN0YNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D&md5=7b3830ad2efaf09a30cbff04b89eb32a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1080%2F00397919208021132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021132%26sid%3Dliteratum%253Aachs%26aulast%3DRamadas%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DIron-Ammonium%2520Chloride%25E2%2580%2594A%2520Convenient%2520and%2520Inexpensive%2520Reductant%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D3189%26epage%3D3195%26doi%3D10.1080%2F00397919208021132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosquera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, J.</span></span> <span> </span><span class="NLM_article-title">Selective monomethylation of anilines by Cu(OAc)<sub>2</sub>-promoted cross-coupling with MeB(OH)<sub>2</sub></span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1677</span>– <span class="NLM_lpage">1680</span>, <span class="refDoi"> DOI: 10.1021/ol802882k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol802882k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFegtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1677-1680&author=I.+Gonz%C3%A1lezauthor=J.+Mosqueraauthor=C.+Guerreroauthor=R.+Rodr%C3%ADguezauthor=J.+Cruces&title=Selective+monomethylation+of+anilines+by+Cu%28OAc%292-promoted+cross-coupling+with+MeB%28OH%292&doi=10.1021%2Fol802882k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Monomethylation of Anilines by Cu(OAc)2-Promoted Cross-Coupling with MeB(OH)2</span></div><div class="casAuthors">Gonzalez, Israel; Mosquera, Jesus; Guerrero, Cesar; Rodriguez, Ramon; Cruces, Jacobo</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1677-1680</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Methylanilines are readily synthesized in high yields through the copper(II)-promoted coupling of anilines and methylboronic acid.  This method represents a new approach for the selective monomethylation of anilines, and it is the first reported example of a Chan-Lam coupling involving the use of methylboronic acid.  An incubation period of the substrate with the copper reagent is needed before addn. of the methylboronic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfxOiIczUGx7Vg90H21EOLACvtfcHk0lhY7IAJLN0YNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFegtb8%253D&md5=3d05bb2320a2276c740fffabe9ad7346</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fol802882k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol802882k%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DI.%26aulast%3DMosquera%26aufirst%3DJ.%26aulast%3DGuerrero%26aufirst%3DC.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DR.%26aulast%3DCruces%26aufirst%3DJ.%26atitle%3DSelective%2520monomethylation%2520of%2520anilines%2520by%2520Cu%2528OAc%25292-promoted%2520cross-coupling%2520with%2520MeB%2528OH%25292%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1677%26epage%3D1680%26doi%3D10.1021%2Fol802882k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span> <span> </span><span class="NLM_article-title">Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx387.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1093%2Fannonc%2Fmdx387.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=522-523&author=Y.+Kurokawaauthor=T.+Doiauthor=A.+Sawakiauthor=Y.+Komatsuauthor=M.+Ozakaauthor=T.+Takahashiauthor=Y.+Naitoauthor=S.+Okuboauthor=T.+Nishida&title=Phase+II+study+of+TAS-116%2C+an+oral+inhibitor+of+heat+shock+protein+90+%28HSP90%29%2C+in+metastatic+or+unresectable+gastrointestinal+stromal+tumor+refractory+to+imatinib%2C+sunitinib+and+regorafenib&doi=10.1093%2Fannonc%2Fmdx387.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx387.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx387.006%26sid%3Dliteratum%253Aachs%26aulast%3DKurokawa%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DSawaki%26aufirst%3DA.%26aulast%3DKomatsu%26aufirst%3DY.%26aulast%3DOzaka%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DNishida%26aufirst%3DT.%26atitle%3DPhase%2520II%2520study%2520of%2520TAS-116%252C%2520an%2520oral%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%252C%2520in%2520metastatic%2520or%2520unresectable%2520gastrointestinal%2520stromal%2520tumor%2520refractory%2520to%2520imatinib%252C%2520sunitinib%2520and%2520regorafenib%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D522%26epage%3D523%26doi%3D10.1093%2Fannonc%2Fmdx387.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battye, T. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiannis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span> <span> </span><span class="NLM_article-title">iMOSFLM: a new graphical interface for diffraction-image processing withMOSFLM</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1107/s0907444910048675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2Fs0907444910048675" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=271-281&author=T.+G.+G.+Battyeauthor=L.+Kontogiannisauthor=O.+Johnsonauthor=H.+R.+Powellauthor=A.+G.+W.+Leslie&title=iMOSFLM%3A+a+new+graphical+interface+for+diffraction-image+processing+withMOSFLM&doi=10.1107%2Fs0907444910048675"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2Fs0907444910048675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444910048675%26sid%3Dliteratum%253Aachs%26aulast%3DBattye%26aufirst%3DT.%2BG.%2BG.%26aulast%3DKontogiannis%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DO.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DiMOSFLM%253A%2520a%2520new%2520graphical%2520interface%2520for%2520diffraction-image%2520processing%2520withMOSFLM%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D271%26epage%3D281%26doi%3D10.1107%2Fs0907444910048675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Collaborative
Computational
Project No. 4</span>. <span> </span><span class="NLM_article-title">The CCP4 suite:
programs for protein crystallography</span>.  <i>Acta
Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume">50</span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>.<span class="refDoi"> DOI: 10.1107/s0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2Fs0907444994003112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative%0AComputational%0AProject+No.+4&title=The+CCP4+suite%3A%0Aprograms+for+protein+crystallography&doi=10.1107%2Fs0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1107%2Fs0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%250Aprograms%2520for%2520protein%2520crystallography%26jtitle%3DActa%250ACrystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2Fs0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplyakov, A.</span></span> <span> </span><span class="NLM_article-title">MOLREP: an automated program for molecular replacement</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1107/s0021889897006766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+automated+program+for+molecular+replacement&doi=10.1107%2Fs0021889897006766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0lg1DBPT0l79Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520automated%2520program%2520for%2520molecular%2520replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025%26doi%3D10.1107%2Fs0021889897006766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/s0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2Fs0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lg1DBPT0l79Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2Fs0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhCLmEmhBdTeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DOB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DOB','PDB','3DOB'); return false;">PDB: 3DOB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MNR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MNR','PDB','3MNR'); return false;">PDB: 3MNR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3','PDB','5ZR3'); return false;">PDB: 5ZR3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WQ9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WQ9','PDB','3WQ9'); return false;">PDB: 3WQ9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i91"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01085">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07631"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01085">10.1021/acs.jmedchem.8b01085</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General chemistry information; complete synthesis procedures and characterization of intermediates and test compounds whose procedures are not included in the main article; and X-ray crystallography data and refinement statistics (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_001.pdf">jm8b01085_si_001.pdf (185.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01085/suppl_file/jm8b01085_si_002.csv">jm8b01085_si_002.csv (2.83 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of HSP90 in complex with compound <b>16d</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>) have been deposited in the Protein Data Bank. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01085%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01085" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996f2e1edc221c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
